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BACKGROUND AND FOCUS OF THIS THESIS
You take the blue pill, the story ends, 
you wake up in your bed and believe whatever you want 
to believe. You take the red pill, you stay in Wonderland, 
and I show you how deep the rabbit hole goes. 
Remember, all I’m offering is the truth, nothing more 
Morpheus, in Matrix, by The Wachowskis
The era of big data opens new means to improve health and health care. 
Observational evidence from large populations can provide guidance to the 
choices of multiple stakeholders. Policymakers can understand how health care 
systems can be better organized, clinicians can explore more in detail all the 
treatment options, patients can put peculiarities of their own diseases at the 
centre of the clinical decisions, and citizens can obtain evidence to inform their 
political options. New methodologies need to be developed, and traditional 
tools and ways of thinking need to be renovated to adapt to the new perspective, 
to avoid drawing incorrect conclusions from studies based on this resource 
[Ray2011, Mooney 2015]. 
The methodological challenge relies not only in the observational nature of 
the studies that can be conducted on big data, but also in the heterogeneous 
characteristics of the data that is now available. We are interested in the latter. 
Data is available from multiple sources such as hospitals and other health 
care settings, like primary care practices.  Besides medical records, large 
administrative data sources are available, as well as disease registries, results 
from surveys etc. Record linkage between existing data sources is surrounded 
by data privacy concerns and possible in special circumstances only. According 
to national regulations and culture, record linkage and secondary use of data 
for the purposes of research is allowed to disparate types of organizations: 
university hospitals, public health institutions, scientific societies, private 
research companies [Trifiro2014]. 
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In the situation of secondary use, variables are derived from existing data sources, 
by mean of data processing. This action mimics the traditional data collection 
process, but is in fact new: the ‘true’ variables should now be conceptualized as 
unobserved quantities, and the study variables entering the actual analysis as 
measurements, resulting from case-finding algorithms applied to the original 
data. The difference between the truth and the result of a case-finding algorithm 
can be assessed by validation studies. In the next subsections we review the 
existing methodology and applications of such studies, and describe the gap that 
we tried to address in this thesis.
Validation studies of case-finding algorithms
The objective of a validation study of a case-finding algorithm is estimating the 
validity indices  of the algorithm. The indices quantify to which extent the study 
variable corresponds to the true variable. Imagine that we want to establish 
whether subjects have type 2 diabetes mellitus, but only have prescription 
information at our disposal to do so. We could adopt a case-finding algorithm 
that assigns a T2DM label if a record of prescribing metformin, a drug whose 
main indication is treatment of T2DM, is found. In this example, four subjects 
are classified according to whether they truly have type 2 diabetes mellitus 
(T2DM) and whether our algorithm would classify them as having T2DM: the 
first is the true variable, the second is the result of our case-finding algorithm 
(Table 1). In the example, Hellen is a true positive (she has T2DM, and has records 
of metformin prescriptions), Robert is a false negative (he has T2DM, but does 
not have an indication for treatment with metformin yet), Susan is a false positive 
(she does not have T2DM, but has polycystic ovary syndrome, a condition treated 
off-label with metformin) and Frank is a true negative (he does not have T2DM, 
and has no record of metformin prescription)
Table 1. A dataset with a true variable and a variable derived from an algorithm on a database of 
prescriptions.
Name Has type 2 diabetes mellitus
(true variable)
Was prescribed metformin
(derived variable)
Hellen Yes Yes
Robert Yes No
Susan No Yes
Frank No No
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Based on these concepts, the following validity indices are defined: sensitivity of 
this algorithm is the proportion of true positives among persons with T2DM; the 
positive predictive value is the proportion of true positives among persons who 
use metformin; specificity is the proportion of true negatives among persons 
without T2DM; negative predictive value is the proportion of true negatives 
among persons without prescription of metformin.
Results from a validation study of algorithms are used to adjust or, if this is 
not possible, to interpret the estimates obtained from analysing the dataset 
[Lanes2015]. Editorials and guidelines explicitly recommend the execution of this 
type of validation studies [GarciaRodriguez2010, Hernan2011, Benchimol2015]. 
Some methodological misconceptions hamper effective conduction and 
application of validation studies of case-finding algorithms. 
Validation studies of case-finding algorithms versus diagnostic accuracy studies
The methodology for validation studies has been developed in the context of 
validation of diagnostic tests, that is, procedures collecting clinical parameters 
from patients [Whiting2003]. The diagnostic accuracy studies are typically 
devoted to estimate the likelihood that a person with specific values of the 
clinical parameters is indeed affected by the target health condition, and 
whether patients with the target condition are accurately captured by that 
same set of clinical parameters. Although the terminology and mathematical 
definition of validity indices is borrowed from diagnostic accuracy studies, the 
interpretation should be much different in studies on health care data that focus 
on identifying subjects with a certain disease from proxies that may indicate 
health status of a subject. 
The parameters of sensitivity and specificity of a diagnostic test are rooted in 
human biology and essentially depend on the characteristics of the population 
where they are estimated [Greenland1996]. On the contrary, validity indices of 
a case-finding algorithm in a database depend on multiple characteristics of the 
system, for instance completeness of data collection, accuracy in coding habits, 
granularity of the coding system, organization of the health care system in 
the geographic area where the data is collected – besides characteristics of the 
population whose data is collected. All those factors are subject to change from 
one database to another, and over time [Quan2009, Reich2012, Herret2013, 
Morley2014, Rahimi2014, Lanes2015].
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An effect of the difference between the two types of validation studies is the 
common misconception that predictive values depend on prevalence of the 
disease, while sensitivity and specificity do not [Greenland1996, Lanes2015b]. 
The rationale behind this statement is that mathematical equations link 
predictive values with prevalence, sensitivity and specificity [Altman1994, 
Altman1994b]. Indeed the equations apply, irrespectively of whether they refer 
to a diagnostic test or to an algorithm on a database, but in the latter case the 
four parameters all depend on one another and on prevalence. 
The following thought experiment helps in understanding the difference. In an 
Italian factory with a workforce that is predominantly male, costs for the canteen 
are reduced, at the expenses of food quality. Many workers gain weight and 
new cases of T2DM are diagnosed, which increases the prevalence of the disease 
among the workforce. Some validity parameters of the algorithm mentioned 
in Table 1 (“Being prescribed metformin”) are affected by this change. In Italy 
the first approach recommended after a diagnosis of T2DM is modification 
of life styles, without indication for pharmaceutical therapy [AMD-SID2014], 
therefore the new cases in the factory do not start a metformin treatment, and 
the sensitivity of the algorithm is reduced. On the contrary, positive predictive value 
of the algorithm is not affected: in the workforce there are no cases of the other 
common indication for metformin, polycystic ovary syndrome, and all patients 
utilizing metformin are cases of T2DM.
Validation studies of case-finding algorithms are difficult to generalize 
Generalizing estimates of validity parameters of a case-finding algorithm outside 
of the environment where a validation study was executed, is questionable. 
The construct of “validity of a diagnostic code” is recurrent in the literature 
of validation studies of case-finding algorithms [Cutrona2013, Valkhoff2014]. 
This construct is misleading: the same code recorded in primary care or during 
an emergency room visit, or in different countries adopting the same coding 
system, or even in the same country over time, may have completely different 
validity indices. Implying that a diagnostic code can be validated in itself may 
lead to inappropriate generalization of the validity indices.
In order to support effectively the interpretation of the results of a study, 
validation of study variables should be as close as possible to the actual dataset 
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that is used for the statistical analysis. Traditional validation studies, which 
imply manual assessment of samples of records, are time-consuming and 
expensive [Hernan2011].  
An alternative solution is exploiting big data to validate big data: this 
methodological advancement is emerging in the recent literature.
 
Validation studies of case-finding algorithms exploiting existing data sources
In recent years, in several countries, many studies exploiting existing data 
sources for purposes of validating case-finding algorithms for diseases have been 
conducted [Lix2008, Lix2008b, Ferretti2009, Kahn2010, Amed2011, Gorina2011, 
Nosyk2013, Quantin2013, Bowker2015, John2016]. In each study at least two 
data sources were considered, with different data-generating mechanisms: 
administrative or claims databases, medical records, disease registries, survey 
responses, cohorts from epidemiologic studies. Two scenarios are common: 
first, when the same parameter can be estimated from different data sources at 
an ecological level on the same population; second, when the same variable can 
be estimated from different data sources at an individual level on a same set of 
individuals.
The first scenario has the advantage that no individual-level record linkage is 
requested between data sources belonging to different organizations. Ecologic 
parameters for comparison can be found in existing publications or national 
survey or census data. On the negative side, estimating validity parameters 
from this design is rarely possible. 
The second scenario has the disadvantage that individual-level record linkage 
between different data sources, even for purposes of validation, often requires 
a complex legal permission procedure because of privacy considerations
Using existing data for validation purposes allows exploring large cohorts, often 
sampled from the general population, testing several algorithms for the same 
variable, identifying the main determinants of validity, and repeating the study 
over time.
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GENERAL INTRODUCTION
15
Focus of this thesis
The main objective of this thesis is advancing the methodology of validation 
studies of case-finding algorithms that exploit diversity across available data, 
rather than collecting new data.
The case study that led us to this advancement was the assessment of the 
capacity of the Italian administrative database to capture cases of chronic 
disease to get estimates for the compliance with standards of care. Primary 
care medical records were the main comparative source. Part I of this thesis is 
focussed on this topic.
In Part II we exploited the results and extended the methodology of Part I to the 
context of multi-database, multi-national studies.
In the next section of this general introduction we describe in detail the research 
questions addressed in Part I and Part II.
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INTRODUCTION TO PART I: VALIDATION OF VARIABLES 
DEFINING CHRONIC DISEASES AND COMPLIANCE WITH 
STANDARDS OF CARE IN ITALIAN ADMINISTRATIVE 
DATABASES
Italy has a universal, single-payer healthcare system.  Chronic diseases impose 
an increasing burden on the Italian aging population, and are a major threat to 
sustainability of the healthcare system [OECD2015]. 
Administrative data are collected on a large set of services provided to the 
population, and are available for secondary analysis to health policy makers. 
Secondary use of Italian Administrative Databases (IAD) to detect patients with 
chronic conditions would allow surveillance, planning, monitoring of quality 
of healthcare, as well as assessment of impact of new organizational models on 
relevant health and quality outcomes. 
Chronic diseases are normally diagnosed in a primary or secondary care setting 
in Italy. General practitioners (GP) have a gatekeeper role with respect to access 
to healthcare, but are paid a capitation fee, and don’t feed administrative data. 
Specialist encounters contracted with the healthcare system are recorded, but 
no diagnostic code is included in the record. The sensitivity of the algorithms 
detecting diagnoses of chronic diseases from hospital discharge records was 
expected to be low. Algorithms using outpatient drug prescriptions or other 
sources of information were expected to be poor in positive predictive value, 
as these services can be provided for multiple indications. Moreover, it was 
relevant to understanding to which extent the validity of the algorithms 
depended on features of the local organization of the healthcare system, as 
this would have hampered the interpretation of comparisons. 
The MATRICE Project, funded by the Italian Ministry of Health, was launched 
in 2011 by the Italian National Agency for Regional Healthcare Services 
(AGENAS), with the aim of defining methodologies and tools to best exploit 
administrative data for the purposes of monitoring quality of healthcare for 
patients with chronic diseases. Among other initiatives, the MATRICE Project 
funded this thesis.
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Research questions
The main research question of Part I of the thesis was: what are the optimal 
algorithms  to detect chronic diseases in the IAD, and what is the validity of 
estimates of compliance with standards of care? 
We split this main question in 5 specific questions.
1.  How do the prevalence estimates derived from finding cases of chronic 
diseases in IAD compare with estimates derived from other data sources?
2.  What is the validity of algorithms detecting chronic diseases and their level 
of severity from medical records of the General Practitioners?  
3.  What are the optimal case-finding algorithms in IAD to find cases of 
chronic diseases?
4.  How do estimates of compliance with standards of care derived from IAD 
compare with estimates derived from the Health Search (HSD), a database 
of medical records of the Italian College of General Practitioners?
5.  How do measures of compliance with standards of care derived from IAD 
compare with measures derived from the medical records of the General 
Practitioners?
Figure 1 shows the research questions and study designs of the five chapters in 
a graphical manner.
Ecological level
In this thesis we used a dataset of administrative data collected during a 
previous project of AGENAS.  Estimates of population prevalence of diabetes, 
ischaemic heart disease and chronic obstructive pulmonary disease could be 
obtained for five regions, and compared with the same parameters estimated 
from HSD and the national survey of the Italian Institute of Statistics (chapter 
1). In chapter 4 the same dataset and HSD could be used to estimate compliance 
with standards of care for the same three conditions.
Individual level
The results of chapter 1 set the stage for chapter 2. We tested our assumption 
that querying automatically medical records of GPs led to a result they would 
have considered accurate themselves. We tested both presence of disease 
42070 Rosa Gini.indd   17 04-09-16   19:33
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Table 2.  Summary of the studies in Part I of this thesis. IAD: Italian Administrative Databases. 
Variable to 
be validated
Study 
design
Data 
sources
Diseases Setting Year Chapter
Case-finding 
algorithm
Ecological 
comparison
between 
existing 
data
IAD, 
primary 
care medical 
records, 
national 
survey
Ischaemic heart 
disease, diabetes 
mellitus, heart 
failure, chronic 
obstructive 
pulmonary 
disease
Population samples 
from 5 Italian 
regions: Veneto, 
Emilia Romagna, 
Tuscany, Marche 
and Sicily
2009 1
Case-finding 
algorithm
Individual-
level 
manual 
validation
Primary 
care medical 
records, 
manual 
assessment 
Type 2 diabetes, 
hypertension, 
ischaemic heart 
disease and heart 
failure, with 
levels of severity
300 cases per 
disease, from 12 
GPs across Italy
2014 2
Case-finding 
algorithm
Individual-
level 
record-
linkage 
between 
existing 
data
IAD, 
primary 
care medical 
records
Type 2 diabetes, 
hypertension, 
ischaemic heart 
disease and heart 
failure
25 clusters of 
subjects, 5 per each 
of the following 
regions: Lombardy, 
Veneto, Emilia 
Romagna, Tuscany, 
Puglia
2012 3
Compliance 
with 
standards of 
care
Ecological 
comparison 
between 
existing 
data
IAD, 
primary 
care medical 
records
Ischaemic heart 
disease, diabetes 
mellitus, heart 
failure
Population samples 
from 5 Italian 
regions: Veneto, 
Emilia Romagna, 
Tuscany, Marche 
and Sicily
2009 4
Compliance 
with 
standards of 
care
Individual-
level 
record-
linkage 
between 
existing 
data 
IAD, 
primary 
care medical 
records
Type 2 diabetes, 
hypertension and 
ischaemic heart 
disease
25 clusters of 
subjects, 5 per each 
of the following 
regions: Lombardy, 
Veneto, Emilia 
Romagna, Tuscany, 
Puglia
2012 5
and their level of severity. This was the only traditional validation study in this 
thesis, and we used manual assessment by the GPs as a gold standard.
At the same time, we underwent the task of asking the National Privacy 
Authority permission to perform a record linkage, at an individual level, 
between IAD and medical records of 25 clusters of persons across the country, 
each counting almost 1,500 people and in charge to the same GP. When 
permission was granted we could perform the study as described in chapter 
3: we were able to  test a wide set of algorithms on IAD, considering GP 
medical records as a gold standard, for T2DM, hypertension and ischaemic 
heart disease (IHD). Moreover, in chapter 5, we used the same dataset to 
estimate compliance with standards of care for T2DM, hypertension and 
IHD in the same clusters, again comparing IAD with medical records. In this 
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case, medical records were not a gold standard. We could explore whether the 
cohorts detected by IAD were representative of the true cohorts, as long as 
compliance with standards of care was considered. 
Figure 1. Graphic representation of the research questions and study designs of the chapters in Part I. On 
the left columns: studies of validity of case-finding algorithms for chronic diseases. On the right column: 
studies validating estimates of compliance with standards of care. On the top row: ecological studies. On 
the lower two rows: individual level study. 
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INTRODUCTION TO PART II: VALIDITY OF VARIABLES IN 
MULTI-DATABASE STUDIES
In 2004, after five year of widespread use, the anti-inflammatory drug rofecoxib 
was withdrawn from the market due to severe safety concerns. It was estimated 
that if a monitoring system had been in place querying the medical records of 100 
million patients, the adverse cardiovascular effect would have been discovered 
in just few months. After this episode, networks of researchers with regular 
access to observational healthcare data sources have been created. Methods 
and procedures have been generated to execute studies in a distributed fashion, 
to take advantage both from size and from diversity of the populations they 
could merge [Trifiro2014]. Those advantages come at the price that the level of 
complexity in deriving study variables scales up, because all the characteristics 
that have an impact on validity may be different across sites.
This is especially true in Europe: diversity in local mechanisms of data collection 
is a consequence of the diversity among European countries in language, 
culture, political and health care organization. Notwithstanding, cross-border 
evidence is necessary to address common questions such as efficacy and safety 
of medical products and vaccines, or comparison of quality of health care. 
Part II of this thesis was devoted to investigate the process adopted by some 
existing networks to derive the study variables in each site and address their 
validity, and to propose and test a novel methodology to streamline this process.
Research questions
The main research question of Part II was: how do networks of databases handle 
the process of generating study variables in the different sites, and how do they 
assess their validity?
42070 Rosa Gini.indd   20 04-09-16   19:33
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We split the question in two parts.
6.  How is the derivation of study variables organized in existing data networks 
in Europe and in the United States?
7.  How can a network of diverse data sources in Europe streamline the 
process of data derivation?
In chapter 6 we introduced a conceptual framework representing the main data 
processing steps that a network needs to organize, and we used this framework 
to compare four case studies: the Italian MATRICE network, the European EU-
ADR network, the OMOP and Mini-Sentinel networks from the United States. 
In particular we investigated how diversity in original data was documented 
and how the data derivation process was structured in the four networks.
In 2013 the Innovative Medicines Initiative, a joint undertaking between the 
European Union and the pharmaceutical industry association EFPIA, funded 
the European Medical Information Framework Project (EMIF), aimed to 
develop common technical and governance solutions and improve access and 
use of health data across Europe.
In chapter 7 we described a novel workflow introduced by EMIF to derive study 
variables, and to exploit diversity across data sources to obtain evidence on their 
validity. We applied the procedure to the case of type 2 diabetes mellitus in 8 
European data sources. The Tuscan instance of Italian administrative databases 
and HSD were among the data sources involved in this study. 
In the discussion at the end of this thesis the findings from this Italian validation 
Odyssey will be described and possibilities for generalization to other big-data 
settings that aim for the creation of local intelligence, will be reflected upon.
42070 Rosa Gini.indd   21 04-09-16   19:33
22
REFERENCES
[Altman1994] Altman DG, Bland JM. Statistics Notes: Diagnostic tests 1: sensitivity and specificity. BMJ. 
1994;308(6943):1552.
[Altman1994b] Altman DG, Bland JM. Diagnostic tests 2: Predictive values. BMJ. 1994;309(6947):102.
[AMD-SID2014] Italian Diabetologist Association, Italian Society for Diabetology. [Italian standards 
for treatment of diabetes mellitus] [In Italian].  http://www.standarditaliani.it/skin/www.
standarditaliani.it/pdf/STANDARD_2014_May28.pdf 
[Amed2011] Amed S, Vanderloo SE, Metzger D, Collet J -P, Reimer K, McCrea P, et al. Validation of 
diabetes case definitions using administrative claims data. Diabetic Medicine. 2011;28(4):424–7.
[Benchimol2011] Benchimol EI, Manuel DG, To T, Griffiths AM, Rabeneck L, Guttmann A. Development 
and use of reporting guidelines for assessing the quality of validation studies of health administrative 
data. Journal of Clinical Epidemiology. 2011;64(8):821–9. 
[Benchimol2015] Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, et al. The 
REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) 
Statement. PLOS Medicine. 2015;12(10):e1001885.
[Bowker2015] Bowker SL, Savu A, Lam NK, Johnson JA, Kaul P. Validation of administrative data case 
definitions for gestational diabetes mellitus. Diabet Med. 2015
[Carnahan2012] Carnahan RM. Mini-Sentinel’s systematic reviews of validated methods for identifying 
health outcomes using administrative data: summary of findings and suggestions for future 
research. Pharmacoepidemiology and Drug Safety. 2012;21:90–9.
[Cutrona2013] Cutrona SL, Toh S, Iyer A, Foy S, Daniel GW, Nair VP, et al. Validation of acute myocardial 
infarction in the Food and Drug Administration’s Mini-Sentinel program. Pharmacoepidemiol 
Drug Saf. 2013;22(1):40–54.
[Ferretti2009] Ferretti S, Guzzinati S, Zambon P, Manneschi G, Crocetti E, Falcini F, et al. [Cancer 
incidence estimation by hospital discharge flow as compared with cancer registries data] [In 
Italian]. Epidemiol Prev.2009;33(4–5):147–53.
[GarciaRodriguez2010] García Rodríguez LA, Ruigómez A. Case validation in research using large 
databases. Br J Gen Pract. 1 2010;60(572):160–1.
[Gorina2011] Gorina Y, Kramarow EA. Identifying Chronic Conditions in Medicare Claims Data: 
Evaluating the Chronic Condition Data Warehouse Algorithm. Health Services Research. 
2011;46(5):1610–27.
[Greenland1996] Greenland S. Basic methods for sensitivity analysis of biases. Int J Epidemiol. 
1996;25(6):1107–16.
[Hernan2011] Hernan MA. With great data comes great responsibility: publishing comparative 
effectiveness research in EPIDEMIOLOGY. Epidemiology. 2011;22(3):290–1.
[Herret2013] Herrett E, Shah AD, Boggon R, Denaxas S, Smeeth L, Staa T van, et al. Completeness and 
diagnostic validity of recording acute myocardial infarction events in primary care, hospital care, 
disease registry, and national mortality records: cohort study. BMJ. 2013;346:f2350.
[John2016] John A, McGregor J, Fone D, Dunstan F, Cornish R, Lyons RA, et al. Case-finding for common 
mental disorders of anxiety and depression in primary care: an external validation of routinely 
collected data. BMC Med Inform Decis Mak. 2016
[Lanes2015] Lanes S, Brown JS, Haynes K, Pollack MF, Walker AM. Identifying health outcomes in 
healthcare databases. Pharmacoepidemiol Drug Saf. 2015;24(10):1009–16.
[Lanes2015b] Lanes S, Esposito D. Case ascertainment in electronic data bases: Where’s Waldo? 
Community Meeting at Innovation in Medical Evidence Development and Surveillance (IMEDS). 
July 2015. http://imeds.reaganudall.org/sites/default/files/IMEDS_Outline_Dv8.pdf
[Kahn2010] Khan NF, Harrison SE, Rose PW. Validity of diagnostic coding within the General Practice 
Research Database: a systematic review. Br J Gen Pract. 2010;60(572):e128–36.
[Lix2008] Lix LM, Yogendran MS, Shaw SY, Burchill C, Metge C, Bond R. Population-based data sources 
for chronic disease surveillance. Chronic Dis Can. 2008;29(1):31–8.
42070 Rosa Gini.indd   22 04-09-16   19:33
GENERAL INTRODUCTION
23
[Lix2008b] Lix LM, Yogendran MS, Leslie WD, Shaw SY, Baumgartner R, Bowman C, et al. Using 
multiple data features improved the validity of osteoporosis case ascertainment from administrative 
databases. Journal of Clinical Epidemiology. 2008;61(12):1250–60.
[Mooney2015] Mooney SJ, Westreich DJ, El-Sayed AM. Commentary: epidemiology in the era of big data. 
Epidemiology. 2015;26(3):390–4.
[Morley2014] Morley KI, Wallace J, Denaxas SC, Hunter RJ, Patel RS, Perel P, et al. Defining Disease 
Phenotypes Using National Linked Electronic Health Records: A Case Study of Atrial Fibrillation. 
PLoS ONE. 2014;9(11):e110900.
[Nosyk2013] Nosyk B, Colley G, Yip B, Chan K, Heath K, Lima VD, et al. Application and Validation 
of Case-Finding Algorithms for Identifying Individuals with Human Immunodeficiency Virus 
from Administrative Data in British Columbia, Canada. Medeiros R, curatore. PLoS ONE. 
2013;8(1):e54416.
[OECD2015] OECD. OECD Reviews of Health Care Quality. Italy 2014: Raising Standards. OECD 
Publishing; 2015.
[Quan2009] Quan H, Khan N, Hemmelgarn BR, Tu K, Chen G, Campbell N, et al. Validation of a Case 
Definition to Define Hypertension Using Administrative Data. Hypertension. 2009;54(6):1423–8.
[Quantin2013] Quantin C, Benzenine E, Velten M, Huet F, Farrington CP, Tubert-Bitter P. Self-
controlled case series and misclassification bias induced by case selection from administrative 
hospital databases: application to febrile convulsions in pediatric vaccine pharmacoepidemiology. 
Am J Epidemiol. 2013;178(12):1731–9.
[Rahimi2014] Rahimi A, Liaw S-T, Taggart J, Ray P, Yu H. Validating an ontology-based algorithm to 
identify patients with Type 2 Diabetes Mellitus in Electronic Health Records. International Journal 
of Medical Informatics. 2014;83(10):768–78.
[Ray2011] Ray WA. Improving Automated Database Studies: Epidemiology. 2011;22(3):302–4.
[Reich2012] Reich C, Ryan PB, Stang PE, Rocca M. Evaluation of alternative standardized terminologies 
for medical conditions within a network of observational healthcare databases. J Biomed Inform. 
2012;45(4):689–96.
[Trifiro2014] Trifirò G, Coloma PM, Rijnbeek PR, Romio S, Mosseveld B, Weibel D, et al. Combining 
multiple healthcare databases for post-marketing drug and vaccine safety surveillance: why and 
how? J Intern Med. 2014
[Valkhoff2014] Valkhoff VE, Coloma PM, Masclee GMC, Gini R, Innocenti F, Lapi F, et al. Validation 
study in four health-care databases: upper gastrointestinal bleeding misclassification affects 
precision but not magnitude of drug-related upper gastrointestinal bleeding risk. Journal of Clinical 
Epidemiology. 2014;67(8):921–31.
[Whiting2003] Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J. The development of QUADAS: 
a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. 
BMC Medical Research Methodology. 2003;3:25.
42070 Rosa Gini.indd   23 04-09-16   19:33
42070 Rosa Gini.indd   24 04-09-16   19:33
PART I
VALIDATION OF VARIABLES DEFINING CHRONIC 
DISEASES AND COMPLIANCE WITH STANDARDS 
OF CARE IN ITALIAN ADMINISTRATIVE 
DATABASES
42070 Rosa Gini.indd   25 04-09-16   19:33
42070 Rosa Gini.indd   26 04-09-16   19:33
CHAPTER 
Chronic disease prevalence from Italian 
administrative databases in the VALORE project: 
a validation through comparison of population 
estimates with general practice databases and 
national survey
Rosa Gini 1,2, Paolo Francesconi 2, Giampiero Mazzaglia 3, Iacopo Cricelli 4, 
Alessandro Pasqua 3, Pietro Gallina 5, Salvatore Brugaletta 6, 
Daniele Donato 5, Andrea Donatini 7, Alessandro Marini 8, Carlo Zocchetti 9, 
Claudio Cricelli 3, Gianfranco Damiani 10, Mariadonata Bellentani 11, 
Miriam CJM Sturkenboom 2 and Martijn J Schuemie 2
1. Agenzia regionale di sanità della Toscana, Osservatorio di epidemiologia; 
50141 Florence, Italy
2. Department of Medical Informatics, Erasmus Medical Center; 
3015 GJ Rotterdam, The Netherlands
3. Health Search, Italian College of General Practitioners and Primary Care; 
50100 Florence, Italy 
4. Genomedics; 50100 Florence, Italy
5. ULSS 16 Padova, Via Enrico Degli Scrovegni 14, 35131 Padua, Italy. 
6. ASP 7 Ragusa, Piazza Igea 1, 97100 Ragusa, Italy. 
7. Assessorato Politiche per la Salute, Viale Aldo Moro 21, 40127 Bologna, Italy. 
8. Zona Territoriale Senigallia, Via Piero della Francesca 14, 60019 Senigallia (AN), Italy. 
9. Regione Lombardia, Piazza Città di Lombardia 1, 20124 Milan, Italy. 
10. Università Cattolica del Sacro Cuore, Largo Francesco Vito 1, 00198 Rome, Italy. 
11. Agenzia Nazionale per i Servizi Sanitari Regionali; 00100 Rome, Italy
Published in
Gini et al. BMC Public Health 2013, 13:15
http://www.biomedcentral.com/1471-2458/13/15
42070 Rosa Gini.indd   27 04-09-16   19:33
Chapter 1
28
ABSTRACT
Background 
Administrative databases are widely available and have been extensively used to 
provide estimates of chronic disease prevalence for the purpose of surveillance 
of both geographical and temporal trends. There are, however, other sources of 
data available, such as medical records from primary care and national surveys. 
In this paper we compare disease prevalence estimates obtained from these 
three different data sources.
Methods
Data from general practitioners (GP) and administrative transactions for health 
services were collected from five Italian regions (Veneto, Emilia Romagna, 
Tuscany, Marche and Sicily) belonging to all the three macroareas of the 
country (North, Center, South). Crude prevalence estimates were calculated 
by data source and region for diabetes, ischaemic heart disease, heart failure 
and chronic obstructive pulmonary disease (COPD). For diabetes and COPD, 
prevalence estimates were also obtained from a national health survey. When 
necessary, estimates were adjusted for completeness of data ascertainment.
Results
Crude prevalence estimates of diabetes in administrative databases (range: from 
4.8% to 7.1%) were lower than corresponding GP (6.2%-8.5%) and survey-based 
estimates (5.1%-7.5%). Geographical trends were similar in the three sources 
and estimates based on treatment were the same, while estimates adjusted for 
completeness of ascertainment (6.1%-8.8%) were slightly higher. For ischaemic 
heart disease administrative and GP data sources were fairly consistent, with 
prevalence ranging from 3.7% to 4.7% and from 3.3% to 4.9%, respectively. In the 
case of heart failure administrative estimates were consistently higher than GPs’ 
estimates in all five regions, the highest difference being 1.4% vs 1.1%. For COPD 
the estimates from administrative data, ranging from 3.1% to 5.2%, fell into the 
confidence interval of the Survey estimates in four regions, but failed to detect 
the higher prevalence in the most Southern region (4.0% in administrative 
data vs 6.8% in survey data). The prevalence estimates for COPD from GP data 
were consistently higher than the corresponding estimates from the other two 
sources.
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Conclusion
This study supports the use of data from Italian administrative databases to 
estimate geographic differences in population prevalence of ischaemic heart 
disease, treated diabetes, diabetes mellitus and heart failure. The algorithm for 
COPD used in this study requires further refinement.
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BACKGROUND
Administrative healthcare data are collected by privately owned health 
maintenance organisations or governmentrun institutions for managerial 
reasons. Due to differences in healthcare systems, the content of the 
administrative data may vary from country to country. They may contain records 
collected at hospital discharge, during encounters with the general practitioner 
(GP) or specialist, at drug prescription or dispensation, or upon request for, or 
conduct of, a diagnostic analysis or procedure. The content also depends on the 
choices of the organisation: data may or may not contain diagnosis codes; drug 
prescriptions may or may not contain indication of use, data from laboratories 
may or may not contain the actual result.
Secondary use of administrative healthcare data has been increasing over the 
years, including the provision of prevalence estimates for chronic diseases 
[1], such as diabetes mellitus, chronic obstructive pulmonary disease (COPD), 
hypertension, ischaemic heart disease, cerebrovascular disease, and depression. 
Case finding and ascertainment algorithms are tailored to the structure and 
type of information that is captured in the specific administrative database. 
Sensitivity and specificity of such algorithms are conditioned on distinguishing 
features such as presence of drug dispensing as well as sources for diagnostic 
codes. The Canadian [2], Swedish [3] and Medicare [4] administrative databases, 
for example, contain diagnosis codes from hospitalization episodes as well as 
from outpatient care, hence enriching the data for estimation of chronic disease 
prevalence. In settings where outpatient care diagnoses are not available, other 
solutions have been explored. For instance, in Luxembourg and France, where 
only drug prescriptions are available, diabetes could be identified in treated 
patients by analysing the volume of prescriptions for anti-diabetic drugs [5].
Observational studies based on administrative databases need careful validation 
of the algorithms they rely on in order to provide sound epidemiologic 
research [6]. Validation of chronic disease case ascertainment algorithms has 
been performed either through direct [7] or indirect [8] clinical assessment or 
through individual record linkage with other electronic data sources, such as 
disease registries [9] or health surveys [4,10]. When individual record linkage 
with non-administrative data sources was not feasible, the performance of 
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the algorithms has been inferred though external comparison with prevalence 
estimates obtained from health surveys [5,11]. Italy has a tax-based, universal 
coverage national health system organised in three levels: national; regional 
(21 regions); and local (on average 10 local health units per region) [12]. 
Administrative data on healthcare reimbursed by the system, such as inpatient 
care and drug dispensations, are routinely collected by local health units and, 
in some regions, sent to the regional level. Transmission to the national level is 
obligatory, and a common data model for data transmission is mandated by law 
on a national level. Before data are sent to the national level, however, unique 
personal identifiers are removed, hence record-linkage cannot be performed 
outside a single region. The Italian administrative databases therefore form a 
virtual national information system, with homogeneous data collected at the 
local level. Actual databases allowing record-linkage only exist up to the regional 
level. Data on diagnosis collected in outpatient settings are not part of the Italian 
administrative databases, therefore algorithms for case ascertainment developed 
in other countries that make use of this information cannot be applied to the 
Italian situation. Several studies have investigated the comparison between 
chronic disease prevalence estimates from Italian administrative data and other 
Italian data sources [11,13]. However studies to date were only performed within 
local or regional databases. Capture–recapture technique, a more sophisticated 
analysis aimed at estimating a suspected underascertainment when more than 
two lists of cases are available [14,15], was applied as well in estimating diabetes 
prevalence from administrative databases, in specific geographic areas of the 
country [16,17]. In light of the strong difference in health and healthcare quality 
across Italy [18] it is relevant to understand whether administrative databases 
can support chronic disease prevalence surveillance in different areas of the 
country.
In 2010 the Italian national project VALORE was launched aimed at assessing 
quality of care for chronic diseases in five different Italian regions, based on 
secondary use of data from administrative databases. In this study we describe 
prevalence estimates for diabetes mellitus, heart failure, ischaemic heart 
disease and COPD from these data and compare the estimates with prevalence 
estimates obtained from a national GP electronic medical record database and, 
where possible, from a national health survey.
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METHODS
Setting
The five regions which contributed data to the VALORE study were: Veneto (A, 
Northern Italy), Emilia Romagna (B, Northern Italy), Tuscany (C, Central Italy), 
Marche (D, Central Italy) and Sicily (E, Southern Italy). The following data files 
were used in the VALORE project: 
•	 	Hospital discharge records with one main and five secondary diagnoses 
coded using the International Classification of Diseases, Ninth Revision, 
Clinical Modification (ICD9CM);
•	 	Drug dispensing records coded using Anatomic Therapeutic Chemical 
(ATC) codes for drug classification; the ATC system is the drug classification 
system adopted by the World Health Organization [19];
•	 	Disease-specific exemptions from copayment to health care coded using 
ICD9CM;
•	 	Inhabitant Registry (IR) with demographic information (birthyear, gender) 
and identifier of the GP in charge.
In each region, record-linkage within and between data files was done 
deterministically with a unique coded personal identifier. Region B could not 
provide the file of exemptions from copayment. For organizational reasons, the 
regions participating in the VALORE project did not provide administrative data 
of the whole regional population, but only of specific geographical subareas. In 
each region raw data were extracted from the local data files and sent via File 
Transfer Protocol (FTP) to a single data management center, after anonymization 
of the coded personal identifier. A standardized automated routine was developed 
in Stata 9.2 to apply the case ascertainment algorithm and to calculate the 
prevalence estimates. Each regional sample consisted of all inhabitants registered 
in the selected geographical subareas and alive at the index date (January 1st 2009).
Case ascertainment
The case finding and ascertainment algorithms that were used to detect the 
specific diseases are shown in Table 1. Regional administrative databases link 
Hospital discharge records (HOSP), Drug dispensation records (DRUG), and 
Disease-specific exemptions (EXE) from 2003 to 2008, and a patient was 
classified as having the selected disease if at least one of the corresponding 
conditions listed in Table 1 were met, i.e. condition 1 OR condition 2 OR 
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condition 3. For 93% of the population, the full six years of follow-up data were 
available and were included in the analysis.
Diverse algorithms for diabetes, COPD and ischaemic heart disease case 
ascertainment from Italian administrative databases have been previously 
described in theliterature. Those published in Simonato et al. [20] were the result 
of a workgoup involving two Italian scientific associations of epidemiologists and 
biostatisticians, and were therefore adopted. However, to deal with a previously 
reported issue of lack of sensitivity, the algorithm for COPD was enriched with 
drug dispensing data [21]. In addition we also calculated a prevalence estimate 
of diabetes based on anti-diabetic treatment alone. The heart failure algorithm 
was defined in the VALORE project.
Comparison data
The Health Search Database (HSD) collects electronic medical record data from 
a network of Italian GPs who are members of the Italian College of General 
Practitioners [22]. The GPs participating in HSD all use the same information 
software, in which they record demographic information, visits and referrals, 
diagnoses (both in free text and ICD9CM codes), drug prescriptions and clinical 
information. For this study, data from 199 GPs practicing in one of the five 
regions of the VALORE project were used. The study population comprised 
patients aged 16- 95 who had been enrolled for at least two years and were 
alive on 1st January 2009. Prevalence estimates were calculated based on the 
number of patients enrolled with the GPs at the index date (January 1st 2009) 
as denominator. The numerator represented all cases with specific diseases as 
ascertained through a query in the PROBLEM field of the clinical database, 
where diagnoses are coded. The diagnosis codes are shown in Table 1.
The Italian National Health Survey is conducted every five years by the National 
Institute of Statistics (ISTAT). In addition, there is a yearly survey that captures 
relevant health-related issues, and in particular diabetes and COPD. The 2008 
survey in the five regions of the VALORE study comprised 11,656 people aged 
16 years and above. The survey sample was extracted according to a two-stage 
weighted cluster sampling design (first level: municipalities; second level: 
families). Answers to two questions were used for this study: Are you affected 
by one or more of the following chronic diseases? Diabetes (Yes/No) Chronic 
bronchitis, emphisema, repiratory failure (Yes/No). Questions about heart 
failure and ischaemic heart disease were not asked.
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Data analysis
Administrative data provided estimates of prevalence in three different ways: 
(1) analysis of distribution of prevalence per GP practices; (2) pooled analysis; 
(3) capturerecapture analysis. While (2) and (3) provided estimates that could 
be compared with the regional estimates from the other two data sources, it 
must be noted that as the population sample from each regional population 
is not random, but rather geographically restricted, it was expected that 
the comparison was biased. The rationale for analysis (1) was therefore the 
following: as both administrative and GP data could be aggregated per practice 
and as practices could be considered to be (non randomly) sampled from the 
same population of regional practices, if the two measurement techniques 
(administrative versus GP data) did measure in fact the same population 
parameter it was expected that the pairs of regional distributions overlapped 
and distributions within the same region were more similar to each other than 
distributions within the same data source.
All the analyses refer to the population aged≥16 years, both male and females, 
although in the GP database ages above 95 were truncated. Sex and age 
distribution of each regional sample were computed. The percentage of the 
regional population covered by the sample was estimated by dividing its number 
by the estimates of the regional population according to the National Institute 
of Statistics [23]. Prevalence was estimated as the total number of existing cases 
divided by the number of subjects in the sample. Every adult Italian inhabitant 
is entitled to choose a GP, and GPs may accept a maximum of 1,500 patients 
[12]. For each GP the population registered with that GP at the index date was 
calculated and used as denominator for the prevalence estimates. Median and 
interquartile (IQ) range of this distribution was computed in each regional 
sample. To avoid spurious results the disease prevalence per GP practice was 
computed only for those practices who had at least 300 people enrolled and at 
least 4 patients with the disease.
In the Health Search Database the same prevalence measures were estimated, 
the sample being the number of inhabitants in charge of the GPs of HSD at 
the index date. From the National Health Survey the variable of the first-level 
sampling design (municipalities) was not available, hence simple weighted 
analysis was performed, with probability weight attributed to each individual. 
Finally, to ascertain the degree of completeness in capturing diabetes cases from 
administrative data, a capturerecapture analysis was performed. Log-linear 
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models were estimated by sequentially incorporating pair-wise dependency 
between sources, andmodel selection was based on the Akaike information 
criterion (AIC) criterion. This was not done for region B, where only two sources 
of data were available, since independence between two data sources could not 
be assumed [15].
All analyses were performed with Stata 9.2.
Table 1. Case ascertainment algorithms for diabetes, ischaemic heart disease, heart failure and COPD
Disease Administrative data GP data
HOSP (ICD9CM) + DRUG 
(ATC)++
EXE (ICD9CM) PROBLEM (ICD9CM)
Diabetes mellitus 250* A10 250 250*
Treated diabetes A10 250* AND A10 ++++
Ischaemic heart 
disease
410-*414* C01DA 414 410-*414*
Heart failure 428*, 40201, 40211, 
40291, 40401, 40403, 
40411, 40413, 40491, 
40493
- 428 428*, 40201, 40211, 
40291, 40401, 40403, 
40411, 40413, 40491, 
40493
COPD 490*-492*, 494*, 
496*
R03 +++ - 490*-492*, 494*, 
496*
+ Either in main or in one of the secondary diagnoses
++ At least two dispensations in different dates in a single year
+++ A specific algorithm involving number, heterogeneity of ATC codes and time span of dispensations 
is used, see [Anecchino2007]
++++ Patients having at least 2 prescriptions in one of the previous 2 years
Ethical approval
No identifiable human data were used for this study. The dataset used in the 
study is not openly available. Permission to use non-identifiable, individual data 
extracted from administrative databases for the VALORE project was granted 
by ULSS 16 Padova, ASP 7 Ragusa, Assessorato Politiche per la Salute Emilia 
Romagna, Zona Territoriale Senigallia, which are responsible for the use of 
the data of the corresponding populations. Agenzia regionale di sanit`a della 
Toscana is enabled by a regional law to use Tuscan data for research purposes. 
Approval for use of encrypted and aggregated data from the HSD was also 
obtained from the Italian College of General Practitioners. Data from the 
National Health Survey are openly available from ISTAT.
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RESULTS
The subpopulations whose data were collected covered a percentage of the 
total population of the regions, as shown in Table 2. The age distribution of 
the three population samples in the five regions is shown in Figure 1. There 
were some differences in age distribution between the populations from the 
different sources (see Figure 1). The prevalence estimates in the five regions 
from the three sources are shown in Figure 2 and Table 3. Administrative 
data underestimated the prevalence of diabetes as compared to both GP and 
survey estimates across most regions although differences were often barely 
or non significant and the increasing North-South trend could be consistently 
observed in the three sources. Adjustement for underascertainment led to 
higher estimates with respect to both GP and Survey figures, except in one 
region. The width of the interquartile range (IQ) of the practice-level estimates 
was higher in GP data than in administrative databases. When prevalence 
of diabetes was estimated based only on diabetes treatment, the prevalence 
Figure 1. Age distribution in each region from each data source. Age distribution in each region of the 
sample extracted from administrative databases (Admin), of the sample extracted from clinical data 
collected by GPs participating to the Health Search Database (GP) and of the sample participating to the 
National Health Survey (Surv).
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Figure 2. Prevalence estimates for diabetes mellitus, treated diabetes, ischaemic heart disease, heart 
failure and COPD from each data source. Crude prevalence estimates for diabetes mellitus, treated 
diabetes, ischaemic heart disease, heart failure and COPD in 5 Italian regions, according to administrative 
data (Admin) and clinical GP data (GP) and, for diabetes and COPD only, the National Health Survey 
(Sur). For diabetes mellitus estimates from administrative data adjusted for ascertainment are also 
presented (Rec). On the left column prevalence is represented by box plots of the distribution of the 
disease prevalence in GP practices: the central line is the median value, the box covers the interquartile 
range, while wiskers range from a minimum to a maximum value except for some observations which 
are detected as outliers and are representes as single dots or diamonds; comparison is only between GP 
and Admin data sources. On the right column prevalence is represented as global estimate. Date: 1 
January 2009 Population: male and females, aged 16+.
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estimates obtained from GP data were fairly consistent with those obtained 
from administrative data in all regions; the width of the IQ range of the practice 
estimates was similar between GP data and administrative data in all regions.
The prevalence of ischaemic heart disease, as estimated using administrative 
data, was similar to that estimated using GP data, prevalence ranging from 3.3% 
(region A, source GP) to 4.9% (region B, source GP). The width of the IQ range 
was similar between GP data and administrative data in all regions.
The prevalence estimates for heart failure were lower in GP data than in 
administrative data in three regions, with the highest difference (1.1% vs 1.4%) 
observed in both regions A and C, where significance was observed as well. 
According to age-specific prevalence estimates shown in Figure 3, the difference 
in estimates were increasing with age. The width of IQ range of the practice 
estimates was higher for GP data in three regions. The prevalence estimates 
from administrative data for COPD in regions A to D fell within the confidence 
interval of the survey estimates and ranged from 3.8% (region A) to 4.9% (region 
D), but failed to detect the higher prevalence in Region E (4.0% in administrative 
data vs 6.8% in survey data). The estimates from GP data were consistently 
higher, ranging from 6.4% (region A) to 9.1% (region E), and detected the 
same increased prevalence in region E. The width of IQ range of the practice 
estimates was much higher for GP data. In all diseases the width of the IQ range 
of the practice estimates were fairly consistent across regions in administrative 
data. Mean and medians were pretty close in both sources and all regions, and, 
except for outliers, distributions were rather symmetric, although in GP data 
data the distribution was slightly skewed to the right for diabetes and COPD.
Table 2. Characteristics of the subpopulations of each region covered, respectively, by administrative or 
GP data. Data on general population from the Italian National Institute of Statistics. Analysis is restricted 
to inhabitants aged 16+
Region Population aged 
16+ (millions)
Administrative data coverage GP data coverage
N GPs N patients % pop N GPs N patients % pop
A 4.2 140 167,805 4.0 51 70,301 1.7
B 3.7 625 840,546 22.5 41 60,590 1.6
C 3.2 511 498,084 15.5 29 36,908 1.1
D 1.3 57 63,125 4.7 18 24,912 1.8
E 4.2 231 264,902 6.3 60 84,483 2.0
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Figure 3. Age-specific prevalence of heart failure. Age-specific prevalence of heart failure in 5 Italian 
regions, according to administrative data (Admin) and clinical GP data (GP). Date: 1 January 2009 
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DISCUSSION
Overall, differences in prevalence estimates among the different sources in a 
region were lower than the differences between regions, and differences observed 
among regions were similar across data sources. The fact that independent 
sources of data showed consistent values across different regions supports the 
claim that they correspond to actual populationmeasures. In case systematic 
differences were observed, they could be interpreted as being due to differences 
in data collection and associated to demographic and disease characteristics. 
This provides evidence that administrative data actually measure a population 
phenomenon that can be interpreted and supports the use of administrative 
data for surveillance of geographical trends of the diseases in study, with the 
possible exception of COPD.
In the case of diabetes mellitus, the observed concordance between estimates 
from GP data and from survey data confirms previous reports [24,25]. Estimates 
from GP data were systematically higher than estimates from administrative 
data. According to reports from other countries [26], the difference is likely to be 
due to the proportion of patients who, although being diagnosed with diabetes 
to the knowledge of their GPs, have mild or well-controlled disease and thus 
have never had either a hospital admission or a prescription for antidiabetic 
drugs, and have not received an exemption from copayment of diabetes-related 
healthcare, therefore escaping the algorithm for administrative databases. 
Indeed, when the subset of patients undergoing therapy with antidiabetics in 
the previous two years were extracted from both administrative and GP data 
sources, the pairs of prevalence estimates almost coincided in all of the regions, 
with one exception. Estimates adjusted for completeness of ascertainment, on 
the other hand, provided slightly higher estimates, a finding consistent with a 
previous study with similar data in another Italian area [16].
Ischaemic heart disease being congruently estimated by administrative and GP 
data in all of the regions is an unexpected finding. Angina, a less severe form 
of the disease, does not lead per se to a hospital admission, and few cases (less 
than 5%) are detected by the registry of exemptions from copayment. As around 
30% of cases are detected only by dispensings of nitrates (data not shown), we 
observe that nitrates therapy is probably specific in detecting cohorts bearing 
this condition, as otherwise data would have been less consistent across regions 
in matching the diagnosis-based figures from GP clinical databases. Heart failure 
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was underestimated by GP data, although non significantly in the majority of the 
regions. Underestimation was highest in the oldest age band available in both 
data sources (85-95), where the prevalence is highest. This is consistent with the 
hypothesis that GPs belonging to HSDmight occasionally performless accurate 
data collection when visiting patients at home [27] or in residential care [22], or 
consider heart failure as a complication of other underlying conditions, such as 
ischaemic heart disease, rather than as a disease of its own. This would imply 
that the population detected by administrative data had a more severe form of 
the disease and was more often affected by disability. Another possibility is that 
administrative database overestimate prevalence because of lack of specificity 
of the case ascertainment algorithm. Indeed, according to a recent review of 
validated algorithms for case ascertainment of heart failure [28], algorithms 
using secondary discharge diagnosis showed lower positive predictive value 
(PPV) in several countries.
For COPD administrative data failed to detect the differences between regions 
that the other two sources consistently measured. Ascertainment of COPD from 
administrative sources has been shown to be challenging in other studies [29,30]. 
In this case, the algorithm detected a particular pattern of drug prescriptions, 
combining duration, intensity and ATC class, that had been identified through 
a consensus process in a group of experts that was reported in Anecchino et al. 
[21]. Although the pattern was specifically meant to avoid misclassification (e.g., 
with respect to asthma), it is possible that the conclusions of the study were in 
fact specific for the geographic area where the experts worked. In light of the 
limitations of the sampling design of our study, the overall good agreement with 
other data sources supports a fortiori validity of chronic disease surveillance using 
administrative data in the regions that were involved in the study. However, 
support for external validity of our results needs to be discussed. Althought we 
only collected data from few geographical areas, the same administrative data 
are available for the whole national population. We are in fact not claiming 
that administrative data from few geographically sparse areas can be used to 
estimate national prevalence of chronic diseases, but rather that administrative 
data seem to be consistently able to detect prevalence of some chronic diseases 
around the area they were extracted from. Our positive findings (treated diabetes, 
ischaemic heart disease, heart failure) are indeed probably due to the fact that 
typical health consumption patterns of such chronic patients are similar across 
regions. On the assumption that regions of the same macroarea of the country 
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(North, Center, South) are similar the one to the other to this respect, our data 
support the claim that estimates relying on the same algorithms should prove 
to be similarly effective. However, in some specific critical areas of the country 
where incomplete administrative data collection is suspected, a local evaluation 
is recommended.
Cohorts can be selected from administrative databases to perform population-
based studies on patients with chronic diseases through further record-linkage 
with the same databases. This study cannot provide analytical tools to assess 
the limitations of the findings of such studies. However, no evidence emerges 
for major bias, except in the case of COPD, where regional differences with the 
other data sources are likely to be due to differences in the characteristics of the 
corresponding local cohorts.
Limitations
The first limitation of studies that make secondary use of existing healthcare 
data sources is that only prevalence of diagnosed cases is taken into account, 
and underestimation of actual population prevalence cannot be estimated [31].
An implicit assumption of both crude and adjusted rate estimation from 
administrative databases performed in this study was that PPV of the case 
detection was 100%, an assumption that we could not verify and that is not 
to be taken for granted, when, for instance, secondary discharge diagnosis or 
drug utilisation with no indication is used as a source of case ascertainment. 
Ecological validation studies cannot directly resolve this issue, as consistent 
ecological estimates between a data source and a reference gold standard 
might as well be due to coincidental inclusion of false positive and exclusion 
of false negative cases. Only validation studies perfomed using individual-level 
comparison with a gold standard could assess PPV and sensitivity.
CONCLUSION
This study supports the use of data from Italian administrative databases to 
estimate geographic differences in population prevalence of ischaemic heart 
disease, treated diabetes, diabetes mellitus and heart failure. The algorithm for 
COPD used in this study requires further refinement.
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ABSTRACT
Objectives
The Italian project MATRICE aimed to assess how well cases of type 2 diabetes 
(T2DM), hypertension, ischaemic heart disease (IHD) and heart failure (HF) and 
their levels of severity can be automatically extracted from the Health Search/
CSD Longitudinal Patient Database (HSD). From the medical records of the 
general practitioners (GP) who volunteered to participate, cases were extracted 
by algorithms based on diagnosis codes, keywords, drug prescriptions and 
results of diagnostic tests. A random sample of identified cases was validated by 
interviewing their GPs.
Setting
HSD is a database of primary care medical records. A panel of 12 GPs participated 
in this validation study.
Participants
300 patients were sampled for each disease, except for HF, where 243 patients 
were assessed.
Outcome measures
Positive predictive value (PPV) was assessed for the presence/absence of each 
condition against the GP’s response to the questionnaire, and Cohen’s kappa 
was calculated for agreement on the severity level.
Results
The PPV was 100% [99-100] for T2DM and hypertension, 98% [96-100] for IHD 
and 55% [49-61] for HF. Cohen’s kappa for agreement on the severity level was 
0.70 for T2DM and 0.69 for both hypertension and IHD.
Conclusions
This study shows that subjects with T2DM, hypertension or IHD can be validly 
identified in HSD by automated identification algorithms. Automatic queries 
for levels of severity of the same diseases compare well with the corresponding 
clinical definitions, but some misclassification occurs. For HF further research 
is needed to refine the current algorithm.
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Italy is facing an increasing burden of chronic health conditions due to aging 
of the population. To provide adequate and fair health care across regions Italy 
was advised by the Organisation for Economic Co-operation and Development 
to develop a set of standards around the processes and outcomes of primary 
care, and to develop a national quality governance model to support regions 
in delivering care of uniform quality across the country [OECD2015]. The 
Italian National Agency for Regional Healthcare Services started the MATRICE 
Project in 2011. MATRICE was aimed at developing tools to compare quality 
of healthcare across Italian regions of four chronic diseases: type 2 diabetes 
(T2DM), hypertension, ischaemic heart disease (IHD) and heart failure (HF). 
One of the objectives was to assess the validity of routine care data to monitor 
quality of healthcare supply [AGENAS2016, ARS2016]. 
The Health Search IMS Health Longitudinal Patient Database (HSD) is a 
longitudinal primary care medical record database that was set up by members 
of the Italian College of General Practitioners (SIMG). More than 900 physicians, 
uniformly distributed across Italy, share their de-identified clinical records in 
the HSD. These data are extensively used for epidemiological and public health 
research [Cricelli2003, Savica2007, Sacchetti2008, Mazzaglia2009, Ravera2009, 
Cazzola2010, Cazzola2013, Sultana2014, HSD2016]. 
The HSD database is very similar to other Primary Care databases: for instance, 
in the United Kingdom, the Clinical Practice Research Datalink (CPRD, formerly 
GPRD) [Walley1997], The Health Information Network (THIN) [Lewis2007] 
and QResearch [Hippisley-Cox2004];  in Canada, the Canadian Primary Care 
Sentinel Surveillance Network (CPCSSN); in the Netherlands, the Integrated 
Primary Care Information database (IPCI) [Vlug1999]; in Spain, the database 
Base de datos para la Investigación Farmacoepidemiológica en Atención Primaria 
(BIFAP) [SalvadorRosa2002]. A common feature of these countries is that the GP 
serves a well-defined population and is the gatekeeper to secondary care.   
In this type of medical records every visit is recorded and all diagnoses, 
prescriptions and measurements are recorded as part of a general practitioner’s 
daily practice. Moreover, information from specialist referrals is reported 
back to the general practitioner (GP) and stored in the same medical records. 
The medical records replace the paper records that once existed and may be 
considered a rather comprehensive list of health problems requiring care. 
Because of its longitudinal, population-based nature, this type of databases 
serves well for many research purposes, such as estimate of burden of disease, 
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parmacoepidemiologic and health services research. Since information is 
collected primarily for the provision of care, the quality of coding diagnoses 
may not always be accurate and also this varies by type of disease [Jordan2004, 
Kadhim-Saleh2013]. Moreover, the same code may be used for different clinical 
definitions of a disease, when diagnostic standards are not uniform across 
healthcare communities or change over time. As a consequence, case-finding 
algorithms that retrieve subjects from such data sources using diagnostic 
codes may unintentionally retrieve subjects whose clinical condition does not 
correspond to the one intended for a study. On the other hand, GPs may record 
clinical conditions as a free text note, and a retrieval strategy using only coded 
diagnoses may miss some cases. As a result, algorithms using other sources, such 
as results from laboratory tests, have been developed to query this type of data 
sources [Tu2011]. Disease-specific validation studies of case-finding algorithms 
in GP medical record databases have been performed in CPRD [Herrett2010, 
Khan2010], CPCSSN [Kadhim-Saleh2013, Williamson2014], IPCI and HSD itself 
[Coloma2013, Valkhoff2014].
A panel of experts in the MATRICE Project established precise clinical 
definitions of T2DM, hypertension, IHD and HF, and identified levels of severity 
of the conditions that had to be distinguished for the purpose of monitoring 
healthcare quality. The aim of this study was to estimate the positive predictive 
value of case-finding algorithms to detect such conditions and levels of severity 
from the GP medical records collected by HSD, against a gold standard based on 
manual comparison with the clinical definitions chosen by the MATRICE panel. 
METHODS
Setting
Italy has a tax-based, universal coverage national health system. Every Italian 
resident is entitled to choose a GP, although parents might instead opt for a 
specialist paediatrician for their children, up to the age of 15. Therefore, each 
resident from the age of 16 onward is specifically registered with a GP. GPs are 
the “gatekeepers” of the system, meaning that patients can only access secondary 
care within the healthcare system upon referral of their GP [LoScalzo2009, 
OECD2015]. Secondary care is accessed either free of charge or upon a small 
copayment.
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During their daily practice, GPs record all clinical findings, diagnoses and 
prescriptions in their electronic medical records. GPs participating in HSD 
all use the same software, which requires that each prescription is associated 
with a specific disease code. A disease code may be labelled as ‘suspect’ when 
further clinical ascertainment is needed. Results from laboratory tests may 
be recorded as well. Moreover, free-text fields are available in the software to 
collect clinical notes on diagnoses, signs, symptoms and referral letters from 
specialists or from hospitals. Every 6 months GPs send their data to a central 
repository, after anonymization. The central repository performs quality 
controls, like estimation of prevalence of common diseases, and selects GPs 
whose data prove to be accurate [Cricelli2003]. Currently, data of 700 out of 
900 GPs, uniformly distributed across Italy, are considered accurate according 
to data quality checking [HSD2016].
Clinical definition of the diseases and of their levels of severity
A panel of cardiologists, diabetologists, epidemiologists and experts in 
organization of primary care services participating in the MATRICE Project 
first established clinical definitions of the four diseases and of their levels of 
severity. The levels of severity were selected according to whether national and 
international clinical guidelines contained specific indications for treatment 
or diagnostic follow-up in the patients with that condition. For instance, a 
patient with IHD after an episode of acute myocardial infarction (AMI) has an 
indication for treatment with beta-blockers [Fihn2012], hence history of AMI is 
a relevant level of severity for IHD. 
The detailed definitions of the diseases and of the levels of severity are 
depicted in Table 1. For T2DM, the clinical definition was at least two abnormal 
measurements among fasting plasma glucose, or two-hour plasma glucose after 
a load of glucose, or glycated haemoglobin; or just one abnormal measurement 
of plasma glucose if symptoms of hyperglycaemia were observed. Four levels 
of severity of the disease were identified, according to presence/absence of 
indication for insulin and presence/absence of complications or organ damage. 
For hypertension, diagnostic criteria were two abnormal measurements for 
both systolic and diastolic blood pressure confirmed either by a Holter blood 
pressure measurement or by home blood pressure monitoring. Three levels 
of severity were identified: no organ damage or diabetes or stroke; organ 
damage or diabetes or stroke without HF; hypertension with HF. For IHD the 
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Table 1. Clinical definition of diseases and levels of severity. ACC/AHA: American Cardiology 
Association and American Heart Association.
Type 2 diabetes mellitus
Clinical definition Levels of severity
Syndrome diagnosed on the basis of the 
following criteria outlined in a first test 
and confirmed with a second test in a 
adult, non-pregnant patient, without 
typical symptoms of the disease: Fasting 
plasma glucose ≥ 126 mg / dl (no caloric 
intake for at least 8 hours), or two-hour 
plasma glucose ≥ 200 mg / dl during an 
OGTT after a load of 75 g  glucose, or 
glycated hemoglobin ≥ 6.5%. 
Or, in a patient with classic symptoms of 
hyperglycemia or hyperglycemic crisis, 
a random plasma glucose of plasma 
glucose ≥ 200 mg/dl (regardless of food 
intake).
LEVEL 1 Clinical definition of the disease, no indication 
for insulin therapy and no of the complications listed in 
level 3
LEVEL 2 Clinical definition of the disease, indication for 
insulin therapy and absence of complications listed in 
level 3
LEVEL 3 Clinical definition of the disease, no indication 
for insulin therapy and one of the following:: (1) Arterial 
stenosis (coronary, carotid, peripheral arteries of lower 
extremities), angina pectoris, MI, TIA, ischemic stroke of 
atherosclerotic origin, intermittent claudication, diabetic 
foot ulcer, lower limb amputation (2) Retinopathy (3) 
incipient diabetic nephropathy (microalbuminuria) or 
overt (albuminuria or GFR abnormal) / Dialysis
LEVEL 4 As in level 3, except that insulin is indicated
Hypertension
Clinical definition Levels of severity
Syndrome characterized by arterial 
systolic blood pressure above 140 mmHg 
and / or diastolic blood pressure above 
90 mmHg in at least two measurements 
(patient at rest) confirmed by Holter 
blood pressure measurements or  by 
home blood pressure monitoring (2 
measurements in the morning and 
two in the evening for seven days and 
then calculating the average of all 
measurements after discarding those 
of the  
first day (as recommended by the ESH 
guidelines)
LEVEL 1 Clinical definition of the disease, absence of 
organ damage and of diabetes
LEVEL 2 Clinical definition of the disease, no HF in 
level at least C of the ACC/AHA classification and at 
least one of the following conditions:  type 2 diabetes; 
hypertrophy (ECG o Echo), dilatation or left ventricular 
asyergy (Echo); hypertensive retinopathy; GFR abnormal; 
microalbuminuria or proteinuria; atherosclerotic 
plaques in carotid arteries; atherosclerotic peripheral 
arterial occlusive disease; angina pectoris; coronary 
revascularization; AMI; TIA or ischemic stroke due to 
atherosclerosis; hypertensive encephalopathy; abdominal 
aortic aneurysm; aortic dissection; cerebral hemorrhage
LEVEL 3 Clinical definition of the disease and HF in stage 
C or D of the ACC/AHA classification
Ischaemic heart disease
Clinical definition Levels of severity
Clinical syndrome characterized by 
typical angina chest pain, and / or 
transient myocardial ischemia verified 
by stress ECG or imaging, and / or 
significant coronary arteries occlusion 
verified with angiography, or history of 
previous AMI.
LEVEL 1 Clinical definition of the disease, no evidence of 
previous AMI nor PTCA, no evidence of HF in stage C or 
D of the ACC/AHA classification
LEVEL 2 Evidence of previous PTCA, no evidence of 
previous AMI, no evidence of HF in stage C or D of the 
ACC/AHA classification
LEVEL 3 Evidence of previous AMI, no evidence of 
previous PTCA, no evidence of HF in stage C or D of the 
ACC/AHA classification 
LEVEL 4  Evidence of previous PTCA and AMI, no 
evidence of HF in stage C or D of the ACC/AHA 
classification
LEVEL 5 Clinical definition of the disease and evidence of 
HF in stage C or D of the ACC/AHA classification
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Heart failure
Clinical definition Levels of severity
Stage C or D of the ACC/AHA 
classification: syndrome characterized 
by the presence of symptoms and signs, 
current or prior dyspnea and / or fatigue 
and / or fluid retention (peripheral 
edema and / or pulmonary stasis), and 
the presence of structural heart disease 
(left ventricular systolic dysfunction 
with ejection fraction (EF) <50% and / 
or left ventricular diastolic dysfunction 
and / or right ventricular dysfunction) 
detected by echocardiography
None
clinical definition referred to symptoms (angina pain) or to history of acute 
myocardial infarction or to bioimaging observation of coronary ischemia.  Five 
levels of severity of IHD were identified: the most severe was HF, and among 
those free from HF presence/absence of history of AMI and presence/absence 
of percutaneous transluminal coronary angioplasty (PTCA) classified the four 
levels. HF was also identified as a condition in its own, and the clinical definition 
was stage C or D of the classification by the American College of Cardiology and 
of the American Heart Association [Hunt2005].
Case identification in the primary care medical records
A panel comprising epidemiologists from HSD and GPs belonging to SIMG, 
with expertise in the clinical areas of interest, developed ad hoc algorithms to 
identify from the GP medical records cases matching the clinical definitions of 
the MATRICE Project. In each algorithm the inclusion and exclusion criteria of 
the clinical definition were mapped to a list of ICD9CM codes or, when deemed 
necessary, to free text and to conditions on diagnostic tests. 
Case validation
An invitation to participate in the validation study was circulated by SIMG to a 
sample of GPs, and participation was voluntary. 
A data collection plugin for the medical record software was developed by HSD 
and installed in the computers of the GPs who accepted to participate in the 
study.
For each disease the plugin applied the algorithm to the whole list of active 
patients in the date of data collection, and selected a random sample of 25 
Table 1. Continued
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patients from the resulting list of cases. The plugin then showed the names of 
the patients in the sample to the GP for assessment. In the same screen, the 
clinical definitions of the disease and of its levels of severity were presented. 
The GP was aware that the cases were selected for a specific condition among 
T2DM, hypertension, IHD and HF, but was blinded to the level of severity. 
The GP had the choice of indicating that the patient was not affected by the 
disease (false positive: FP), or that the patient was affected but the level of 
severity could not be assessed on the basis of the information available to the 
GP (not staged: NS), or to assign a level. In the process, the GP was free to 
access the patient’s medical record. Figure 1 shows a screenshot of the data 
collection plugin (patients listed are not real).
When the GP had completed the manual assessment of the 4 samples of 
patients, the plugin applied the algorithms for the level of severity, linked the 
new columns to the dataset resulting from the questionnaire, anonymized the 
final dataset and transmitted it to HSD for statistical analysis.
Data collection was performed in July 2013.
Statistical analysis
The formula to compute Positive Predictive Value (PPV), both for presence/
absence of the condition and for each of the levels of severity, was
PPV= True Positives/(True Positives + False Positives)
and 95% confidence intervals (CI) were estimated. For the three diseases where 
levels of severity had been validated (T2DM, hypertension and IHD), Cohen’s 
kappa was computed to the categorical distribution of levels of severity. Cohen’s 
kappa discounts from observed concordance (the percentage of subjects who 
are classified in the same level by the algorithms and the GP) the expected 
concordance (the percentage of subjects who would be classified the same if 
assignment had been performed randomly) by means of the following formula
K = (Observed Concordance – Expected Concordance)/
                          (1 – Expected Concordance)
Cohen’s kappa provides an overall measure of agreement about levels of severity.
Analysis was performed using Stata 12.
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RESULTS
Algorithms for  primary care medical records
The algorithms detecting the diseases and levels of severity from the primary 
care medical records are listed in Table 2. Each algorithm consists of a sequence 
of rules, each acting as an inclusion criterion, a refinement criterion (linked 
to the inclusion criterion with the logical connector AND), or a refinement 
criterion (linked to the inclusion criterion with the logical connectors AND 
NOT). Each rule is itself composed by subqueries (represented in the table 
by keywords in round parenteses), and subjects matching at least one of the 
subqueries are included in the rule, that is, the subqueries are linked to each 
other with the logical connector OR. No specific  temporal sequence between 
subqueries is requested. Every sub query selects records matching a specific list 
of codes, free text keywords and/or diagnostic test levels, which are listed in the 
Electronic Supplementary Material 1 (http://www.ars.toscana.it/files/progetti/
informatica_medica/thematrix/ESM_1_revised.pdf). All the subqueries are 
applied to the whole set of longitudinal observations of the patients up to the 
index date, except when specified otherwise. 
In all subqueries, records labelled with ‘suspect’ were excluded, except in the 
case of the subquery  detecting patients with acute myocardial infarction, used 
to detect levels of severity 3 and 4 in patients with IHD.
Validation
A panel of 12 GPs participated in the validation study. A total of 300 patients 
were identified and validated for each disease, except for HF, where due to low 
prevalence of the condition only 243 patients were included.
The PPV of the algorithms were 100% (CI: 99-100) for T2DM and hypertension 
and 98% (CI: 96-100) for IHD. For HF PPV was 55% (CI: 49-61).
For T2DM the second and fourth levels of severity had very high PPV (88% 
and 93% respectively). Around the 20% of patients without indication for 
insulin (first and third level of severity) had their presence of complications 
misclassified. Both possibilities took place: patients with complications were 
identified as being free from them, and vice versa. Overall Cohen’s kappa was 
0.70, a good level of agreement (Table 3).
Among hypertensive patients every level of severity was misclassified in less 
than the 20% of patients, and in the case of the middle level (organ damage 
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and/or diabetes, no HF) patients were in fact almost all less severe with respect 
to the level they were automatically assigned to. Cohen’s kappa was 0.69, 
showing good agreement (Table 3).
In the case of IHD the first and fifth levels of severity had excellent PPV, while 
AMI was incorrectly identified by the algorithm in 22% of cases. The two levels of 
severity characterized by presence of PTCA were never manually indicated by the 
GPs, and the automatic algorithm was in almost perfect agreement in both cases. 
Overall, Cohen’s kappa was 0.69, showing good agreement (Table 3).
Table 2. Algorithms to detect diseases and levels of severity. The algorithms are described by means of 
subqueries, represented by keywords in upper case between parentheses, whose details are in 
Supplementary Table 1. In particular, measurements are as follows. (GFR): Glomerular filtration rate  < 
mL/min/1.73 m2  (BP): Systolic blood pressure>140 mmHg at least twice ever OR Diastolic blood pressure 
>90 mmHg at least twice ever (LVEF): Left ventricular ejection fraction< 50%  (DM TESTS):  plasma 
glucose >200mg/dl after an oral load of 75 g glucose OR fasting plasma glucose>=126 mg/dl OR glycated 
haemoglobin>=6.5%. In all subqueries records labelled with ‘suspect’ were excluded, except in the case of 
the subquery (AMI) (Acute myocardial infarction) used to detect levels of severity 3 and 4 of IHD.
Type 2 diabetes mellitus
Algorithm for the disease Algorithms for levels of severity
[(DM)  OR (GFR) OR
(DM TESTS)]
AND NOT
(DM1) 
Algorithm for the disease 
AND (DM UNCOMPLICATED) 
AND NOT  [(INSULIN) OR (DM2 CHRONIC COMPLICATIONS) OR 
(DM2 ASYMPTOMATIC COMPLICATIONS)  OR (CVD)]
Algorithm for the disease 
AND (DM UNCOMPLICATED) 
AND (INSULIN)
AND NOT [(DM2 CHRONIC COMPLICATIONS)  OR (DM2 
ASYMPTOMATIC COMPLICATIONS) OR (CVD)]
Algorithm for the disease 
AND [(DM CHRONIC COMPLICATIONS)  OR (DM 
ASYMPTOMATIC COMPLICATIONS) OR (CVD)]
AND NOT  (INSULIN)
Algorithm for the disease 
AND [(DM CHRONIC COMPLICATIONS)  OR (DM 
ASYMPTOMATIC COMPLICATIONS) OR (CVD)]
AND (INSULIN)
Hypertension
Algorithm for the disease Algorithms for levels of severity
(HYPERTENSION)  OR  (BP) Algorithm for the disease 
AND NOT 
[LEVEL 2 OR LEVEL 3]
Algorithm for the disease 
AND  [(DM2) OR (HYPERTENSION COMPLICATIONS) OR 
(HYPERTENSIVE RETINOPATHY) OR (CHRONIC KIDNEY 
DISEASE) OR (ATHEROSCLEROTIC ARTERIOPATHY) OR 
(CAROTID ATHEROSCLEROSIS) OR (HYPERTENSIVE 
ENCEPHALOPATHY) OR (AORTIC ANEURYSM)]
AND NOT [(HF) OR (LVEF)]
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Algorithm for the disease 
AND [(HF) OR (LVEF) OR (VENTRICULAR DYSFUNCTION)]
Ischaemic heart disease
Algorithm for the disease Algorithms for levels of severity
(CHD) Algorithm for the disease 
AND (CHD NO AMI)
AND NOT [(AMI) OR (PAST AMI) OR (CORONARY 
REVASCULARIZATION ICD9CM) OR (CORONARY 
REVASCULARIZATION FREE TEXT) OR (HF) OR (LVEF) OR 
(VENTRICULAR DYSFUNCTION)]
Algorithm for the disease 
AND [(CORONARY REVASCULARIZATION ICD9CM) OR 
(CORONARY REVASCULARIZATION FREE TEXT)]
AND NOT [(AMI) OR (PAST AMI) OR (HF) OR (LVEF) OR 
(VENTRICULAR DYSFUNCTION)]
Algorithm for the disease 
AND [(AMI) OR (PAST AMI)]
AND NOT [(CORONARY REVASCULARIZATION ICD9CM) OR 
(CORONARY REVASCULARIZATION FREE TEXT) OR (HF) OR 
(LVEF) OR (VENTRICULAR DYSFUNCTION)]
Algorithm for the disease 
AND [(AMI) OR (PAST AMI) OR (CORONARY 
REVASCULARIZATION ICD9CM) OR (CORONARY 
REVASCULARIZATION FREE TEXT)]
AND NOT [(HF) OR (LVEF) OR (VENTRICULAR DYSFUNCTION)]
Algorithm for the disease 
AND [(HF) OR (LVEF)]
Heart failure
Algorithm for the disease Algorithms for levels of severity
(HF) OR (LVEF) OR 
(VENTRICULAR 
DYSFUNCTION)
None
 
Table 2. Continued
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Figure 1. Screenshot of the data collection plugin. The GP participating to the study was asked to fill in 
the four tables, one per disease. In the table “S.P.” meant “without the disease” and “N.S.” meant that the 
patient had the disease but the GP was not able to assess the level of severity. The clinical definition of 
the condition and of each level of severity could be browsed in the upper part of the screen, while, 
whenever the pointer stopped on a cell in the table, a tooltip suggested the label of the corresponding 
level. The patients listed in the figure are not real.
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DISCUSSION
This study shows that almost all of the automatically detected cases of T2DM, 
hypertension and IHD, but only the 55% of cases of HF were true cases as 
assessed by the GP, on the basis of their own records and personal knowledge. 
Automatic classification of levels of severity of T2DM, hypertension and IHD 
was acceptable although less accurate. In the case of IHD mild cases were 
misclassified as severe, while in T2DM and hypertension both possibilities 
took place: severe patients were automatically classified as mild and vice versa. 
Our results provide guidance to the interpretation of results of studies using 
those algorithms to define variables in medical records or HSD, for instance to 
monitor quality of healthcare.
The excellent PPV of some algorithms is not unexpected: algorithms to 
detect diabetes (irrespective of type) and hypertension, as well as other 
chronic conditions, had similarly high validity in the CPCSSN [Kadhim-
Saleh2013, Williamson2014]. The low PPV that we observed in the case of HF 
is unsurprising as well. Indeed, HF is a syndrome, and several different clinical 
definitions of HF have been used among clinicians in the recent past, such as 
the Framingham and European Society of Cardiology criteria. It has been shown 
that changing definition has a noticeable impact on the epidemiology of the 
condition [DiBari2004]. Our definition comprises two of the four stages of the 
classification of the American College of Cardiology and of the American Heart 
Association, which has been itself revised repeatedly in recent years [Hunt2005]. 
It is likely that the GPs in the sample themselves adopt a different definition to 
diagnose HF with respect to the one proposed by the MATRICE panel. Further 
research could investigate whether a clinical definition modelled on the Italian 
guidelines may be more easily identified in primary care medical records. Finally, 
poor performance of ICD9CM codes in identifying a specific clinical definition 
of HF has been consistently reported in literature [Quach2010].
The results we observed for levels of severity are probably due to reasons which 
are more specific to HSD. In the case of T2DM, some misclassification occurred 
between Level 1 and Level 3, that is, patients with or without complications 
but without indication for insulin use. Adding rules that explore free text 
comments to the diagnostic codes may improve those algorithms. In the 
algorithm developed for this study, patients with IHD labelled with ‘suspect’ 
AMI were included in the ‘AMI’ level of severity, because in a previous study 
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specific algorithms to identify AMI had been observed to have low sensitivity in 
HSD [Coloma2013]. As a result, our sensitive algorithm did indeed capture all 
the cases of AMI in patients with IHD; however, 22% of patients had not had an 
AMI, so this strategy needs to be reconsidered for future research. Remarkably, 
GPs were not aware of a single case of PTCA in their patients, as confirmed by 
automatic querying their records. The absence of PTCA could be due to the 
fact that this procedure is only performed in hospital. In Italy, hospitals do not 
provide GPs with discharge letters, rather patients themselves must describe 
to the GP what happened during an inpatient care episode, and the PTCA 
procedure may be communicated inadequately to the GP. 
Strategies to improve communication between hospital and primary care 
should be implemented in Italy, not only for the purpose of improving quality 
of primary care medical records, but also to improve healthcare for patients 
with severe cardiovascular conditions.
Limitations
The sample of GPs was self-selected and may have been composed of those with 
more accurate data recording attitudes. In particular, 2 GPs in the validation 
sample also participated in the panel that created the algorithms. Positive 
predictive value of the algorithms may be lower in the general group of GPs 
contributing to HSD.
Providing a direct estimate of sensitivity of the case-finding algorithms was 
not an aim of this study, because it would have been unfeasible for GPs to 
assess a large enough sample of their patients. Indeed, the number of patients 
needed to estimate sensitivity of a test is bigger with less prevalent conditions: 
for instance, to estimate sensitivity of a case-finding algorithm for T2DM with 
a marginal error of 5%, even assuming 10% prevalence (an overestimation, 
according to common estimates in Italy [Gini2013]) and 95% sensitivity, would 
have requested an additional sample of more than 700 subjects; to obtain a 
valid estimate of sensitivity for HF, which has much lower prevalence and a 
lower expected sensitivity, GPs  would have needed to assess thousands of 
subjects [Hajian-Tilaki2014]. 
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CONCLUSIONS
This study shows that subjects with T2DM, hypertension or IHD can be validly 
identified in HSD by automated identification algorithms. Automatic queries 
for levels of severity of the same diseases compare well with the corresponding 
clinical definitions, but some misclassification occurs. For HF further research 
is needed to refine the current algorithm. 
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ABSTRACT
Background
Italy has 60 million inhabitants and a universal coverage health care system. 
The country is divided in around 100 Local Health Units (LHUs), and each LHU 
collects administrative data about health care delivered to the inhabitants of 
its community. The data model of Italian Administrative Databases (IAD) is 
common across the country: information is collected for instance on inpatient 
care, dispensed drugs, delivery of diagnostic exams and secondary care. 
Attendance and costs of health care are recorded but not the diagnostic codes 
in outpatient specialist care, while encounters in primary care are not recorded. 
In the past years, several algorithms have been proposed to identify patients 
with chronic conditions in IAD utilizing data from discharge diagnoses, drug 
utilization or utilization of other healthcare services. This study was initiated 
to validate the case-finding algorithms for type 2 diabetes mellitus (T2DM), 
hypertension and ischaemic heart disease (IHD) from the IAD against the case 
identification in primary care medical records that do have the diagnoses for 
these conditions. 
Methods
All the subjects registered with  25 General Practitioners (GPs) with good quality 
clinical medical records, and 16 years or older,  living in 5 different regions 
entered the study. Medical records of study subjects were collected from their 
GPs. IAD data of the same subjects was collected as well from the local health 
units. Sensitivity, specificity, positive (PPV) and negative (NPV) predictive 
values of a set of set of case-finding algorithms on IAD were estimated using 
the medical records as gold standard. The effect on validity indices of adding 
more years of look-back to the case-finding algorithms was estimated.
 
Results
33,949 persons entered the study. According to the medical records 2,852 (8.4%) 
had T2DM, 11,320 (33.2%) had hypertension and 1,414 (4.1%) had IHD.
The algorithms that were used on the IAD records with best balance had 
sensitivity, specificity, PPV and NPV of, respectively, 72%, 100%, 95%, 98% for 
T2DM, 68%, 95%, 88%, 86% for hypertension and 44%, 100%, 81%, 98% for IHD. 
Adding years of look-back improved sensitivity, in particular for IHD. When 
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drug utilization in less recent years was added as an inclusion criterion, PPV 
was reduced. 
Conclusion
For the three conditions that we investigated, case-finding algorithms on IAD 
records had excellent specificity and good PPV and NPV, but sensitivity lower 
than 75% and, in the case of IHD, lower than 50%. Longer look-backs of data are 
expected to improve these figures, but caution should be adopted in including 
too many years of look-back from drug utilization. Calibration can be used to 
assess the impact of imperfect case-finding algorithms on study results.
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INTRODUCTION
Italy’s population is among the oldest in the world, and good management 
of chronic conditions, such as diabetes or cardiovascular diseases, is essential 
to prevent complications and disability, to avoid hospitalization and intense 
healthcare utilization, and ultimately to ensure sustainability of a universal 
coverage health care system [OECD2015].
Italy has a tax-based, universal coverage national health system 
[LoScalzo2009]. Regional health care systems adopt different policies, and the 
Italian National Agency for Regional Health Systems is mandated to compare 
quality of healthcare across regions. The MATRICE Project was an initiative 
of the Agency, aimed to create tools to perform surveillance of prevalence 
and monitor quality of healthcare for type 2 diabetes (T2DM), hypertension 
and ischaemic heart disease (IHD) on the basis of Italian  administrative 
databases (IAD), a data source covering the entire national population that 
has a standardized content.
Many high prevalent chronic conditions are usually diagnosed and taken care 
of in primary care settings. Unlike other countries such as the United States, 
in Italy administrative databases do not collect the diagnostic codes recorded 
during primary care. Each Italian adult inhabitant has the right of choosing 
a GP, and GPs are paid by LHUs on a capitation fee. Therefore there is no 
administrative need to record a specific visit, let alone the disease that led to it. 
Specialist physicians are employees of hospitals, and while the occurrence of 
an encounter with a patient is recorded in IAD, diagnostic codes are not. Lack 
of diagnostic codes poses challenges to use these data for quality monitoring 
as the validity of case-finding algorithms may be affected. For instance, a 
recent Canadian study found that inpatient data alone underestimate the 
population prevalence of heart failure by at least 33% [Blais2014]. Although 
IAD do not have outpatient diagnoses, they do record inpatient diagnosis, as 
well as utilization of other health care services, such as dispensing of drugs or 
administration of tests for diagnosis or follow-up. These services may be used 
as proxies. Moreover, patients with specific diseases are exempted from co-
payment to healthcare, and IAD contains a registry of such exemptions. This 
wealth of data is available for research. In many previous studies using IAD 
42070 Rosa Gini.indd   70 04-09-16   19:33
3Validation of chronic diseases in Italian Administrative Databases
71
as a data source, different case-finding algorithms have been used to identify 
populations with chronic diseases [Maio 2005, Gnavi 2008, Simonato 2008, 
Chini 2011, Belleudi 2012, Gnavi 2008b, Gnavi 2011, Giorda 2012, Gini 2013b, 
Buja 2013, Visca 2013, Gini 2014]. However, a formal validation study has never 
been performed.
In order to provide guidance about using IAD for surveillance and monitoring 
of quality of healthcare for chronic diseases, the MATRICE Project aimed to 
conduct a population-based validation study to estimate validity indices of a list 
of case-finding algorithms detecting T2DM, hypertension and IHD from IAD.
METHODS
Study design
This is a population-based validation study. Sensitivity, specificity, positive 
predictive value (PPV) and negative predictive value (NPV) of a list of algorithms 
detecting T2DM, hypertension and IHD from IAD are estimated in a large 
sample of the Italian adult population. Primary care medical records are used as 
a gold standard. The impact on validity of adding one year of look-back to IAD 
was assessed.
Italian administrative databases
Each Italian region is divided in geographic subareas (on average 10 per region). 
Healthcare for the population in each area is managed by organizations called 
Local Health Units (LHU). LHUs collect administrative data on the healthcare 
they provide to their inhabitants which together form the basis of the IAD. 
The main components of IAD are the following tables 
•	 	Inhabitant registry (PERSON) is the list of subjects who live in a defined 
geographical area, recorded with gender, date of birth, date of entry, date 
of exit, identifier of the chosen GP, citizenship, residence municipality; the 
dataset is longitudinal, meaning that if a person changes GP, or citizenship, 
or municipality, a new record is added. 
•	 	Hospital discharge records (HOSP) is the table of hospital discharge records 
reimbursed by the healthcare system, recorded with up to six diagnosis 
codes and up to six procedure codes in ICD9CM
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•	 	Exemption registry (EXE) is the table of disease-specific exemptions from 
co-payment to the healthcare system, recorded with a disease code which 
is a truncated ICD9CM code
•	 	Drug dispensing registry (DRUGS) is the table of drugs dispensed by 
community or hospital pharmacies free of charge or upon co-payment. 
Drugs are coded with a specific Italian coding system, which is mapped to 
the Anatomical Therapeutic Chemical classification system (ATC) and to 
the Defined Daily Dose (DDD) [WHO2016]; 
•	 	Outpatient services registry (OUTPAT) is a list of outpatient activities 
dispensed by the healthcare system free of charge or upon co-payment, 
among which specialist encounters (with no diagnostic code), laboratory 
or instrumental or bio-imaging diagnostic tests (without results), recorded 
with a specific Italian coding system
Within a LHU, all the tables above can be linked with each other at the individual 
level, using the national fiscal identifier as a common key. 
Collection of IAD tables is mandatory by national law. The first table to be 
established was HOSP. LHUs have started to collect IAD tables in different time 
periods. At 1st January 2012, at least 4 years of look-back for hospital discharge 
records and 2 of drug dispensing registry were available in all LHUs. At least 3 
years of exemption registry were available in 4 LHUs and one year was available 
in the other. The outpatient services registry was not available in one LHU. 
The hospital discharge records had a maximum of 11 years in one LHU. The 
exemption registry had a maximum of 12 years in 3 LHUs. The drug dispensing 
registry had a maximum of 6 years in one LHU. The outpatient services registry 
had a maximum of 6 years in one LHU (Table 1).
Primary care medical records
The National College for General Practitioners (SIMG) is the national scientific 
society of General Practitioners (GPs) in Italy. SIMG has trained the GPs to 
improve the quality of recording in their medical records. More than 900 
members of SIMG use the same clinical software and share their de-identified 
medical records in Health Search, a database which is regularly used for 
epidemiological, public health and health services research [Mazzaglia2009, 
Sultana2014, Gini2014, Gini2016].  
42070 Rosa Gini.indd   72 04-09-16   19:33
3Validation of chronic diseases in Italian Administrative Databases
73
Study population
Five regions belonging to the three macro-areas of Italy participated in the 
MATRICE Project, with one LHU per region: three from the Northern area 
(LHU 1 from Brescia in Lombardy, LHU 2 from Vicenza in Veneto, LHU 3 from 
Bologna in Emilia Romagna), one from the Central area (LHU 4 from Arezzo in 
Tuscany) and one from the Southern area (LHU 5 from Taranto in Puglia). Every 
Italian inhabitant is entitled to choose a GP, although parents might opt for a 
specialist paediatrician instead for their children, up to the age of 15. Therefore, 
each inhabitant older than 15 is registered with and in charge of a dedicated GP. 
SIMG identified, in each of the participating LHUs, five GPs that participated 
also in the Health Search database at January 1st 2012. The study population was 
composed of the persons registered with these 25 GPs on January 1st 2012, and 
older than 15 at the same date.
Clinical definitions of the diseases
A panel of cardiologists, diabetologists, epidemiologists and experts in 
organization of primary care services participating in the MATRICE Project 
established clinical definitions of T2DM, hypertension and IHD, which are 
shown in Table 2 of Chapter 2 of this thesis.
Selection of algorithms
Using the clinical definitions in Supplementary Table 1 as a reference, a 
panel of experts selected ICD9CM codes corresponding to diagnoses of the 
three conditions, ATC codes of the drugs indicated for treatment, and codes 
for the most common follow-up exams. Italian literature and gray literature 
was searched to obtain algorithms that had commonly been used. A national 
workshop gathered the main Italian investigators in the field to validate the 
final list of candidate algorithms on IAD to be tested in this study.
Component and composite algorithms
To streamline data processing and analysis, the algorithms from the final list 
were divided in components. Each component required data from a single data 
table.
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The complete list of components can be found as Supplementary Material (www.
ars.toscana.it/files/progetti/informatica_medica/thematrix/Supplementary 
Material.zip). Each component algorithm was described as a sequence of two 
steps: 
1.  record selection from a single table among HOSP, EXE, DRUGS and 
OUTPAT; 
2.  identification of subjects with a specific pattern of records in the selection 
(for instance: at least two in a 365 days).
To obtain composite algorithms, components were combined by means of 
logical operators (OR, AND, AND NOT).
Gold standard
Case-finding algorithms on primary care medical records for the three conditions 
were tested in a previous study against a questionnaire submitted to the GPs, 
to assess their validity [Gini2015]. Algorithms had excellent PPV for T2DM 
and hypertension (100%), and very high for IHD (98%), therefore the number 
of false positives is expected to be negligible. The number of false negatives is 
expected to be very low as well among diagnosed cases, because the prevalence 
of the diseases we observed in this study are higher than the estimates obtained 
in other data sources, such as national surveys [Gini2013,Cricelli2003].
We assumed that medical records were providing a perfect description of 
diagnosed cases.
Data collection
All administrative records from the main IAD tables collected by the 5 LHUs on 
the study population were sent to the National Council of Research (CNR). The 
medical records of the 25 GPs were queried using the gold standard algorithms, 
and the resulting datasets were sent to CNR as well. 
Before transmission to CNR, fiscal codes were pseudonymised from both types 
of data sources using the same encryption key, which was transmitted to LHUs 
and GPs by the Agenzia Regionale di Sanità della Toscana (ARS). Due to the use 
of the same encryption key, CNR could perform deterministic record linkage 
between the medical records arriving from GPs and the IAD data from the 
LHU. Data extraction, pseudonymization and transmission were performed 
automatically by a tailored suite of software tools. 
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Data processing
Each component case-finding algorithm was applied to the linked dataset. In 
a first data processing step, a look-back period homogeneous across LHUs was 
used: records from hospitalizations were queried for 4 years (from 1st January 
2008 to 31st December 2011), exemptions for 3 years (from 1st January 2009 to 
31st December 2011), while drugs  and outpatient visit records were queried for 
2 years, from 1st January 2010 to 31st December 2011, where data was available. 
In the second data processing step, all the algorithms were applied repeatedly, 
adding one year of look-back per data table at a time, where data was available. 
Data processing was embedded in the domain-specific language of an open-
source software tool developed for MATRICE [TheMatrix].
The final dataset contained a single record per subject, with gender, age band, 
GP, LHU, and, for each disease, the values of case-finding algorithms and of 
the gold standard. The pseudonymized subject identifiers were removed and 
the dataset was transmitted to ARS for data analysis. Figure 1 is a graphical 
representation of this process.
Data analysis
The prevalence of diagnosed T2DM, hypertension and IHD in the study 
population was estimated from the gold standard.
For each case-finding algorithm, sensitivity, specificity, PPV and NPV were 
computed, for the overall population and stratifying by LHU.  Sensitivity was the 
proportion of subjects positive for the gold standard that were positive for the 
algorithm; specificity was the proportion of subjects negative for the gold standard 
that were negative for the algorithm; PPV was the proportion of subjects positive 
for the algorithm that were positive for the gold standard; NPV was the proportion 
of subjects negative for the algorithm that were negative for the gold standard.  
For a selection of algorithms (both in terms of significance and of performance in 
the crude analysis) adjusted sensitivity, specificity, PPV and NPV were estimated. 
We adjusted for the fact that these metrics might depend on gender, age, and 
LHU, and GPs have different distributions of these dependent variables. This 
was done by averaging predictive margins per GP in a random effects model 
[Williams2012]. Heterogeneity of sensitivity, specificity, PPV and NPV across 
sites was estimated with the Wald test of significance for the variable LHU in 
the corresponding model. 
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The algorithm with best balance among sensitivity and PPV (‘recommended 
algorithm’) was identified per each disease.
In some LHUs more years of look-back were available. If there is a longer look 
back period for a person there is more opportunity to have a diagnosis or some 
disease proxy, and that would increase sensitivity, maybe at the expense of a lower 
PPV. We first computed the validity indices of the recommended algorithms 
using all available data. We created for each disease a dataset including, per 
each combination of available look-back years of hospital discharge records, 
exemption and drug dispensing registry, all the study subjects from those LHUs 
which had the corresponding span of look-back available. For simplicity, we 
truncated the available years to 6 or more, so the triples ranged from (4,3,2) to 
(6+,6+,6+). In each copy we computed the algorithm for all the study subjects 
using the corresponding triple of look-back years. We then estimated sensitivity 
and PPV from LHU-specific logistic models, using the triple of numbers of look-
back years as independent variables with interactions, adjusted by gender and 
age. We finally estimated, per triple, the variation of sensitivity and PPV when 
adding a new year of look-back of each data table as the mean value among 
LHU-specific variations.
Statistical analysis was performed using Stata version 12.1 (Stata Corporation). 
Ethics
Permission to perform record linkage between IAD and medical records was 
granted by the Italian National Authority for the Privacy regulation. Specifically, 
permission was granted to CNR to store and process the data, and to ARS to 
obtain the linked individual-level analytical dataset, for statistical analysis.
RESULTS
Study population
The study population from the LHUs comprised 36,414 subjects, 34,560 (94.9%) 
of which had complete and unambiguous data (gender, birth date, date of entry 
and exit) and were present in the LHU and older than 15 years at the index 
date. The 25 GPs sent data on 34,933 subjects. Data on 33,949 persons (98.2% of 
those from LHUs, 97.2% of those from GPs) could be linked across the two data 
sources. Of this study population 51.7% was composed of female persons, 39.2% 
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was 16-44 years old, 33.6% was 45-64 years old, 22.9% was 65-84 years old and 
4.3% was 85 or older. LHU 3 had the largest share of population, and LHU 4 the 
smallest. The population in LHU 5 was slightly younger. According to the gold 
standard, 2,852 (8.4%) persons had T2DM, 11,320 (33.2%) had hypertension and 
1,414 (4.1%) had IHD in the study population (Table 1).
Table 1. Study population and years of look-back per LHU. HOSP: hospital discharge records, EXE: 
exemptions rgistry; DRUGS: drug dispensing registry. OUTPAT: outpatient activity registry.
LHU 1 LHU 2 LHU 3 LHU 4 LHU 5 Total
N 6,949 6,803 8,040 5,756 6,401 33,949
F 3443 (49.5) 3499 (51.4) 4306 (53.6) 3017 (52.4) 3281 (51.3) 17546 (51.7)
Age 16-44 2835 (40.8) 2605 (38.3) 2916 (36.3) 2130 (37.0) 2815 (44.0) 13301 (39.2)
45-64 2514 (36.2) 2246 (33.0) 2624 (32.6) 1813 (31.5) 2201 (34.4) 11398 (33.6)
65-84 1424 (20.5) 1643 (24.2) 2082 (25.9) 1456 (25.3) 1171 (18.3) 7776 (22.9)
85+ 176 (2.5) 309 (4.5) 418 (5.2) 357 (6.2) 214 (3.3) 1474 (4.3)
GP 1 1464 (21.1) 1526 (22.4) 1755 (21.8) 1416 (24.6) 1416 (22.1) 7577 (22.3)
2 1444 (20.8) 1509 (22.2) 1682 (20.9) 1156 (20.1) 1372 (21.4) 7163 (21.1)
3 1407 (20.2) 1492 (21.9) 1664 (20.7) 1137 (19.8) 1323 (20.7) 7023 (20.7)
4 1373 (19.8) 1262 (18.6) 1620 (20.1) 1086 (18.9) 1288 (20.1) 6629 (19.5)
5 1261 (18.1) 1014 (14.9) 1319 (16.4) 961 (16.7) 1002 (15.7) 5557 (16.4)
Disease T2DM 567 (8.1) 580 (8.5) 594 (7.4) 478 (8.2) 633 (9.9) 2,852 (8.4)
Hypertension 2,456 (35.4) 2,340 (34.0) 2,701 (33.4) 1,799 (31.5) 2,024 (31.7) 11,320 (33.2)
IHD 258 (3.7) 275 (4.0) 433 (5.4) 235 (4.0) 213 (3.4) 1,414 (4.1)
Years of 
look-
back
HOSP 11 7 6 6 4
EXE 12 12 12 3 1
DRUGS 3 5 2 6 2
OUTPAT 3 3 2 6 0
Validity indices
The validity indices of the list of algorithms are shown in Supplementary 
Table 3. Table 2 shows the validity indices of the most relevant algorithms, which 
are represented also in Figure 2, for T2DM, hypertension and IHD. In all three 
cases, algorithm A is the one detecting subjects only from discharge diagnoses: 
the PPV is very high (from 84% for IHD to 94% for T2DM), but the sensitivity is 
lower than 25% (from 22% of IHD to 11% of hypertension). Adding subjects with a 
disease-specific exemption (algorithm B) does not change the PPV but improves 
the sensitivity slightly, up to 30% in both T2DM and IHD. Adding persons utilizing 
specific drugs (algorithm C) has a different impact on the three conditions: in 
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Figure 1 Data collection process
Ministry of Health
ARS
Local Health Unit
ID V1 . . . VN
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ID V1 . . . VN
XYW 1 . . . 1
WYX 1 . . . 0
YXW 0 . . . 0
WXY 0 . . . 0
GP
ID GS
ABC 1
CBA 0
BAC 1
CAB 0
ID GS
XYW 1
WYX 0
YXW 1
WXY 0
National Research
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the case of T2DM inclusion of non-insulin glucose lowering drugs increases 
sensitivity dramatically to 67% while the PPV remains the same. In the case of 
hypertension utilization of selective antihypertensive drugs (alpha blockers) has 
only a modest impact on the indices of the algorithm. For IHD utilization of 
nitrates increases sensitivity to 44% while significantly lowering PPV to 80%. 
For IHD algorithms D and E (respectively, adding subjects who utilize platelet 
aggregation inhibitors excluding heparin; and adding only those subjects who 
utilize both this class of drugs and beta-blockers) improves the  sensitivity 
greatly (respectively, to 82% and 69%) but at the price of lowering dramatically 
the PPV (29% and 51% respectively). In the case of hypertension, inclusion of 
beta-blockers or renin-angiotensin agents (algorithm D) leaves the PPV almost 
unchanged (88%) while the sensitivity (68%) is increasing substantially. In the 
case of T2DM addition of persons with repeated measurements of glycated 
haemoglobin (a component algorithm which is only available in 4 of the 5 LHUs) 
increased the sensitivity to 75%, but the PPV was reduced (90%); in algorithm E 
insulin use is added, which increases the sensitivity to 71% while keeping PPV 
at 94%. 
The best balance between PPV and sensitivity is therefore Algorithm E for 
T2DM, algorithm D for hypertension and Algorithm C for IHD. They entered 
the following analysis as ‘recommended algorithms’.
Variation in positive predictive value between LHUs is not significant for 
diagnostic components in T2DM and IHD, but it is significant for hypertension; 
for drug utilization components it is significant for T2DM and hypertension (in 
both cases LHU 4 had worst performance), but not for IHD. The variability 
in sensitivity of the preferred algorithm across LHUs is high for hypertension, 
with LHU 5 showing worst performance: this is because the  drugs component 
adds less. Heterogeneity in sensitivity is important for IHD as well, due to high 
contribution from exemptions in LHU 1 (Table 2 and Supplementary Table 3).
Adding more years of look-back
When we pooled all available look-back years, the crude estimates of sensitivity, 
specificity, PPV and NPV of the recommended algorithms were, respectively: 
76%, 99%, 86%, 98% for T2DM, 73%, 93%, 83% e 87% for hypertension and 63%, 
98%, 79% e 99% for IHD. 
The impact of adding years in the look-back period for hospitalizations and 
exemptions was modest in the case of T2DM and hypertension, but very 
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relevant, especially the latter, in the case of IHD, without loss in PPV. Adding 
years of look-back to the drug registry produced a small increase in sensitivity, 
at the expense of the PPV, especially in the case of T2DM (Figure 3 and Table 3).
DISCUSSION
This paper provides the validity of algorithms to identify type 2 diabetes 
mellitus, hypertension and ischaemic heart disease in Italian administrative 
databases, which miss primary care diagnostic information. 
We demonstrated that exploiting both diagnostic and other available 
information in IAD, algorithms with very good PPV could be found for T2DM 
(94%) and hypertension (88%), and with good PPV for IHD (80%). However, 
sensitivity was suboptimal for T2DM (71%) and hypertension (68%), and low 
(44%) for IHD. Adding more years of look-back to hospital discharge records 
and exemption registry is likely to improve substantially sensitivity of the 
IHD algorithm: we estimated that more than 15 percentage points would be 
added if more 6 years of look-back in the two data sources were included in the 
algorithm. Adding more time to the two years of look-back of the drug registry 
seemed to reduce PPV, particularly in the case of T2DM.
Sensitivity and positive predictive value of diagnoses and other component 
algorithms in IAD
Diagnostic codes are only collected in Italian Administrative Databases during 
inpatient care or when a disease-specific exemption from copayment is dispensed. 
As expected, this hampers the sensitivity of algorithms selecting subjects recorded 
with diagnostic codes. Persons aged 65 or more are exempt from any copayment, 
regardless of a disease, therefore patients who develop a chronic condition 
in older age are not recorded in the exemption registry. Hospital discharge 
records are more sensitive in older ages, because older patients are more often 
admitted to hospital, regardless of the condition. Hospital discharge records 
and exemption registry are therefore complementary, the former being more 
sensitive in older age bands and the latter in the younger. The consequence is that 
in T2DM, a condition which arises at younger age with respect to IHD, hospital 
discharge records are less sensitive, and exemption registry is complementary. 
Misclassification is low both inpatient setting and in the exemption registry.
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The amount of misclassification associated with drug utilization depends 
on the prevalence of the other conditions which are indications for the 
same drug. In the case of non-insulin anti-diabetics for T2DM, which have 
some low-prevalence off-label indications, misclassification is negligible. In 
the case of platelet aggregation inhibitors for IHD, the prevalence of other 
indications (atrial fibrillation, ischaemic stroke, transient ischaemic attack, 
high cardiovascular risk) is very high, and the amount of misclassification 
is correspondingly high. Even if hypertension is not the only indication for 
beta-blockers, the prevalence of the other indications is low in comparison, 
and this explains why this component does not reduce dramatically the PPV 
of the composite algorithm for hypertension. Sensitivity of drug utilization 
components is high if treatment with the drug is needed early in the 
development of the condition, as is the case of non-insulin antidiabetics 
for T2DM. Moreover, adherence must be high in the population for a drug 
utilization component to be sensitive: this is not the case of antihypertensives 
for hypertension in Italy [Poluzzi2005, Corrao2011], and this explains the 
observed imperfect sensitivity. 
Outpatient activity registry was not available in all the LHUs at the index date 
of our analysis, nevertheless an algorithm based on repeated tests showed a 
promising performance for T2DM in the LHUs where it was available (PPV of 
79% or higher, sensitivity 40% or higher). Similar components are active part 
of algorithms used in Denmark administrative databases, which share many 
features of IAD [Carstensen2008]
Adding look-back years
Adding years of hospital discharge records and exemptions had a modest 
impact in the case of T2DM. Patients who have had a hospital admission 
or an exemption in a more remote past, due to the natural evolution of the 
disease, are likely to be now in treatment. They are therefore included in the 
composite algorithm via the drug utilization component. The opposite is true 
in the case of IHD: patients with a more remote history of infarction, or with an 
old exemption, may be non-adherent to their preventive treatment, and would 
therefore not be detected by the drug utilization algorithm. The contribution of 
remote years from hospital discharge records and exemption registry becomes 
therefore relevant. Hypertension is rarely mentioned as a discharge diagnosis, 
as can be observed from the low sensitivity of algorithm A from Table 2, so it 
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is unsurprising that adding more years of hospital discharge records does not 
improve the characteristics of this algorithm.
In all cases, however, long look-backs of discharge records and exemptions 
proved to be consistent in PPV. An exception is the case of T2DM, where a 
small decrease in PPV for exemptions may be due to misclassification with type 
1 diabetes: indeed, the truncated version of ICD9CM adopted in the exemption 
registry does not tell one form of diabetes from the other. 
Comparison with literature
Multiple algorithms were tested by Morley et al to identify patients with atrial 
fibrillation from the National Linked Electronic Health Records in the United 
Kingdom. They assessed the contribution from non-diagnostic algorithms, 
such as treatment or procedures, to a composite case-finding algorithm, and 
found that procedures were not a signifiacant component, while treatments 
could help in establishing more precisely the date of onset of the condition 
[Morley2014].
In a study with a design similar to ours, Li et al tested various case-finding 
algorithms for systolic dysfunction in a claims database, using medical records 
as a gold standard. Similarly, they found low sensitivity and high PPV. They 
provided examples of bias induced by imperfect validity of their algorithms, and 
discussed when it resulted in an acceptable error of the resulting estimate. This 
depended critically on the research question [Li2011].
In a study on febrile convulsions, Quantin et al validated four case-finding 
algorithms, and found the optimal balance between validity and power to 
conduct a study on vaccine safey [Quantin2013].
Brunelli et al observed that using all the available look-back time of each 
person, rather that a fixed window for all the population reduced confounding 
[Brunelli2013]. Based on our results, caution should be taken in generalizing 
this finding, because longer look-back time may hamper validity of the variables 
included in the analysis. 
Application of the results of this study
When a study variable is obtained from a case-finding algorithm with known 
validity indices, it is possible to calibrate the statistical models that include 
the variable, and adjust the resulting estimates [Green1983, Flegal1986, 
Magder1997]. For instance, calibration to estimate prevalence for surveillance 
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purposes consists in multiplying the estimate by the PPV, and dividing it by 
sensitivity [Rogan1978, Leong2013a].
Quality of health care in cohorts of patients with chronic diseases in Italy is 
typically measured by means of compliance with standards of care. In a previous 
study on aggregated Italian data we found that IAD estimated compliance with 
standards of care for diabetes and IHD consistently with GP data across Italian 
regions [Gini2014]. Similarly, in a recent study on Medicare data patients false-
positive to a case-finding algorithm for diabetes were shown to have a similar 
healthcare utilization profiles, thus suggesting that the population detected 
by the algorithm could be used to estimate measures of service utilization 
[Sakshaug2014]. In general, it is possible that for some specific purposes the 
populations detected by an imperfect algorithm share the same relevant 
characteristics with the true target population so that calibration is not 
necessary.
Recommendations
Overall, adding years of look-back for discharge records and exemption registry, 
as soon as they become available, is recommended. The same is not true for 
drug registry. 
Beyond adding longer spans of look-back, new components may be added in the 
near future. Components based on outpatient activity registry look promising. 
New treatments, more specific for each disease, may become available, and this 
would provide new components as well. Adherence may improve, and this may 
increase sensitivity of drug components. To conduct this validation study, a suite 
of tailored software tools was developed, and permission was granted by the 
Italian National Authority for the Privacy regulation to perform record-linkage. 
This experience can now be repeated periodically, when the need arises. This 
would allow testing new algorithms and update validity indices. This would 
keep up-to-date the capacity of the Italian investigators to perform studies on 
T2DM, hypertension and IHD using IAD. In particular, this would maintain 
confidence in estimates of compliance with standards of care estimated with 
IAD.
The generalizability of our estimates to the national level can be challenged: 
heterogeneity across LHUs was high for many indices. For instance, LHU 4 
having low PPV for non-insulin antidiabetic drugs utilization may be linked to a 
frequent off-label use of metformin as a treatment of obesity that is anecdotally 
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widespread in Tuscany (Fabio Baccetti, personal communication) but not in 
other parts of Italy. It is therefore advisable to discuss the results from calibrated 
analysis along with the results of a traditional analysis.
Developments
The medical records algorithms were validated in another sample of GPs. 
PPV may be lower in the case of the GPs participating in this study. Moreover, 
absence of false negatives in the medical records was an assumption based on 
prevalence estimates. Both assumptions could be weakened: scenarios where 
sensitivity and specificity of medical records are imperfect could be designed and 
dealt with, using appropriate statistical methods [Gart1966, Valenstein1990].
Limitations
Our gold standard is diagnosed chronic disease. There is evidence that a 
substantial proportion of population with chronic conditions is not diagnosed, 
for instance for diabetes the figure could be up to 40% [Leong2013b].
CONCLUSION
For the three conditions that we investigated, case-finding algorithms on IAD 
records had excellent specificity and good PPV and NPV, but sensitivity lower 
than 75% and, in the case of IHD, lower than 50%. Longer look-backs of data are 
expected to improve these figures, but caution should be adopted in including 
too many years of look-back from drug utilization. Calibration can be used to 
assess the impact of imperfect case-finding algorithms on study results.
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ACRONYMS AND SHORT NAMES
ATC –  Anatomical Therapeutic and Chemical classification system for 
drugs. It is an element of the ATC/DDD system of the World 
Health Organization.
DRUGS –  list of drugs dispensed by community or hospital pharmacies 
free of charge or upon copayment. It is a table in the Italian 
Administrative Databases.
DDD –  Defined Daily Dose of a drug. It is an element of the ATC/DDD 
system of the World Health Organization.
EXE –  disease-specific exemptions from copayment to the healthcare 
system. It is a table in the Italian Administrative Databases.
HOSP –  hospital discharge records. It is a table in the Italian 
Administrative Databases.
IAD – Italian Administrative Databases
IHD – ischaemic heart disease
LHU – Local Health Units
OUTPAT –  outpatient healthcare dispensed by the healthcare system 
free of charge or upon copayment. It is a table in the Italian 
Administrative Databases. 
PERSON –  list of subjects who live in a defined geographical area. It is a 
table in the Italian Administrative Databases.
T2DM – type 2 diabetes mellitus
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ABSTRACT
Background
Italy has a population of 60 millions and a universal coverage single-payer 
healthcare system, which mandates collection of healthcare administrative data 
in a uniform fashion throughout the country. On the other hand, organization 
of the health system takes place at regional level, and local initiatives generate 
natural experiments. This is happening in particular in primary care, due 
to the need to face the growing burden of chronic diseases. Health services 
research can compare and evaluate local initiatives on the basis of the common 
healthcare administrative data.
However reliability of such data in this context needs to be assessed, especially 
when comparing different regions of the country. In this paper we investigated 
validity of healthcare administrative databases to compute indicators of 
compliance with standards of care for diabetes, ischaemic heart disease (IHD) 
and heart failure (HF).
Methods
We compared indicators estimated from healthcare administrative data 
collected by Local Health Authorities in five Italian regions with corresponding 
estimates from clinical data collected by General Practitioners (GPs). Four 
indicators of diagnostic follow-up (two for diabetes, one for IHD and one for 
HF) and four indicators of appropriate therapy (two each for IHD and HF) were 
considered.
Results
Agreement between the two data sources was very good, except for indicators 
of laboratory diagnostic follow-up in one region and for the indicator of 
bioimaging diagnostic follow-up in all regions, where measurement with 
administrative data underestimated quality.
Conclusions
According to evidence presented in this study, estimating compliance with 
standards of care for diabetes, ischaemic heart disease and heart failure 
from healthcare databases is likely to produce reliable results, even though 
completeness of data on diagnostic procedures should be assessed first. 
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Performing studies comparing regions using such indicators as outcomes is a 
promising development with potential to improve quality governance in the 
Italian healthcare system.
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INTRODUCTION
Primary care is specifically suitable to face the growing chronic disease 
epidemic in a sustainable way [Starfield  2010, Fani Marvasti 2012] . Therefore it 
is the object of novel attention and of innovative policies [Barnes 2012] which 
specifically need health services research for timely effectiveness evaluation 
[Ettelt 2011, Klazinga 2011, Schafer 2011, Hansen 2011].
Many observational studies have been performed to evaluate the impact of 
innovative policies in primary care, for instance alternative rewarding policies 
for General Practitioners (GPs) in Ontario [Jaakkimainen 2011] or incentives 
for the introduction of Electronic Health Records in the United States [Cebul 
2011, Reed 2012]. Such studies use administrative data to obtain evidence on the 
impact of policies in a inexpensive, timely and reproducible fashion [Solberg 
2006]. Indicators measuring compliance with standards for management of 
chronic diseases were used as outcomes in those studies, similar to the clinical 
indicators of the Quality and Outcome Framework of the UK National Health 
System [NICE 2014], such as regular prescription of recommended therapies 
and regular diagnostic follow-up. However, concerns have been raised that 
such indicators estimated on the basis of administrative databases might not 
reflect the actual compliance of standards in the population bearing the disease, 
as methods to identify patients from administrative data, rather than clinical 
information, might lead to biased samples. Studies addressing this issue have 
obtained contradictory findings  [Tang 2007, Green 2012].
As a result of those concerns, comparison of quality of primary care between 
regions or countries is generally performed by means of hospitalization rates 
for the so-called ambulatory care sensitive conditions [AHRQ 2007], which are 
readily obtained from administrative databases but do not require identification of 
cohorts of patients with a specific condition. However the relationships between 
quality of primary care and avoidable hospitalization is complex and population-
based trends can be confounded by socioeconomic factors [Saxena 2006], by 
prevalence of morbidity or general hospitalization habits [Francesconi 2012]. 
In Italy, the VALORE Project was the first national-level study which evaluated 
a national policy in primary care by using administrative healthcare data for 
calculation of indicators of compliance [Visca 2013]. This paper presents the 
validation study on the reliability of administrative databases in estimating 
such indicators.
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MATERIALS AND METHODS
Ethics Statement
No identifiable human data were used for this study. The dataset used in the 
study is not openly available. According to the Italian law on data confidentiality 
(decree 196/2003), permission to use individual-level data, albeit non-
identifiable, must be granted by the institutions which bear the responsibility 
of the custody of the data. Permission to use data extracted from administrative 
databases for the VALORE project was granted to Agenzia regionale di Sanità 
della Toscana by ULSS 16 Padova (Veneto region), ASP 7 Ragusa (Sicily region), 
Assessorato Politiche per la Salute Emilia Romagna (Emilia Romagna region), 
Zona Territoriale Senigallia (Marche region), which are responsible for the 
custody of the data of the corresponding populations. Agenzia regionale di 
sanità della Toscana (Tuscany region) is  enabled by a regional law (40/2005) 
to use Tuscan data for research purposes. Approval for use of encrypted and 
aggregated data from the HSD was also obtained from the Italian College of 
General Practitioners. 
Setting
Italy has a tax-based, universal coverage national health system organised 
in three levels: national; regional (21 regions); and local (on average 10 Local 
Health Authorities per region). Healthcare is managed for every inhabitant by 
the Local Health Authority where she has her regular address [Lo Scalzo 2009]. 
Coordination of primary care within a Local Health Authority is performed at 
a smaller geographical level called Health District [Visca 2013]. Every Italian 
inhabitant is entitled to choose a GP, although parents might opt for a specialist 
paediatrician instead for their children, up to the age of 15. Therefore, each 
inhabitant from the age of 16 onward is specifically associated with a GP. GPs 
are the “gatekeepers” of the system, meaning that only upon GP prescription 
can specialist encounters be obtained free of charge. Dispensing of drugs or 
administration of diagnostic procedures can be obtained free of charge upon 
prescription of either a GP or a specialist physician employed by the healthcare 
system [Lo Scalzo 2009]. 
The five regions which contributed data to the VALORE validation study were: 
Veneto (A, Northern Italy), Emilia Romagna (B, Northern Italy), Tuscany (C, 
Central Italy), Marche (D, Central Italy) and Sicily (E, Southern Italy). 
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Study design
The VALORE project had selected several indicators to measure compliance 
with standards of care for diabetes, IHD and HF. In each region from the pool 
of regional GPs two convenience samples of groups of GPs were extracted and 
included in the validation study. In each regional pair, GPs of one sample had 
indicators computed from administrative databases, GPs of the other from their 
own clinical databases. Measurements of indicators were compared within and 
between regions. 
The true values of an indicator across all the GPs in a region are an unobservable 
distribution. The rationale of this study design is based on the assumption 
that if measurements performed with two different methods in two different 
samples of GPs provide similar results, the likelihood that they both measure 
the true distribution is higher than the likelihood that they systematically make 
the same mistakes across different regions.
Data collection: sample of GPs with administrative- based measures
The national Italian government has mandated since the early Nineties 
collection of healthcare administrative data across the whole country. The 
healthcare activities which are mandated to be reported to the government have 
progressively expanded, from inpatient care [NSIS 1993] to drug dispensings 
and diagnostic tests [MINECO 2003]. Moreover an inhabitant registry is 
maintained by each Local Health Authority, where the GP chosen by the 
inhabitant is recorded, as well as other information, such as gender, birth date, 
date of entry in the territory of the Local Health Authority, date of exit from the 
territory [MINECO 2003]. However, outpatient diagnoses are not recorded in 
health administrative databases yet. Therefore cohorts of patients with chronic 
diseases must be selected by means of disease-specific longitudinal algorithms 
involving hospital discharges diagnoses, drug and/or other healthcare services 
utilization. 
In each region, a convenience sample of Health Districts was chosen. All the GPs 
serving in those Health Districts were identified from the inhabitant registries 
of the corresponding Local Health Authorities and included in the sample. 
The healthcare administrative data of the whole population who chose a GP 
in this sample was loaded in the VALORE  database.  Patients aged 16-95 with 
diabetes, IHD and/or HF at the index date 1/1/2009 were detected by means 
of ad hoc algorithms based on past healthcare received. More details on this 
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process are described elsewhere [Gini 2013]. Indicators were computed during 
a one-year follow-up by linking the cohorts to the administrative databases of 
drug dispensings and diagnostic tests. 
GPs were excluded from the samples if they had less than 300 persons registered 
or less than 4 patients with the disease, as indicators computed on small 
numbers were considered to be non robust.
Data collection: sample of GPs with clinical- based measures
The samples of GPs with clinical-based measures were drawn from the Health 
Search CSD Longitudinal Patient Database (HSD), a longitudinal observational 
database that is representative of the general Italian population. HSD was 
established in 1998 by the Italian College of General Practitioners and, at the 
time when the study was conducted, it contained data from from more than 800 
GPs throughout Italy, covering a total population of around 1.2 million patients 
[Filippi 2005]. The GPs participating in HSD all use the same information 
software, in which they record demographic information, visits and referrals, 
diagnoses, drug and diagnostic tests prescriptions and clinical information 
of their patients. They are accepted as participants in HSD if their records 
are arguably complete, i.e. the prevalence of the principal diseases measured 
from their records is comparable with the expected prevalence of the general 
population. For this study, data from the 190 GPs practicing in the five regions 
of the VALORE project were used. The study population comprised patients 
aged 16-95 who had been registered with the GP for at least two years and 
were alive on 1st January 2009. Patients with diabetes, IHD and/or HF at the 
index date 1/1/2009 were detected by means of algorithms based on recorded 
diagnosis, which is described in detail elsewhere [Gini 2013]. Indicators were 
computed from the prescribed drugs or diagnostic tests.
Indicators
The indicators that were included in the study are shown in Table 1, and are 
classified as therapy indicators (for IHD and HF only), laboratory diagnostic 
tests, and bio-imaging diagnostic tests (HF only). All the indicators were based 
on clinical guidelines for the management of the disease that recommended 
regular therapy and yearly testing, respectively. The standard for a therapy 
recommendation was considered to be compliant with when at least two 
dispensings (in VALORE) or prescriptions (in HSD) were recorded in 2009, 
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at least 180 days the one from the other. The standard for a diagnostic 
recommendation (laboratory or bioimaging) was considered to be achieved 
when at least one test was performed (in VALORE) or prescribed (in HSD) 
during 2009.
Table 1. Indicators for the care of chronic diseases selected by the VALORE project and included in the 
validation study.
Therapy (>1 dispensations 
per year, distance>180 days)
Laboratory diagnostic test 
(>0 per year)
Imaging diagnostic test (>0 
per year)
Diabetes Glycated emoglobin
Creatinine
IHD ACE inhibitors
Antithrombotics
Total colesterol
IF ACE inhibitors 
Beta-blockers
Ecocardiogram
Statistical analysis
In each sample the number of GPs, the number, age and gender distribution of 
patients aged 16+, and the average number of patients per GP were computed, 
both for the general population and for the population with each of the diseases. 
Differences in the variables within each regional pair of samples were tested 
either by a two-tail difference in means or a Chi-square test.
For each GP indicators were computed as percentage of patients who were 
compliant with the recommended standards of care. The distribution of the 
indicators of each regional pair were represented in a box-plot. To test whether 
each pair of measurements was drawn from the same distribution, the non-
parametric Wilcoxon-Mann-Whitney two-sample statistic (also known as 
Wilcoxon rank-sum statistic) was performed in each region and for each 
indicator. In a sensitivity analysis, the test was repeated for achievements of 
standards in patients aged 45-74 years. 
Data management and data analysis were performed with Stata 10.1.
RESULTS
Of the 1671 GPs serving in the Health Districts participating to the VALORE 
study, 1501 (89.8%) had enough registered patients and entered the study. Few 
GPs were discarded from the disease-specific studies because they had less than 
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four patients, the maximum was the 7% of GPs in region A in the HF study. All 
the 190 GPs in the HSD sample entered the study.
The description of the study population is shown in Table 2. Every HSD sample 
contained less GPs than the VALORE sample. The GPs  in the HSD sample had 
a bigger registered population on average in all the five samples (range in HSD: 
1238-1431, range in VALORE: 925-1223). The average number of patients per GP 
was higher in HSD GPs as well for diabetes (range in HSD 92.0-107.5, range in 
VALORE: 55.9-81.6) and IHD (range in HSD: 50.8-78.6, range in VALORE: 40.0-
61.9), but for HF the numbers were similar in the two groups (range in HSD: 
13.7-22.2, range in VALORE: 12.8-20.0). Age distribution was different within 
all pairs in all the populations, and the VALORE samples were older except in 
region B. Women were slightly more represented in the VALORE populations, 
except again in region B and in region E. This difference in gender did not show 
up in diabetic patients  and was not consistent across regions in IHD and HF 
patients.
Figure 1 shows the box-plots of the pairs of distributions of the crude values 
of each indicator. A qualitative examination of the box-plots detected that 
distributions are very similar within the pairs. A notable exception are laboratory 
measurements in region E and bio-imaging test in all the regions, and VALORE 
showed lower values in all cases. The geographical trends, represented by 
orderings of the median values of the distributions, were similar between 
regions when measured in either data source, but less so in the case of the bio-
imaging test.
Table 3 shows the results of the Wilcoxon-Mann-Whitney tests. Among therapy 
indicators the test found no differences in the distributions, with the exception 
of the samples in region C and, for HF only, region A, and the VALORE 
samples had higher values. The test confirmed that the distributions for all the 
laboratory diagnostic indicators of region E were different. Among diabetes the 
test detected slightly different distributions in three regions in either of the 
indicators, and in the IHD indicator region C and B had different distributions. 
The test confirmed that the only indicator of bio-imaging testing resulted in 
incoherent measurements in all but one region. Restricting the distributions to 
age-specific indicators (45-74)  improved the comparability of the distributions 
of the therapy indicators of HF, and left unchanged the comparability of the 
other indicators.
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Figure 1. Box-plots of the distribution of indicators of quality of care for diabetes (2 indicators), IHD (3 
indicators) and HF (3 indicators) in 5 pairs of samples of GPs. Each pair contains the distribution obtained 
from the VALORE data (dark grey) and the distribution obtained from HSD data (light grey). For each 
indicator the pair of samples are ordered according to the median value in the VALORE sample.
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Table 3. P-values of the Wilcoxon-Mann-Whitney tests. P-values smaller than 0.05 are represented by a 
single star, P-values smaller than 0.001 are represented by a double star.
Disease Indicators Region Pooled 45-74
Diabetes Creatinine test A 0.357 *
B 0.587 0.701
C 0.840 0.957
D * *
E ** **
Glycated emoglobin test A 0.628 0.653
B ** *
C * *
D 0.441 0.441
E ** **
Ischaemic heart disease ACE inhibitors A 0.728 0.067
B 0.695 0.671
C ** **
D 0.116 0.065
E 0.504 0.877
Antithrombotics A 0.508 0.174
B 0.328 0.084
C 0.651 0.440
D 0.497 0.588
E 0.754 0.095
Total cholesterol test A 0.225 0.962
B ** **
C * **
D 0.279 0.720
E ** **
Heart failure ACE inhibitors A * 0.960
B 0.454 0.107
C * *
D 0.701 0.961
E 0.267 0.052
Beta-blockers A * 0.670
B 0.389 0.490
C ** 0.091
D 0.914 0.523
E 0.293 0.614
Ecocardiogram A 0.134 0.245
B * *
C 0.059 0.944
D ** **
E ** **
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DISCUSSION
Even though in Italy the data items to be collected in health administrative 
databases are mandated by the central government, and the resulting central 
databases are therefore formally homogeneous, data collection takes place 
locally. Italy is characterized by long-standing regional differences in general 
and in healthcare in particular [AIE 2011]. Therefore it is possible that inaccurate 
local data collection processes hamper data quality and completeness, and 
in particular quality of personal identifiers that allow for record-linkage. 
Moreover, outpatient diagnosis are not among the data items collected, 
therefore identification of cohorts of patients with chronic diseases must rely on 
algorithms linking inpatient diagnosis with drug and other healthcare services 
utilization. Inhomogeneous quality of personal identifiers and completeness 
of recordings might lead to inhomogeneous accuracy in defining cohorts of 
patients and in identifying healthcare services that they access. This in turn 
might result in non-comparable measures of compliance with standards of care 
for chronic diseases.
This study addressed this concern by comparing such measures with measures 
obtained from a different data source, in five Italian regions. The database which 
was chosen as a comparator collects clinical data from GPs, and is therefore 
complementary to the healthcare administrative data.
The results show that administrative databases provide reliable estimates on 
regional level. Indeed, the four therapy indicators had the same distribution 
within the pairs of regional samples in the large majority of cases. The same 
was observed for the three diagnostic indicators except in one region, where the 
distributions were systematically different. The only bio-imaging indicator had 
different distributions within pairs. Geographical trends between regions were 
consistent across the two data sources. This provides evidence that the two data 
sources both estimate the same population distribution, thus supporting the 
use of indicators computed on health administrative databases for comparisons 
between regions.
It was not possible to obtain measurements from the two data sources on the 
same samples of GPs. This was partly due to the fact that the identity of the 
GPs belonging to the database HSD is confidential. Moreover, data linkage at 
individual or even GP level between different data sources had legal implications 
in terms of privacy regulations and the procedures needed to obtain permissions 
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for such data collection [OCSE 2013] could not be managed in the context of the 
VALORE Project. 
Therefore, observed differences in the distributions might be attributable to 
the composition of the following main effects: (a) due to non-random selection 
of the two samples, the GPs in the two samples were qualitatively different 
with actually different performance; (b) due to the different selection process 
that was conducted in the two type of data sources, the cohorts of patients 
of the two samples were qualitatively different subpopulations of the actual 
patients, which actually received different care; (c) difference in measurement, 
and HSD was likely biased (d) difference in measurement, and VALORE was 
likely biased. In the following paragraphs we provide plausible explanations to 
disentangle the effect (d), which is the object of this study, from (a), (b) and 
(c). It is a limitation of this study (see Limitations subsection) that some of the 
hypotheses we generated could not be tested. For cause (b), the main reference 
is the study by Gini et al, which found evidence that diabetic patients without 
therapy are less prevalent in the VALORE sample, and patients with heart 
failure are younger in the GP sample [Gini 2013].
For therapy indicators some differences are observed for HF in regions A and C. 
This is most likely due to reason (c), that is, patients included in the cohorts of 
HSD samples are different than patients included in the cohorts of the VALORE 
samples: indeed, age distribution of patients is different within the pairs, with 
the older cohort in VALORE being more likely to be assisted at home or in 
residential facilities, where GPs are likely to not record their activity completely 
[Filippi 2005, Gini 2013]. To test this assumption, analysis was restricted to 
patients aged 45-74, and indeed differences disappeared in region C in one 
indicator and in region A in both.  
For laboratory testing indicators, region E seem to underestimate consistently 
the actual values of the indicators, across the three diseases. This could 
amount to incomplete collection of administrative data from laboratories, or to 
higher use of out-of pocket services: indeed, the most recent National Health 
Survey found that in region E (Sicily) attitude to use diagnostic services that 
are non reimbursed by the Health System is higher than in the other regions 
participating to our study [Rosano 2011]. In the other regions differences do 
not show a consistent pattern, except perhaps in region C, where however (a) 
rather than (d) could be the cause, that is, GPs in the HSD sample and GPs in 
the VALORE sample in region C actually have different quality of care. Indeed, 
42070 Rosa Gini.indd   109 04-09-16   19:33
Chapter 4
110
in region C therapy indicators differ slightly between samples as well.
The bio-imaging indicator is probably underestimated by healthcare 
administrative databases: this might be due to out-of-pocket payment of this 
analysis, or to the fact that bio-imaging occurring during hospital admissions 
was not recorded by VALORE.
The overall similarity in measurements that was observed in this study 
generates in turn two observations. First, the standards of care in the sample 
of GPs participating to the HSD database seem to be representative of the 
distribution of the whole population of GPs. This was surprising, as GPs in HSD 
are selected because of completeness in their recordings, and good recording 
habits were expected to be associated with better standards of care. The second 
observation is that specialist physicians who assist chronic patients are likely to 
involve GPs in regular prescription of therapies and diagnostic tests: indeed, if 
GPs were unaware of such prescriptions in the share of patients who are visited 
by a specialist, their clinical data would detect lower standards. 
Our study was performed in samples drawn from regions belonging to three 
macro-areas of the country. Only a study performed in all regions could rule out 
the possibility that major issues show up in other areas, however the evidence 
we observed points to the direction of greater confidence. On the other hand, 
we do not claim that our results support reliability of similar measurements for 
any chronic disease. Indeed, this is determined by how reliable the algorithm for 
identifying the case is, and it was shown that this depends specifically on the 
disease, as frequency of hospital use, specificity of drug indication and pattern 
of healthcare may vary [Gini 2013]. 
In summary, the evidence we provide is promising enough to support comparison 
of regions with respect to indicators of compliance with standards of care for 
diabetes, IHD, and HF. Moreover, it supports the reliability of empirical studies, 
as the VALORE study [Visca 2013], using such indicators to evaluate the impact 
of organizational innovation in primary care.
Limitations
In this study indicators were computed on a population level for a convenience 
samples of GPs instead of directly being compared on a patient level for the 
same GPs. Similarity between samples could be due to random combination 
of contrasting effects rather than being attributable to the factors that we 
discussed. Although this is unlikely to have happened consistently in five 
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regions, an individual-level validation study only could address this concern. 
Italy, like several other countries, has a national legislation that permits 
exemption to the requirement for patient consent for projects in the public’s 
interest [OECD 2013], but this pathway was too complex to be faced in the 
context of the VALORE project.
It was not possible to test some of the hypotheses we generated to explain 
observed differences. A study involving more regions and different points in 
time could provide counterfactuals to test our hypotheses.
CONCLUSION
According to the evidence presented in this study, estimating compliance 
with standards of care for diabetes, ischaemic heart disease and heart failure 
from healthcare databases is likely to produce reliable results, even though 
completeness of data on diagnostic procedures should be assessed first. 
Performing studies comparing regions using such indicators as outcomes is a 
promising development with the potential to improve quality governance in 
the Italian healthcare system.
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ABSTRACT
Background
A recent comprehensive report on healthcare quality in Italy published by 
the Organization of Economic Co-operation and Development (OECD) 
recommended that regular monitoring of quality of primary care by means 
of compliance with standards of care for chronic diseases is performed. In a 
previous ecological study we explored whether compliance with standards of 
care could be reliably estimated on regional level using administrative databases. 
However, many questions remained. 
Methods
We compared estimates of compliance with diagnostic and therapeutical 
standards of care for type 2 diabetes (T2DM), hypertension and ischaemic heart 
disease (IHD) from administrative data (IAD) with estimates from medical 
records (MR) for the same persons registered with 24 GP’s. Data were linked at 
an individual level. For all the diseases MR was considered a gold standard for 
the denominator. MR and IAD were considered to contribute equally to the 
numerator of all the measures of compliance.
Results
32,688 persons entered the study, 12,673 having at least one of the three diseases 
according to at least one of the two data sources. The number of false negatives 
in IAD was relevantly high for all three conditions. IAD had imperfect sensitivity 
in detecting compliance to standards, especially in the case of diagnostic 
standards. Compliance with diagnostic standards was underestimated by IAD. 
The estimates of compliance with therapeutical standards were similar between 
IAD and MR. This finding can be partly explained through the coincidental 
combination of the high rates of false negatives and the low sensitivity on 
standards for IAD. 
Conclusion
Using Italian administrative databases for purposes of quality monitoring is 
possible, but limitations should be noted. IAD seems a good source to monitor 
the quality of care, especially with respect to compliance with therapeutical 
standards. However, estimates are still flawed through the relatively high 
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numbers of false negatives and underestimation of compliance with standards. 
IAD can help signalling critical or excellent clusters at local or central level 
informing discussions on performance between GP’s and local health unit 
managers and discussions between national and regional policy makers. An 
audit based on medical records is still the preferred method to assess a more 
comprehensive compliance with standards on the different levels. A close 
collaboration among GP’s, managers and policy makers is needed to ensure 
further refinement of data collection, measurement of quality and accurate and 
actionable interpretation of results.
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INTRODUCTION
A recent comprehensive report on healthcare quality in Italy published by 
the Organization of Economic Co-operation and Development (OECD) 
recommended that regular monitoring of quality of primary care by means 
of compliance with standards of care for chronic diseases is performed Italian 
National Healthcare System (NHS). Indeed, strengthening the national quality 
governance model on this sector of health care is a strategic objective in an 
ageing population, with an expected growing burden of chronic conditions. 
In the report, smarter payment systems for general practitioners that reward 
quality are advocated for, with specific reference to compliance with standards 
of care for chronic conditions [OECD2015]. 
However, measuring compliance with standards of care for chronic diseases is a 
challenging task for the Italian NHS [Gini2014]. Italian administrative databases 
(IAD) are available to the NHS uniformly from the whole country, and are the 
natural candidate data source. However their use poses a double problem: 
accuracy in the estimate of the denominator, and accuracy in the estimate of 
the numerator.
As for the denominator, the data items collected in IAD do not allow direct 
identification of patients with chronic conditions. Indeed, diagnoses performed 
in an outpatient setting are not collected in IAD, and this is generally the case 
when a chronic disease is diagnosed [Gini2013]. In Italy every adult patient 
is entitled to choose a general practitioner (GP), and specialist care can be 
requested to the NHS by patients only upon referral by their GPs. GP’s soon 
become aware if a chronic disease is diagnosed in their patients. Primary care 
medical records (MR) rather than IAD may be the right source of information 
to define denominator. 
On the other hand, for the numerator, compliance with standards of care may 
go undetected both by IAD and by MR. Over-the-counter purchase of prescribed 
drugs is not recorded in IAD, and drug prescriptions issued by specialists are 
not recorded by GPs. Diagnostic tests ordered by GPs or specialists are only 
recorded by IAD if they are performed in facilities belonging to, or contracted 
by, the NHS. This may fail to happen when access to such facilities is perceived 
as slow or cumbersome by patients and tests are performed outside the 
NHS system. Diagnostic exams are recorded in the MR either if GPs are the 
prescribers or if patients themselves provide the result to their GPs, since 
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there is no automatic transmission of test results in place in Italy. Ordering of 
diagnostic tests may more often be done by a specialist for more severe patients, 
or when the local organization of the healthcare system fails to encourage 
patients to access primary rather than secondary care. Hence sensitivity of MR 
in detecting diagnostic tests depends both on patient-level and on geographic-
level characteristics [Gini2014].
For the reasons provided above, it was unclear whether compliance with 
standards of care in a population of patients with chronic diseases could be 
reliably estimated using IAD and, as a consequence, could be used to inform 
discussions on quality improvement and accountability on a local and central 
level. It was however evident that comparison with primary care MR had a 
chance to provide more knowledge on these questions.
In previous studies, case-finding strategies in IAD have been developed and 
validated [Gini2013, Gini2015b], and compliance with standards of care measured 
on this denominator has been compared with indicators obtained from a 
database of MR [Gini2014]. The results were encouraging, because estimates 
were very similar across the two data sources. However, the comparison was 
an ecological study, and many questions remained. It was not known whether 
the sample of patients detected by IAD was representative of the true set of 
patients with the disease, or rather false positives and false negatives in the 
denominator had different values of compliance. This could have combined 
with incompleteness of IAD in the numerator, to provide a falsely reassuring 
similarity between estimates. 
The MATRICE Project, started by Italian National Agency for Regional Health 
Systems in 2011, aimed to assess in a more comprehensive way the validity of 
IAD as a data source to monitor quality of health care for chronic diseases. 
MATRICE obtained from the National Authority for Personal Data Protection 
permission to link IAD and MR of a large sample of patients. In this study we 
could therefore compare compliance with standards of care for type 2 diabetes 
mellitus (T2DM), hypertension and ischaemic heart disease (IHD) using both 
data sources, at the individual level.
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METHODS
Study design
On each subject we defined denominators and numerators of each standard of 
care, both using IAD and using MR. Based on a previous study, we considered 
MR to be a gold standard for the denominator [Gini2015a, Gini2015b]. 
Therefore, for each disease, we considered as true positives the persons who 
were in the denominator for both sources, as false positives the persons who 
were in the denominator for IAD, but not for MR, and as false negatives the 
persons who were in the denominator for MR, but not for IAD. Based on the 
arguments in the Introduction, we considered that neither IAD nor MR had 
complete information on the numerator, so we assessed concordance among 
the two variables, in the whole study population. To assess concordance among 
measures of indicators, and representativeness of the IAD denominators, 
we compared the indicators (ratio of numerator to denominator) in several 
subpopulations (denominators according to IAD, denominator according to 
MR, true positives, false positives, false negatives) using as numerator in turn 
IAD, MR and either of the two sources.
See the subsection “Study variables” below for more details on how the variables 
were defined, and the subsection “Data analysis” for more details on the 
statistical analysis.
Setting
From the point of view of organization of health care, Italy is divided into 21 
regions, and each region is divided in geographic subareas (on average 10 per 
region). Health care for the population in each area is managed by organizations 
called Local Health Units (LHU). LHUs collect administrative data on the health 
care they provide to their inhabitants which together form the basis of the IAD. 
The National College for General Practitioners (SIMG) is the national scientific 
society of General Practitioners in Italy, which provides training to the GPs to 
improve the quality of recording in their medical records.
A sample of 25 GPs belonging to five regions was recruited in this study. Three 
regions were in the North (Lombardy, Veneto, Emilia-Romagna), one in the 
Center (Tuscany) and one in the South (Puglia). All the GP’s of the same region 
belonged to the same LHU.
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Standards of care
A panel of experts in organization of primary care services, epidemiologists and 
clinicians selected clinical guidelines for T2DM, hypertension and IHD which 
were expected to be easy to monitor on IAD. The result is depicted in Table 1: 
six indicators for annual diagnostic follow-up and treatment with four drug 
classes were chosen, each applying to one or more of the three conditions, 
totalling 18 indicators. Each recommendation is labelled with the name of the 
scientific society who published it, and with its grade and level [GRADE2004]. 
Data collection
A script was developed by SIMG to automatically query the medical records 
of the 25 GPs. The script first identified all subjects in charge to the GP at 1st 
January 2012. Then it computed variables estimating compliance with the 
standards of care during 2012 for each subject. Finally it applied validated 
algorithms to detect whether subjects had one or more of the diseases under 
study [Gini2015a]. 
All the IAD data available to the healthcare system on the same population 
was extracted from the LHUs, using TheMatrix, an open source software tool 
[TheMatrix]. 
Personal identifiers were pseudonymized at extraction, using the same 
encryption key, and all the data was automatically transmitted to the National 
Research Council (CNR), which had been granted permission to store and 
process this data. Investigators from Agenzia regionale di sanità della Toscana 
(ARS) developed a script to compute the study variables from IAD data, and 
CNR ran it on the IAD data. Finally, CNR linked the analytical dataset and 
medical records at individual level and transmitted the resulting dataset to ARS 
for statistical analysis.
One of the GPs from Lombardy was on leave in 2012 and was therefore discarded 
from the study after data collection.
Study variables
Case-finding algorithms to compute denominators for T2DM, hypertension 
and IHD from MR were selected based on a previous validation study. This 
study proved that the case-finding algorithms of the three diseases all had 
almost perfect positive predictive value [Gini2015a]. Since population prevalence 
estimated with those algorithms are very high, sensitivity must be very high 
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as well [Gini2013]. For this reason, in this study we used the denominator 
from MR as a perfect identification of the true denominator. Case-finding 
algorithms for denominators from IAD used a combination of diagnosis from 
hospital discharge records, disease-specific exemptions from copayment, and 
utilization of treatments. These algorithms are described in detail in Chapter 3 
of this thesis. Sensitivity and positive predictive values of those algorithms were 
estimated in a separate study [Gini2015b].
Numerators were defined similarly across the two data sources. The subject 
was considered to be compliant with a treatment if at least two records of 
the treatment with different dates were found in 2012, and compliant with a 
recommended diagnostic test if at least one prescription for that test was found 
in 2012, except in the case of glycated hemoglobin where two records were 
requested. 
As discussed in the Introduction, both IAD and MR have imperfect sensitivity 
to define the numerators. For each standard of care we analysed three different 
variables: numerator as measured by IAD, numerator as measured by MR, 
numerator as measured by either source (EITHER). 
Measures of compliance
For each person in the study population we had variables estimating 
denominators and variables estimating numerators computed both from IAD 
and from MR. We were therefore able to compare three ways of estimating the 
ratio between numerator and denominator; based on IAD only, based on MR 
only, and based on either IAD or MR. When based on IAD only:  both denominator 
and numerator are estimated from IAD. This is mainly the perspective from 
the national and regional NHS policy maker, who have only IAD data available. 
When based on MR only, the denominator and numerator both come from MR. 
This is usually the perspective of the GP when evaluating his/her own practice. 
A third perspective takes the whole set of services used by the population into 
account. This perspective, the true value of compliance with the standard of 
care in the population with the disease, is often lacking. With our data we could 
estimate this measure by using denominator from MR and numerator from 
either MR or IAD: MR is the best possible denominator, because it is a gold 
standard, and “either MR or IAD” is the best possible numerator, because the 
two data sources compensate each other’s incompleteness. We refer to this as 
the “best possible estimate”.
42070 Rosa Gini.indd   122 04-09-16   19:33
5Measuring standards of care in IAD: strengths and limitations
123
Quality governance scenarios
We considered two scenarios of quality governance where the results of our 
comparison can be useful, as shown in Table 1: a local scenario, when local 
or regional decision makers discuss quality of care with GPs with a focus 
on quality improvement, and a central scenario, when regional or national 
decision makers discuss quality of care, respectively, with local or regional 
decision makers with a focus on quality monitoring. To support the local 
governance we compared the point of view of the healthcare system with 
the point of view of GP’s, on clusters of patients assisted by the same GP. 
To support the central governance we compared the point of view of the 
healthcare system with the estimated population-based value on clusters of 
patients assisted by the same LHU.
Table 1. Standards of care, with levels and grades of recommendation. SID: Italian Diabetes Society. 
ESC/EASD: European Society of Cardiology and European Association for the Study of Diabetes. ACC/
AHA: American Cardiology Association and American Heart Association. A symbol * means that the 
recommendation only applies when the condition is at a high level of severity. Diagnostic tests are 
recommended once per year, except HbA1c for T2DM which is recommended twice a year.
Guideline type Recommendation 
in  the guideline
T2DM Hypertension IHD
Therapeutic Statins level I, grade A 
(SID)
Level  IIa, grade B
(ACC/AHA)
Beta-blockers Level  I, grade A
(ACC/AHA) *
ACE inhibitors Level  I, grade A
(ACC/AHA) *
Antithrombotics Level  I, grade A
(ACC/AHA)
Diagnostic Microalbuminuria 
test
level VI, grade B
(SID)
level I, grade B
(ESH/ESC)
HbA1c tests level VI, grade B 
(SID)
level I, grade B
(ESH/ESC) $
Level  I, grade A
(ESC/EASD)
Lipid profile level III, grade B 
(SID) (ESH/ESC)
Level  III, grade B
(ACC/AHA)
Clearence/
creatinine test
level VI, grade B 
(SID)
level I, grade B
(ESH/ESC)
ECG level I, grade B
(ESH/ESC)
X*
Eye exam level III, grade B 
(SID)
level IIa, grade C
(ESH/ESC)
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Data analysis
For each disease we identified the denominator according to IAD, and computed 
false positives and false negatives using MR as a gold standard.
Since we didn’t have a gold standard for numerators, we computed Cohen’s 
kappa between the MR and IAD numerators. Concordance was categorized 
as “Poor” (<0.20), “Fair” (0.21-0.40), “Moderate” (0.41-0.60), “Good” (0.61-0.80), 
“Very good” (0.81-1.00) [Landis1977].  Moreover, we computed the percentage of 
those in the numerator in one source that overlaps with those in the numerator 
in the other source. We computed the increase in the numerator when adding 
EITHER to IAD. 
For each standard and each cluster (GP or LHU), the three measures (ratios of 
numerator to denominator) were standardised per age and gender, using as a 
standard the age and gender distribution obtained from MR (data not shown). 
We estimated average difference between the indicators computed by pairs of 
sources on each cluster and tested significance. Estimates were obtained by 
fitting logistic models on a dataset with a record per patient and source, with 
the source of information (IAD vs MR, or IAD versus EITHER) as a dependent 
variable. Variance was estimated by clustering the observations on the same 
subject. Models were adjusted per LHU, age band and gender, with interaction 
between source and cluster variable (GP or LHU).
For each disease, to assess whether patients in the IAD denominator (true 
positives + false positives) were representative of the true population with the 
disease (true positives + false negatives), we estimated the difference between 
compliance computed on true positives and, respectively, false positives and 
false negatives. In this analysis compliance was estimated with EITHER, and 
was adjusted per LHU, age and gender.
Ethics
Permission to perform record linkage between pseudonymized administrative 
data and medical records was granted by the Italian National Authority for the 
Privacy regulation. Specifically, permission was granted to CNR to store and 
process the data, and to ARS to obtain the linked individual-level analytical 
dataset, for statistical analysis.
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RESULTS
Study population
Data on 32,688 subjects was collected. The average number of patients per GP 
was 1,362 (IQ range: 1,209-1,500). 
Comparison of variables detecting diseases (denominators)
12,673 subjects had at least one of the three diseases according to at least one of 
the two data sources. According to IAD, 2,047 subjects had T2DM: only 107 (5%) 
were false positives, but additional 823 subjects were false negatives, according 
to MR (+40%).  8,392 subjects had hypertension according to IAD: 1,103 (13%) 
were false positives, and additional 3,573 subjects were false negatives, according 
to MR (+42%). 745 subjects had IHD according to IAD: 145 (19%) were false 
positives, and additional 776 subjects were false negatives (+ 104%).
Comparison of variables measuring compliance (numerators)
On the general population Cohen’s kappa showed very good concordance 
(from 0.92 to 0.89) in the four indicators of compliance with therapies. Among 
diagnostic tests, concordance was very good (0.84) for microalbuminuria, 
good (from 0.76 to 0.66) for glycated hemoglobin, lipid profile and creatinine, 
moderate (0.44) for ECG and fair (0.27) for eye exams (0.27) (Table 3). Information 
provided by MR was almost complete (from 97% to 94%) for compliance with 
therapies, and was more complete than IAD in all the other indicators except 
eye exam (20%) (Table 3). Adding EITHER to IAD increased the numerator by 
less than 15% in the case of therapies and of eye exam, from 24% to 32% in 
microalbuminuria, glycated hemoglobin, creatinine and lipid profile, and more 
than 50% for ECG.
Comparison of indicators of compliance
Scatter plots of the age-and-gender standardized indicators on the clusters of 
patients are represented in Figure 2. 
IAD and MR had on average very similar estimates for therapeutic indicators, 
although for statins in both T2DM and IHD, and for betablockers in IHD, 
IAD had a significantly higher estimate (respectively +4.1, +4.5 and +5.4). The 
results were confirmed when comparing IAD with the “best estimate”, and 
differences were reduced. In the case of diagnostic indicators, the picture was 
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Table 2. Scenarios of quality governance where the results from this study can be used. IAD: 
administrative databases, MR: primary care medical records, EITHER: either among IAD or MR
Quality governance 
scenarios
Local Central
Activity Quality improvement Quality monitoring
Actors Local decision-
makers 
GPs Local  (regional) 
decision-makers
Regional 
(national) 
decision-makers 
Clusters Patients assisted by the same GP Patients assisted by the same LHU 
(region)
Point of view Healthcare 
system
GP Healthcare 
system
Best estimate
Denominator IAD MR IAD MR
Numerator IAD MR IAD EITHER
more complex, with IAD showing higher values than MR and lower values than 
the “best estimate”, often significantly. Average difference between IAD and MR 
was significant and higher than 5 percentage points for glycated hemoglobin 
and eye exam in T2DM. Average difference between IAD and “best estimate” 
was significant in all indicators except glycated hemoglobin, and in all but 
microalbuminuria and eye exam (Table 4).
Representativeness of subpopulations
Indicators in false negatives were much lower (from 15.8 to 40.1 percentage 
points difference) with respect to indicators in true positives in the case of 
T2DM, and substantially lower (from 6.7 to 24.6 percentage points difference) 
in the case of IHD (Table 3). They were lower in the case of hypertension, too, 
but less so (from 4.8 to 13.9 percentage points difference). Differences were 
higher for indicators of therapies. Differences between true positives and false 
positives were similar but slightly smaller (Table 3).
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DISCUSSION
Numerators in the whole population were concordant between MR and IAD 
in the case of therapies, less so in the case of diagnostic testing, especially 
when more complex tests were considered (ECG and eye exam). Indicators 
of compliance with therapies showed low average difference between data 
sources, although still significant in some cases. Indicators of compliance with 
diagnostic monitoring were imbalanced: IAD estimated higher compliance 
with respect to MR, and lower compliance with respect to the best possible 
estimate. This was the result of a combination of different errors. Patients in 
the denominators for IAD were not representative of the true population of 
patients, especially in the case of T2DM and of therapeutic indicators. Small 
average differences between the estimates of IAD and the best estimates are 
partially coincidental and therefore run the risk of not being reproducible in all 
the regions and across time.
Interpretation of the findings: estimating compliance with recommended therapies 
and diagnostic tests 
This individual-level study showed that the confounding effects anticipated in 
the limitations of the ecological study were indeed playing an important role in 
the estimate of indicators performed on IAD. 
The effects of different misclassifications were balanced in the case of therapies, 
because concordance between MR and IAD was high, and MR was almost 
complete; therefore, the absence from the denominator of false negatives, who 
had lower compliance, compensated the small overall underestimation of the 
numerator. A small contribution was also provided by the comparatively small 
share of false positives, who had similar profile as false negatives.
As expected, numerators from IAD and MR were less concordant in the 
case of diagnostic tests, and numerators measured by IAD were lower. The 
combination of errors produced both balanced and imbalanced results. In the 
case of glycated hemoglobin test, in false negatives the indicator was less that 
40 percentage points lower than in true positives and the overall agreement 
between the administrative and “best estimate” was due to underestimation 
of the numerator on the IAD denominator. However there was in important 
imbalance between IAD and MR estimate in T2DM patients. In recent, similar 
validation studies of estimates of measures of performance on diabetic patients 
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from administrative databases from the United States, similar mixed effects 
were observed [Hirsch2013, Sakshaug 2014].
Consequences on the use of Italian administrative data in a systematic quality 
monitoring and improvement strategy 
In a quality monitoring strategy IAD seems a reliable tool for signalling 
purposes: when IAD detects either an excellent or a poor performance in a 
cluster of patients, according to our data it is very likely that the observation 
corresponds to a truly interesting fact, particularly in the case of compliance 
with therapeutic standards, and with yearly laboratory diagnostic tests.
However, we found that a combination of mutually balancing misclassifications 
is at the root of the similarity between IAD results and our best estimate of the 
true compliance in the patients with a diagnosed chronic disease, especially in 
the case of diagnostic recommendations. Specific caution should be taken in 
interpreting coverage of the twice-yearly glycated hemoglobin test in diabetic 
patients. Likewise, the measures of compliance with annual eye exam in 
diabetics, and annual ECG in hypertensive and IHD patients look fragile.
This has slightly different implications for a “local” quality improvement rather 
than a “central” quality monitoring scenario. 
In a local scenario the main actors are, on the one hand, the local (or regional) 
decision-makers for the organization of healthcare for chronic diseases and, 
on the other, the GPs. The main objective is promoting appropriateness in 
healthcare for chronic diseases, that is, supporting the role of primary care as the 
main driver, in close collaboration with specialist care [OECD2015]. Thanks to 
IAD, decision makers have the possibility of producing estimates of compliance 
across a range of GPs.  While this sort of comparison is in itself very informative, 
it is clear from our validation that it is not precise enough to provide a reliable 
ranking of the performance of GPs, nor to support quality-based payment 
systems, such as a pay-for-performance scheme. Rather it should be taken as the 
starting point for quality improvement initiatives, such as a more detailed audit 
of quality based on medical records. Clusters of patients with low compliance, 
as signalled by IAD, must be analysed in conjunction with context information, 
such as accessibility to local NHS facilities for diagnostic tests, and possible 
drive of local specialist healthcare providers towards replacing, rather than 
supplementing, primary care, sometimes implying out-of-pocket purchase of 
care. Both those elements can provide input to action for local decision-makers. 
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Clusters with high compliance, in turn, must be critically analysed: if patients 
with mild forms of chronic diseases are not appropriately followed-up, they will 
remain undetected by IAD, which will therefore measure higher compliance 
only on the more severe patients, thus providing a falsely reassuring picture. 
This is likely to be associated with clusters where IAD detects low prevalence. 
Aside from those extremes, quality governance at the local levels should focus 
on an integrated interpretation of IAD and MR data, which are both available 
to the actors. 
In a central scenario the main actors are all decision-makers for the organization 
of healthcare system, at different levels: local vs regional, or regional vs national. 
The main objective is monitoring quality of healthcare and making comparisons 
between the different geographical entities to assure equity in quality of care 
amongst the whole Italian population. Integrated analysis of IAD and MR is 
not possible in this scenario, therefore context for interpretation of signals 
from IAD must be carefully built in collaboration with local decision-makers, 
who can provide crucial context information, in particular findings from local 
analysis of MR. Several resources are available to inform this assessment: SIMG 
produces a yearly report comparing compliance with standards of care across 
Italian regions estimated from MR of a sample of GPs [HS2015], and survey data 
are produced every five years by the National Institute of Statistics, estimating 
access to NHS specialist facilities [ISTAT2015]. 
Developments 
Routine data-linkage between administrative data and key elements from 
primary care medical records, such as diagnosis of a chronic disease and 
compliance with standards of care, would critically improve the quality 
governance of primary care. Local initiatives have been initiated to this respect, 
such as the SOLE network in Emilia-Romagna [OECD2015].
Analytical calibration methods that include the results from this validation 
study, as well as aggregated measures produced by SIMG and the National 
Institute of Statistics, could be developed to improve estimates produced by 
IAD.
Implications for the use of the indicators in studies of impact
Indicators of compliance with standards of care can be used to evaluate the 
impact of innovative strategies [Chien2012, Visca2013]. Our results support 
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overall this use of the indicators, provided a difference-in-differences design 
is adopted, and the impact is measured across a short time span, so that it can 
be assumed that misclassification does not change differentially across exposed 
and non exposed to the intervention. If this is not possible, elements that may 
imbalance misclassification across exposed and non-exposed, or across time, 
need to be discussed in the limitations of the study.
Permission to perform record linkage was an extraordinary result
This study was made possible by an explicit permission of the Italian National 
Authority for the Privacy regulation, which allowed individual-level record 
linkage between IAD and MR on a large sample of patients. It is encouraging 
that such permission was granted, and routes for expedited permission should 
be created, especially for validation studies of administrative data. Indeed, this 
would allow rapid generation of evidence crucial for public health and health 
system governance in a transparent and legal manner.
Limitations
The numerator that we used as a “best estimate” may have overestimated the 
true compliance, as GP drug prescriptions may have not been filled in, and GP 
test orders may have not been performed in reality. The first effect is however 
likely to be small, as a second prescription is required for the patient to be 
compliant. Moreover, the concordance we observed between MR and IAD data 
was very high in numerators of therapeutic standards (Table 3). 
CONCLUSION
Using Italian administrative databases for purposes of quality monitoring is 
possible, but limitations should be noted. IAD seems a good source to monitor 
the quality of care, especially with respect to compliance with therapeutical 
standards. However, estimates are still flawed through the relatively high 
numbers of false negatives and underestimation of compliance with standards. 
IAD can help signalling critical or excellent clusters at local or central level 
informing discussions on performance between GP’s and local health unit 
managers and discussions between national and regional policy makers. An 
audit based on medical records is still the preferred method to assess a more 
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comprehensive compliance with standards on the different levels. A close 
collaboration among GP’s, managers and policy makers is needed to ensure 
further refinement of data collection, measurement of quality and accurate and 
actionable interpretation of results.
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ABSTRACT
Introduction
We see increased use of existing observational data in order to achieve fast 
and transparent production of empirical evidence in health care research. 
Multiple databases are often used to increase power, to assess rare exposures 
or outcomes, or to study diverse populations. For privacy and sociological 
reasons, original data on individual subjects can’t be shared, requiring a 
distributed network approach where data processing is performed prior to 
data sharing. 
Case Descriptions and Variation Among Sites
We created a conceptual framework distinguishing three steps in local data 
processing: (1) data reorganization into a data structure common across the 
network; (2) derivation of study variables not present in original data; and (3) 
application of study design to transform longitudinal data into aggregated data 
sets for statistical analysis. We applied this framework to four case studies to 
identify similarities and differences in the United States and Europe: Exploring 
and Understanding Adverse Drug Reactions by Integrative Mining of Clinical 
Records and Biomedical Knowledge(EUADR), Observational Medical Outcomes 
Partnership(OMOP), the Food and Drug Administration’s (FDA’s) Mini-Sentinel, 
and the Italian network—the Integration of Content Management Information 
on the Territory of Patients with Complex Diseases or with Chronic Conditions 
(MATRICE).
Findings
National networks (OMOP, Mini-Sentinel, MATRICE) all adopted shared 
procedures for local data reorganization. The multinational EU-ADR network 
needed locally defined procedures to reorganize its heterogeneous data into a 
common structure. Derivation of new data elements was centrally defined in 
all networks but the procedure was not shared in EU-ADR. Application of study 
design was a common and shared procedure in all the case studies. Computer 
procedures were embodied in different programming languages, including SAS, 
R, SQL, Java, and C++.
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Conclusion
Using our conceptual framework we found several areas that would benefit from 
research to identify optimal standards for production of empirical knowledge 
from existing databases.
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INTRODUCTION
Observational studies based on secondary use of existing data collected in the 
process of health care delivery have the potential to deliver sound evidence 
quickly enough to support health policy making, which it is often subject to 
time constraints [1] thus complementing evidence generated by means of 
primary data collection. However, some epidemiological questions, especially 
those concerning rare events, rare exposures, and small groups of patients, 
require more data than is available in any single observational database.[2,3,4] 
Therefore a growing number of studies use data from networks of databases, 
sometimes from different countries. Although some of these networks were 
formed ad hoc for a particular study, several more permanent networks have 
now been established, where the partners have agreed on an infrastructure and 
workflow to be reused for different studies.
Privacy regulations and concerns about data ownership and interpretation 
prevent easy central pooling of original health care data that is now stored in 
different databases and can be used for secondary purposes.[5] In spite of these 
barriers several approaches can be used to still employ this data for secondary 
purposes and pool the results. For example, investigators at each data source 
can independently create a protocol and execute the study, and estimates are 
only generated afterward through meta-analysis. A further step is to share the 
protocol across sites, but asking the local partners to adapt it to their local data 
and to implement it in their own usual software, to produce local estimates for 
meta-analysis that are compatible by design. However, most networks now go 
even further and adopt a distributed analysis approach: each database is locally 
transformed to a representation that is similar across the network, and one 
single computer program performing the analysis is shared and executed at 
each site.[4,6]
The need to pool data across different databases is most pronounced in the 
area of drug safety surveillance.[7] In Europe, the Exploring and Understanding 
Adverse Drug Reactions by Integrative Mining of Clinical Records and 
Biomedical Knowledge Project (EU-ADR)[8,9] was initiated in 2008 for 
investigating the feasibility of signal detection across multiple health care 
databases. Meanwhile, the United States Food and Drug Administration’s 
(FDA’s) Mini-Sentinel Project[10] was developed to support medical product 
safety monitoring and now includes 18 data partners within a distributed 
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network. Also in the United States, from 2010 to 2014 the Observational Medical 
Outcomes Partnership (OMOP)11 performed methodological research on drug 
safety studies and developed tools and a database network for performing risk 
identification. Other networks have been developed in other countries, like the 
Canadian Network for Observational Drug Effect Studies (CNODES) project in 
Canada and the Asian Pharmacoepidemiology Network (ASPEN) network in 
Asia.[4] Pharmacoepidemiology is not the only field where the opportunities 
for combining multiple databases are increasing: in the context of public health 
or health services research, gathering data from different regions or countries 
has the added value that different policies can be compared. Mini-Sentinel and 
EU-ADR are also used to evaluate the impact of regulatory actions. And the 
Italian network—the Integration of Content Management Information on 
the Territory of Patients with Complex Diseases or with Chronic Conditions 
(Integrazione dei Contenuti Informativi per la Gestione sul Territorio di Pazienti con 
Patologie Complesse o con Patologie Croniche)(MATRICE) Project,[12,13] funded 
by the Italian Ministry of Health— created a distributed network to evaluate 
the impact of health policies on quality and equity of health care.
We developed a conceptual framework to analyze the process of data 
management in a network of databases adopting the distributed analysis 
approach to perform observational studies. We applied the framework to four 
case studies, and identified similarities and substantial differences.
Purpose and Target of This Study
The purpose of this study was to compare processes that share the same aim 
but are presently described in separate scientific papers or other documents. 
Our intent was to find which choices were common among different networks 
and what the differences were. The comparison findings highlight topics for 
research. Research should be aimed to further explore if common choices 
are indeed optimal, and to assess which among the observed differences have 
an impact on the quality of the processes and on the generated evidence: as 
such, our findings may be of interest for researchers in medical informatics 
and methodologists of observational studies. Moreover, the framework and 
the findings from the comparison provide a unified presentation of strategic 
choices that are of interest to researchers who are setting or modifying their 
own networks.
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METHODS
Sampling and Data Collection
Some of the paper’s authors first conceived of the conceptual framework as an 
abstraction of the process in place in the European network EU-ADR and in 
the Italian network MATRICE. They reached out to the authors participating 
in the United States networks OMOP and Mini-Sentinel, to compare networks 
of different continents. Data collection was performed via document (scientific 
papers and websites) analysis and interviews with coauthors. The manuscript 
was reviewed by all the authors.
The Four Networks
The EU-ADR Project was funded by the European Commission under 
Framework Programme [7] (FP7) and ran from 2008 to 2012 with the aim of 
producing a computerized integrated system for the early detection of drug 
safety signals. The project used data from eight databases from four European 
countries (Denmark, Italy, the Netherlands, and the United Kingdom) covering 
a population of about 20 million individuals overall with almost 60 million 
person-years (PYs) of follow-up.[3] Subsequently, the EU-ADR workflow has 
been further improved and applied in several collaborative drug-safety studies 
concerning NSAIDs (SOS),[14,15] pandemic influenza vaccine (VAESCO),[16] 
the arrhythmogenic potential of drugs (ARITMO),[17] and hypoglycemic drugs 
(SAFEGUARD).[18] The subjects of the studies performed in this network 
include methodology[19,20,21,22] drug utilization, disease incidence,[23] 
signal detection,[24] testing,[25,26] filtering,[27] and substantiation.[28] The 
workflow is currently being extended in the European Medical Information 
Framework (EMIF) project.[29] 
The United States FDA’s Mini-Sentinel program[30] began in 2008 and has 
created a distributed data network of 18 data partners covering a population 
of over 150 million persons and 380 million PYs in the United States.[6] Mini-
Sentinel was structured to produce both fast, standardized replies to specific 
queries (called Rapid Response queries) and studies based on ad hoc developed 
protocol (i.e., Protocol-based Assessments). Hundreds of Rapid Response 
queries are executed each year, and 14 Protocol-based Assessments have been 
completed or are underway. Network activities cover a broad range of topics 
including drug utilization, disease burden, the impact of regulatory policies, 
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and the comparative safety of medical products.[31] At the same time, several 
studies focusing on methodology have been completed.[32,33,34,35,36,37] In 
2015 the Mini- Sentinel pilot transitioned to the Sentinel system that is become 
part of the FDA’s regulatory framework.
OMOP was a public-private partnership that ran from 2010 to 2014 and was 
part of the Innovation in Medical Evidence Development and Surveillance 
(IMEDS) program of the Reagan-Udall Foundation for the FDA. Its goal was to 
help determine best practices for use of observational health care data. OMOP 
currently maintained five commercial databases covering 164.[9] million 
persons in its own central venue, and its data partner network included six 
other databases covering an additional 105 million persons.[8,38] The network 
was used to develop tools for performing observational studies in a database 
network, including the OMOP Common Data Model (CDM),[39] the OMOP 
Vocabulary,[40] and tools for assessing data quality,[41] as well as research into the 
development and evaluation of methods for drug-associated risk identification.
[42] In 2014 the OMOP research team launched the Observational Health Data 
Sciences and Informatics (OHDSI) (pronounced “Odyssey”) program[43] which 
is currently continuing the activity of OMOP.
The MATRICE project was funded by the Italian Ministry of Health and ran 
from 2011 to 2014 under the coordination of the Italian National Agency for 
Regional Health Services to measure quality of health care for chronic diseases. 
MATRICE developed a distributed network infrastructure specific to local and 
regional Italian administrative databases and is rapidly growing to include 
participants beyond the project. Currently, it covers a population of about 9 
million subjects living in some of the Local Health Authorities in 9 of the 21 
regional health care systems in the country. Studies completed so far using data 
from this network were aimed at evaluating the quality and equity of primary 
care, the impact of policies in this field [44,45,46,47] and methodological 
challenges of such studies.[48,49] The network currently participates in several 
studies funded by the Italian Ministry of Health.
Conceptual Framework
Figure 1 depicts our conceptual framework, showing a workflow consisting of 
data sets (D1, D2, D3, and D4) and transformation processes (T1, T2, and T3). 
The conceptual framework does not contain recommendations in itself: it is 
just a conceptual abstraction of the logical sequence of steps needed to
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Box 1. Definition of the Conceptual Framework
DATA SETS AND DATA TRANSFORMATIONS
D1 (original databases: DBs) is a collection of data sources controlled by a single organization that has 
procedures in place to link them with each other at the individual level, thus creating a single data pool 
on the same subjects. The term “DB” refers to an organization that has access to the data.
T1 (data reorganization) is a data modeling step: transformation from the locally defined data 
repository into a global (common) schema with standardized variable and attribute names, without 
loss of information. Simple one-on-one recoding is performed as well, such as making data formats and 
coding of attributes (e.g., gender) identical. T1 is specific per DB but independent of the specific study.
D2 (global schema, GS) is a general database schema that contains all the attributes thatare necessary 
to answer a realm of study questions (“use cases”) that are of general interest to the network, such 
as incidence of disease, drug utilization, or association studies. D2 has a defined set of table names, 
attribute names, and formats. D2 plays the same role as a GS of a data integration system.50 Therefore, a 
set of correspondences are defined between this schema and the D1. Note that (1) these correspondences 
may not be complete for all databases: for instance, if a D1 does not have information about primary care 
diagnoses, these attributes will remain empty in the D2; and (2) some attributes (typically, diagnoses or 
drugs) might have different coding for different DBs in the network.
T2 (data derivation) is the step where novel meaning is obtained from D2 by means of an explicit 
manipulation and combination of D2 data. These manipulations are necessary when a study variable 
is not among those collected by one of the DBs in the network, and must therefore be represented, by 
proxy, as a combination of whatever pertinent information is available. When the study variable is a 
disease, this process is referred to in the literature as disease phenotyping.51 T2 is often specific per DB, 
as it depends on the information that was originally collected, and is often specific per study, although 
conceivably past data derivations could be reused in new studies. As an example of T2, if the presence 
of diabetes in study subjects needs to be assessed, DBs collecting data from primary care can identify 
the information from a general practitioner’s (GP’s) diagnosis, whereas claims databases without clinical 
data from primary care may use dispensing of antidiabetic drugs as proxy, and combinations may also 
be possible.
D3 (derived data) are the data sets derived in T2, each containing one or more study-specific variables. 
Derived data may be occurrence of a disease, or other information like the duration of exposure to a 
specific drug. For instance a drug safety study has three basic types of derived data: the outcome of 
interest (often sudden occurrence of a condition), the exposure (a sequence of drug utilization episodes), 
and presence in the study cohort, with beginning and end dates of follow-up. While the tables forD2 
contain multiple, longitudinal observations per subject, each generated during an encounter and each 
containing multiple codes, D3 contains as many observations per subject as requested by the study 
design (often one single observation). Original data (as modeled in D2) is therefore “rolled up”during T2 
to create in D3 the best possible approximation of the variables needed in the specific study.
T3 (study design application) is data transformation for a specific analytic: based on the protocol 
of a study with specific design (application of inclusion and exclusion criteria, selection of exposure 
windows, propensity and disease score estimation, control selection, matching). T3 produces the data 
sets for statistical analysis. Within this transformation data may be de-identified and aggregated to 
various levels. T3 is specific to the study, butis the same across participant DBs. 
D4 (data sets for analysis) is the result of T3. D4s from all the partners in the network are similar. Based 
on the level of sharing that is allowed, D4 may stay local at the database custodian or be pooled in a 
central repository. In both situations, statistical analysis on D4 follows and produces estimates to be 
interpreted.
QUALITY
1. Process verification: assuring quality, transparency and reproducibility of the stepwise data extraction 
process, e.g., common standard process documentation, process automatization with common use of 
dedicated software, and parallel programming; and
2. Outcome verification: checking intermediate and final output against standards, including the 
following: 
• Benchmarking of D3 (derived data) against external data (e.g., determining whether observed disease 
rates are in line with those reported in literature);
• Benchmarking of D3 within the network (comparison of DB-specific output to assess homogeneity);
• Validation of D3 using a gold standard (e.g., chart review) to assess performance of data derivation 
(e.g., positive predictive value); and
• Validation of D4 using expected results (i.e., using a reference set of known causal or non causal 
associations).
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perform studies in a network. Figure 2 describes each step in detail. During a 
typical study, data transformation T2 and T3 might be performed iteratively: if 
additional analyses are required to shed light on preliminary results, then T3 
or both T2 and T3 can be repeated and new D4 can be produced to undergo 
statistical analysis. In some studies T2 (data derivation) may not be performed, 
if data needed for the study are all contained in the original data.
D1
ORIGINAL
DBs
T1
REORGANIZATION
T2
DATA DERIVATION
T3
STUDY DESIGN
APPLICATIOND2
GLOBAL
SCHEMA
D3
DERIVED
DATA
D4
DATA SETS
FOR
ANALYSIS
Figure 1. Flowchart of the Data Transformation Process Occurring Locally in a Study Collecting Data 
from a Network of Databases. D1, D2, D3, and D4 represent data sets; T1, T2, and T3 represent data 
transformations.
To ensure that T1–T3 are valid, both in terms of how well the transformation 
reflects the original data and of whether it achieves the aim of the transformation, 
quality control processes need to be in place. In Box 1 process and outcome 
verification steps are highlighted.
To illustrate the steps of the workflow, an example from the MATRICE network 
is shown in Box 2.
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Box 2. An Example of Data Management in the MATRICE Network
The Italian National Agency for Regional Health Services promoted a study to assess whether regional 
Italian administrative databases can be used to measure whether patients with Chronic Obstructive 
Pulmonary Disease (COPD) are treated with recommended therapies. The study objective was to 
establish whether different cohorts, defined with different case-identification strategies, resulted in 
consistent estimates of therapy adherence. The MATRICE network was used for this study.
Five regions were involved in the study. In each Italian region several tables of administrative data are 
collected with content regulated by national law, in particular the following: the list of residents (citizens 
and regular migrants) entitled to receive health care; hospital discharge records, with six diagnosis codes; 
exemptions from copayments for health care; and drug prescriptions. In each region participating in the 
study, a copy of the four tables (D1) was stored, with different data models and format. The MATRICE 
network has established a specific data model for the above mentioned four tables(list of residents; hospital 
discharge records; exemptions from copayments for health care; and drug prescriptions), and the format 
is flat comma-separated files (D2). Two of the regions had already participated in a previous study of the 
MATRICE network, so T1 had already been performed. In the other three regions, the format D2 was 
explained to a local expert by means of structured documents and a teleconference, a common software 
named TheMatrix was installed (see “T1: reorganization” in the “FINDINGS” Section below), and T1 was 
performed by the local expert and was checked with standard procedures embedded in the software. The 
study protocol had defined several variables to be extracted or derived: gender, presence in the region at 
index date, age at index date, presence of a COPD diagnosis in the 1–5 years before index date, presence 
of some patterns of utilization of respiratory drugs in the 1–3 years before index date, and adherence 
to recommended therapies during follow-up. D3 was composed ofa group of data sets, one per derived 
variable, each with a single observation per subject. Since in MATRICE all the participating data partners 
share the same data content (see “D1: original DBs” in the “FINDINGS” Section below), the transformation 
T2 was uniform across data partners. T2 was therefore embedded by the principal investigator in a single 
ad hoc procedure of the software TheMatrix, shared with the local partners and executed locally. The 
data set D4 was designed in the protocol to be the aggregated data set that counted the frequency of each 
combination of the variables in D3. The transformation T3 was embedded by the principal investigator in 
another ad hoc procedure of the software TheMatrix, shared with the local partners and executed locally.
The D4s produced by the five regions were shared with the principal investigator, who executed the 
statistical analysis of the pooled data set using the statistical software Stata 13.1.
FINDINGS
We describe and compare T1–T3 and D1–D4 in the four networks.
D1 (Original DBs)
We use “DB” to refer to an organization that has access to the data. Table 1 
summarizes the DBs participating in the four networks. For each network a 
column represents a combination of data sources that are linked in at least 
one database. We classified data sources according to their provenance, and 
we indicated the data items available in the DB from that data source. If more 
than one DB in a network share the same combination, only one column is 
shown: the number of columns fora network in Table 1 is therefore a measure 
of heterogeneity of the DBs participating in the network. MATRICE has a single 
combination (M1), EU-ADR has seven (EU1–EU7), Mini-Sentinel has three 
(MS1–MS3), and OMOP has four (O1–O4)
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Differences and Similarities
First, in the two United States–based networks (OMOP and Mini-Sentinel) 
almost all databases (O1–O3 and MS1–MS3) obtain administrative information 
from primary, secondary, and inpatient care, while in both European networks 
(EU-ADR and MATRICE) each database lacks at least one setting. Second, EU-
ADR pools data from the most heterogeneous databases: the eight databases 
showed seven different combinations. Third, in Italy, although administrative 
information from secondary care (such as specialty of the physician visiting 
the patient) is available, it does not contain diagnostic codes (M1 and EU1–
EU2). Fourth, access to laboratory test results is rare among databases in all 
networks. Fifth, in all but one United States database, enrollment of subjects 
in the data collection is due to the eligibility criteria for social insurance or an 
insurance company, while in Europe criteria include geographical residence or 
being listed with a GP. Sixth, only in EU-ADR and Mini-Sentinel are death and 
immunization registries available. Finally, only Mini-Sentinel involves partners 
collecting information from both clinical and administrative data sources. 
This is achieved by integrated delivery systems that operate medical facilities 
from which they collect electronic health care records data. In addition, all the 
Box 3. Short Illustration of the Differences in Original Data
In 2005, Irina, age 36, developed gestational diabetes during her second pregnancy, which was diagnosed 
by her gynecologist and treated with insulin prescribed by her GP. Irina gave birth to Louise in a hospital, 
and had her vaccinated against tetanus and diphtheria when the baby was six months old. The following 
year Irina’s father Mario, age 67 and a smoker with a history of coronary heart disease, moved to the 
region where Irina lived. In 2007, Mario was diagnosed with diabetes by his GP, who was also his 
daughter’s GP. After trying for a while to cope with his condition only through following a new diet, 
he started taking antidiabetic drugs in 2008. In 2010 he had severe angina and was admitted to the 
hospital for a few days. In 2013 Mario died in his sleep, and his death certificate indicated that the cause 
of death was myocardial infarction.
If Irina, Louise, and Mario were part of the database population of the four networks, the image of 
the story would be different. For databases lacking diagnosis from primary or secondary care, like M1 
or EU1–EU4, Irina’s beginning to take insulin could be misinterpreted as an occurrence of diabetes, 
even though a complex algorithm using hospital admittance for delivery or the ending of insulin 
prescriptions could effectively avoid misclassification. Louise’s vaccine would be detected by MS1, MS2, 
and MS3. When Mario moved to Irina’s region and entered the database population, only databases 
collecting clinical history from primary care—like EU6, EU7, MS1, and O4—could have detected that 
he was the father of Irina and was a smoker. While the history of coronary heart disease could also be 
deduced from the same databases or clinical notes of a cardiologist in MS1, the presence of the disease 
may be inferred from drug utilization data in all the databases, and angina precisely in 2010 in databases 
with diagnoses from inpatient care (MA1, EU1–EU4, all MS, and O1–O3). Diabetes would be detected 
in 2007 from primary care diagnosis in EU5–EU7 and all the United States databases, and in 2008 only 
from drug utilization in the others. Occurrence of myocardial infarction would be detected only by 
EU2, EU3, and all the MS databases.
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partners of Mini-Sentinel and some partners of the other networks can access 
full-text medical records for chart validation for their population.
Box 3 is a fictional example of the impact of the differences in D1 on the 
information captured from a patient history.
T1 (Reorganization)
In Table 2, T1 is compared across case studies.
Differences and Similarities
Besides local storage, in OMOP some databases also allow creating a central and 
cloud-based copy of the transformed data. In MATRICE and Mini-Sentinel, all 
original databases used the same coding systems, while in OMOP participating 
databases used different coding systems and even unstructured free text in 
different languages, in EU-ADR.
Different strategies were adopted to transform the original data into a common 
data set: in EU-ADR, the transformation T1 was used only in internal discussions 
to define T2, and data sets in the common data model were never created. In 
MATRICE, standard procedures for T1 are in place, and results are evaluated 
by local partners. In Mini- Sentinel, data is transformed to a general, common 
data model and is updated frequently; and checks for data completeness and 
consistency with the data model are Standard Operating Procedures (SOP) 
executed as part of each transformation and approval process.[52] OMOP 
recoded all data to a single system during T1, independently of a study question, 
the transformation in T1 is evaluated by first generating descriptive statistics 
of all elements in D2 using a tool called Observational Source Characteristics 
Report (OSCAR), and by subsequently performing internal and external 
comparison of these statistics using a tool called Generalized Review of OSCAR 
Unified Checking (GROUCH). Both in OMOP and Mini-Sentinel, a formal 
Extraction, Transformation, and Loading (ETL) document is created as part 
of development and implementation of the data model. In MATRICE the 
transformation is executed via ad hoc software, called TheMatrix,[53] whose 
configuration is stored in a text file.
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Table 2. Comparison with respect to T1, D2, T2
T1 (data reorganization)
Network Recoding Quality:  
data completeness
Quality: documentation
EU-ADR Does not require 
mapping to external 
standard: original 
coding or free text is 
maintained.
Demanded
to local partners, no formal 
procedure
No formal documentation
Mini-
Sentinel
Source data are 
homogeneous in 
coding systems.
Local report on specific 
issues,plus feedback from 
standard programs checking 
for completeness and 
consistency
Data model, data elements, 
and guiding principles 
approved by partners. ETL 
formal document, ad hoc 
per DB
OMOP Source data 
standardized to 
common vocabulary 
by domain: Drug 
(RxNorm), Condition 
(SNOMED), Labs 
(LOINC)
Formal procedures: OSCAR 
and GROUCH tools
ETL formal document, ad 
hoc per DB 
MATRICE Source data are 
homogeneous in 
coding systems
Formal procedures checking 
data completeness
Local configuration of the 
TheMatrix software (text file) 
D2 (Global schema)
Network Table Names based on AttributeNames based 
on
Every CDM 
table has 
a view in 
every DB
Attributes 
are coded 
uniformly 
across DBs
EU-ADR Reason/setting of data 
recording
Clinical contents N N
Mini-
Sentinel
Clinical content and 
data source (diagnosis, 
procedures, encounters, lab 
results); or reason/setting 
(outpatient pharmacy, death, 
enrollment) 
Reason/setting of data 
recording for diagnosis 
and similar, clinical 
contents for pharmacy 
and death
N Y
OMOP Clinical content Reason/setting of data 
recording 
Y Y
MATRICE Reason/setting of data 
recording
Clinical contents Y Y
T2 (data derivation)
Network Logic Single 
definition 
per derived 
data
Quality:  
process control
Quality: validation
EU-ADR DB-specific 
algorithms, 
harmonized through 
a formal negotiation 
process
Y No common 
procedures were 
implemented, 
although logic of 
local procedures 
was shared.
Internal incidence rates 
comparison, literature 
comparison, some 
validation with external 
gold standard (PPV)
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T2 (data derivation)
Network Logic Single 
definition 
per derived 
data
Quality:  
process control
Quality: validation
Mini-
Sentinel
The same algorithm 
was used across all 
DBs.
Y Shared SAS script Systematic review of 
previously published 
validation studies, 
expert clinical, data, and 
epidemiologic guidance, 
medical chart review for 
PPV, and assessment of 
difference in dates
OMOP Multiple alternative 
algorithms were 
adopted to derive 
the same data; some 
were DB-specific.
N Shared 
parameterized 
SQL queries 
stored in common 
procedure (RICO)
Internal prevalence rates 
comparison, no external 
validation performed
MATRICE Multiple algorithms 
were explored, 
decision was taken 
by means of a 
validation study.
Y Shared script in a 
scripting language 
developed ad hoc 
(TheMatrix)
Validation of algorithms 
with external gold 
standard: sensitivity, 
specificity, PPV, NPV
D2 (Global Schema)
In Table 2, D2 is compared across case studies. 
Differences and Similarities
The main difference we observed in the evaluation of the data models was 
the way two main characteristics of an encounter were captured: the setting 
where the health care was administered (e.g., general practice, inpatient 
care, laboratory) and the medical content of the encounter (e.g., diagnosis, 
procedure, laboratory test). One possibility was that information was grouped 
in tables according to the setting (e.g., a table for hospital admissions, another 
for laboratory tests) and facts were recorded as attributes. The alternative was 
that encounters were grouped in tables defined by medical content (e.g., a table 
for diagnoses, a table for procedures) and the care setting was recorded as an 
attribute. EU-ADR and MATRICE adopted the first approach, OMOP adopted 
the second, and Mini-Sentinel adopted a combination of the two approaches—
death and pharmacy dispensations were organized in the first way and other 
information was organized in the second. 
Table 2. Continued
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Table 3. Comparison with respect to T3 and D4
T3 (application of study design)
Network Local partners 
execute shared 
procedure
Common 
among 
DBs
Scores 
estimation
Specific software Programming 
language
EU-ADR Y Y N Jerboa Java andJerboa 
scripting languages
Mini-
Sentinel
Y Y Y Modular programs 
and macros;
PopMedNet 
SQL, SAS, Java, R, 
OMOP Y Y Y - SQL, SAS, R, C, Java
MATRICE Y Y N TheMatrix Java and TheMatrix 
scripting languages
D4 (data sets for analysis)
Network Type Format Quality: study results validation
EU-ADR Intermediate files that 
can be shared among 
partners, analysis will 
follow
CSV Drug safety methodology: comparison of observed 
drug-event associations with previously classified 
true and false causal associations; impact on this of 
different definitions of the derived data
Mini-
Sentinel
Level of granularity of 
data set depends on 
study needs; always 
transfer minimum 
necessary. Some 
analyses transfer 
aggregate data, some 
use highlysummarized 
patient-level data. 
Intermediate files 
saved locally by data 
partners.
CSV, SAS 
datafiles, 
HTML
To test code known associations are used. Rapid 
Response queries include data characterization 
and are reviewed manually by a data expert and 
an epidemiologist. Results are also reviewed by 
data partners. Protocol-based assessments might 
include chart reviews.
OMOP Final estimates, 
intermediate files are 
discarded.
CSV, SAS 
data files, 
SQL tables 
Drug safety methodology: comparison of observed 
drug-event associations with previously classified 
true and false causal associations; impact on this of 
different definitions of the derived data; estimate 
of residual bias per event by means of known 
noncausal associations.
MATRICE Intermediate files to 
be used for analysis or 
report generation
CSV Results are reviewed by data partners for 
comparison with similar analysis performed 
independently.
T2 (Data Derivation for Specific Studies)
In Table 2, T2 is compared across case studies.
Differences and Similarities
In EU-ADR each data custodian executed its algorithm with its own usual 
extraction tool to derive simple input files for a specific study, while execution 
was performed with common software on the GS in the other networks. 
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OMOP and Mini-Sentinel adopted shared SQL and SAS code, respectively. 
In MATRICE an ad hoc scripting language was designed and a compiler (a 
computer program that transforms source code written in a programming 
language into another) from this language toward the Java virtual machine 
was developed; extraction in a shared code was then executed locally. Since 
OMOP focused on methods development, it often used multiple algorithms 
for data derivation, to study the impact of the differences. In MATRICE, 
ongoing validation studies test several algorithms, but the plan is to use a 
single best definition per study in the end.
In EU-ADR, to overcome the heterogeneity across terminologies, a shared 
semantic foundation was built by using Unified Medical Language System 
(UMLS) concepts to define events5. Then, the definitive choice of algorithms 
was obtained through an iterative negotiation between databases: DBs with 
similar structures were invited to query the same tables and fields.54 In Mini-
Sentinel, algorithms are developed (or reused) for specific analyses and applied 
at the time of analysis; the result of those algorithms is not stored in the 
database, but analytic files for each assessment are retained locally.
As for validation of the event resulting from data derivation, all the networks 
compared incidence or prevalence rates among databases as a tool to assess 
consistency. OMOP did not routinely compare with external standards nor with 
the literature. The other networks performed either population-based external 
validation to estimate all validity indices (MATRICE) or external validation of a 
random sample of automatically detected events to estimate positive predictive 
value (EU-ADR, Mini-Sentinel).
T3 (Study Design Application)
In Table 3, T3 is compared across case studies.
Differences and Similarities
During steps T1 and T2, local partners in some of the networks were asked 
to implement the processes that had been agreed upon in their own local 
procedures; moreover the procedures were not shared. In step T3 (study design 
application), data transformation into analytical data sets was performed in 
all four networks using shared and common software. In Mini- Sentinel and 
OMOP, statistical analysis was needed in T3 to estimate propensity and disease 
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scores, while in the studies implemented in the other networks only simpler 
tasks were needed: linkage between different tables, time splitting, random 
selection, matching, de-identification, and aggregation. The software Jerboa 
was developed and used by EU-ADR to execute T3. The software TheMatrix 
developed by MATRICE executes both T2 and T3: a Domain Specific Language 
(DSL) was designed and developed for this purpose. DSLs are computer 
programming languages whose features and expressiveness are restricted and 
designed ad hoc to fit a given field of application. They target a narrower set 
of programs than general-purpose languages like Java, but in exchange they 
provide a higher level of abstraction and can be programmed directly by domain 
experts rather than computer programmers.[55] In MATRICE, a DSL generating 
tool called Neverlang was used to develop the language,[16,56] and scripts in the 
language were generated by domain experts. Mini-Sentinel and OMOP both 
used existing software (SQL, SAS, C, Java and R).
D4 (Data Sets for Analysis)
In Table 3, D4 is compared across case studies.
Differences and Similarities
In OMOP only final estimates were shared, while in the other networks 
integrated data sets were shared to be pooled before statistical analysis. EU-ADR 
and OMOP both adopted a similar validation strategy for their methodological 
studies in drug safety, which implicitly validated the whole sequence of data 
transformations at once: a set of positive controls (known adverse drug 
reactions) and negative controls (drug-outcome pairs that are believed to have 
no causal relationship) was created. The quality of each method of analysis 
was assessed by measuring its discriminating power, i.e., the ability of telling 
positive from negative controls.
DISCUSSION
In this paper we introduce a conceptual framework to analyze the data 
management process of a network performing distributed analyses. By applying 
the framework to four case studies we identify similarities and substantial 
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differences. With this as the foundation, we highlight areas that need further 
research to identify optimal strategies.
Differences in Original Databases (of DBs) Have Huge Consequences
The differences observed in the four networks when comparing the original 
databases (D1) are huge. Understanding such differences is a challenge in itself, 
as terminology describing health data sources is not shared across countries.
[57] The three national networks (MATRICE, OMOP, and Mini-Sentinel) 
were much more homogeneous than EU-ADR. Since we expect that networks 
will continue to grow and new DBs will be different from existing DBs, the 
problems that EU-ADR encountered could indicate challenges other networks 
will face in the future if the geographical area is extended. United States 
databases often have in- and outpatient diagnoses, whereas these are rarely all 
captured in European administrative databases. In contrast, in Europe general 
practice databases are very rich since in many countries GPs have a gatekeeper 
function, that is, nonemergency health care can be accessed free of charge only 
upon the prescription of a GP. Death registries are infrequently part of the data 
sources available to databases, and this hampers detection of conditions, like 
acute myocardial infarction or stroke, which may cause death before the patient 
can reach a health care facility. Due to the differences in available information 
in the different databases, various strategies need to be used in order to have 
a comprehensive data derivation of study variables, e.g., in the absence of 
outpatient diagnostic data, drug utilization or laboratory values may be used to 
identify certain conditions.
Differences in global schemas are not substantial
Differences in the GS (D2) between the networks exist but are not substantial, 
as each GS can be mapped into another, except for those data items that are 
specifically collected in a single network (for instance, exemptions from 
copayment, which are documented only in Italian DBs). It would be very valuable, 
however, to explicitly create such a mapping, as this would make it possible to 
run existing software procedures embodying T2 and T3 independently of the 
network: this happened, for instance, in a study replicating—in the EU-ADR 
network—results from the OMOP network.[58] One area of research should be 
the impact of different formats of GSs on study outcomes.
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Different Approaches to Terminology Mapping
In two networks (OMOP and EU-ADR), different disease and drug coding 
systems needed to be managed. In OMOP the differences were addressed by 
mapping to homogeneous coding systems during T1, although the original 
codes were not discarded but were also included in D2. In EU-ADR, mapping 
was not conducted in T1, therefore all mapping was performed during T2 and 
only for study-specific conditions. Due to the large differences in the granularity 
and type of coding schemes, in European databases mapping was very time-
consuming—yet this was necessary to obtain consensus across data custodians 
and investigators[6]—and is progressively growing a shared library. The impact 
of different mapping strategies, and whether mapping should be done at all 
versus addressed in the analytic phase, should be investigated.
Sharing Aggregated Data Sets Versus Sharing Estimates
If network partners can share aggregated data sets in D4, the investigators 
maintain freedom to perform some subset and sensitivity analysis that were 
not strictly foreseen in the protocol without performing a new round of 
transformation. Sharing aggregated data would allow different levels of pooling 
and potentially more power with respect to meta-analysis, although previous 
research shows no improved performance of one approach over the other.
[14,59,60,61] Given the privacy related issues around data sharing, it should be 
investigated when different levels of sharing may be indicated.
Software Tools, Professional Skills, and Information Technology
Software tools used during the transformation process differed across case 
studies. This had implications for the type of professional skills needed to 
perform studies in the network as well as the readability of the programs for 
other investigators. In principle, all data transformations must be documented 
to allow investigators to correctly interpret study results and to understand 
study limitations and strengths. OMOP and Mini-Sentinel have complete 
websites where information is stored and can be openly accessed, while EU-
ADR and MATRICE rely mainly on scientific papers and reports, a less efficient 
way of storing information. How to develop transparent programs and how 
to store and share the corresponding complex body of information to make it 
easily available to investigators is also a relevant research topic.
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Validation
Validation of derived data is an imperative condition to produce good 
epidemiological estimates,[62] and this is even truer when heterogeneous 
databases participate ina network. Indeed, regularizing the process of creating 
research data sets from secondary data sets, although necessary, is not enough 
to ensure high data quality; and validation can quantify how much derived data 
fail in correctly identifying the study variables—failure that can differ across 
data partners.
In MATRICE—as data from primary care is lacking and information from 
secondary care is sparse— deriving chronic conditions, the primary focus of 
the network, is cumbersome. This is why MATRICE is leading a population-
based validation study using diagnosis from a sample of GPs as a gold standard. 
In Mini-Sentinel a model for a typical validation study was developed13 and 
implemented for some events, in particular acute myocardial infarction.[14] 
EU-ADR adopted a similar study design in some validation studies.[7,8] Only 
positive predictive value could be estimated from the study design adopted 
in the two networks. A similar study was performed on an occasional basis in 
OMOP.[63] In order to estimate sensitivity, access to a populationbased data 
source would be required, which is more complex than accessing clinical charts 
of selected candidate events. However, in the specific case of acute myocardial 
infarction, death registries are estimated to add from 15 percent to 25 percent 
of cases to inpatient data where both data sources are available.[6] Therefore 
misclassification of non-cases, in principle, could have a relevant impact on 
study results, especially in older subpopulations. In EUADR it was observed 
that improving the positive predictive values of the outcome definition had 
a very small impact on estimates of additional risk of upper gastrointestinal 
bleeding in users of four drugs,[7,64] and in OMOP methodological studies 
varying the definition of several outcomes had little impact on system 
performance overall,65 thus suggesting that outcome misclassification may not 
be a paramount concern when studying the safety of short exposure to drugs. 
This area has generated some research66 and deserves further study. The only 
attempt to automatically incorporate the result of a quality procedure in the 
interpretation of study results was performed in OMOP: the association with 
an outcome observed in a set of drugs that are a priori known not to cause 
the outcome was computed and applied as an estimate of overall bias in the 
association of any drug with the same outcome.[67]
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Designing and developing a framework that allows for automatically 
incorporating validity indices in study design and analysis would be a useful 
followup for the effort invested in validation. 
Epistemological Framework of Reference 
Unlike in the other steps, in T3 there was a very similar approach in the four 
networks: there is a uniform attempt to make study designs clearly specified and 
reusable across studies. This was achieved in all four networks by embedding this 
step into shared software, where the same procedure was executed across all data 
sites. It could be argued that complexity arising from the network setting forces 
investigators to specify—right from the study design stage —every detail of data 
management and analysis, embedded in a sequence of computer instructions. 
A priori specification of the detail of the experiment is at the epistemological 
core of the experimental method, as it ensures falsifiability.[68] From this point 
of view, the intricacies of the network settings force investigators to do the right 
thing. Computer engineers have joined pharmacoepidemiologists and other 
populationbased health scientists in supporting this effort, not just because 
computer programming is needed, but also and most of all, because a novel, 
more formal process must be streamlined and stabilized before investigators 
take control again of the new level of complexity.
Limitations
The conceptual framework was useful to interpret similarities and differences 
among the four networks, which are heterogeneous for geographical coverage 
and purpose. However the choice of the sample of four was nonsystematic, 
therefore the framework may prove insufficient to include other networks in the 
comparison. Data processing in networks of databases may suffer from subtle 
challenges: privacy laws may enable patients to opt out of sharing information 
based on some encounters only (for instance, for mental health issues); some 
databases may collect information from smaller health care providers, whose 
information is not effectively shared in digital form; regional or national 
differences in privacy regulations may affect differentially the partners of a 
network. We did not investigate how the four networks faced such challenges.
42070 Rosa Gini.indd   162 04-09-16   19:33
6Data extraction and management in networks of databases
163
CONCLUSION
We proposed a conceptual framework to analyze the data management 
process involved in observational studies taking place in distributed networks 
of databases. The framework was applied to four case studies to identify 
similarities and differences. Several research questions were highlighted by this 
comparison, including interoperability among the available GSs, optimization 
of data harmonization, use of validity indices in study design and statistical 
analysis, development of an information infrastructure to support investigators 
in accessing details of data transformation, and optimal level of programming 
skills needed to manage the process. Medical informatics is called on to support 
transparency, and quick and sound application of the experimental method to 
the production of empirical knowledge.
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ABSTRACT
Due to the heterogeneity of existing European sources of observational 
healthcare data, data source-tailored choices are needed to execute multi-
data source, multi-national epidemiological studies. This makes transparent 
documentation paramount. 
In this proof-of-concept study, a novel standard data derivation procedure was 
tested in a set of heterogeneous data sources. Identification of subjects with 
type 2 diabetes (T2DM) was the test case. 
We included three primary care data sources (PCDs), three record linkage 
of administrative and/or registry data sources (RLDs), one hospital and one 
biobank. Overall, data from 12 million subjects from six European countries 
were extracted. Based on a shared event definition, sixteeen standard algorithms 
(components) useful to identify T2DM cases were generated through a top-
down/bottom-up iterative approach. Each component was based on one single 
data domain among diagnoses, drugs, diagnostic test utilization and laboratory 
results. Diagnoses-based components were subclassified considering the 
healthcare setting (primary, secondary, inpatient care). The Unified Medical 
Language System was used for semantic harmonization within data domains. 
Individual components were extracted and proportion of population identified 
was compared across data sources. Drug-based components performed 
similarly in RLDs and PCDs, unlike diagnoses-based components. Using 
components as building blocks, logical combinations with AND, OR, AND 
NOT were tested and local experts recommended their preferred data source-
tailored combination. The population identified per data sources by resulting 
algorithms varied from 3.5% to 15.7%, however age-specific results were fairly 
comparable. The impact of individual components was assessed: diagnoses-
based components identified the majority of cases in PCDs (93-100%), while 
drug-based components were the main contributors in RLDs (81-100%).
The proposed data derivation procedure allowed the generation of data 
source-tailored case-finding algorithms in a standardized fashion, facilitated 
transparent documentation of the process and benchmarking of data sources, 
and provided bases for interpretation of possible inter-data source inconsistency 
of findings in future studies.
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INTRODUCTION
In recent years, an increasing number of projects have been focusing on re-
using existing electronic health records (EHR) for clinical research.[1] In 
particular, huge efforts have been made to combine health data from isolated 
environments and perform valid multi-data source observational studies.[2, 3] 
In this context, the European Medical Information Framework (EMIF) project was 
launched with the main objective of building an infrastructure for the efficient 
re-use of existing European health care data for epidemiological research (http://
www.emif.eu/). Within the project, a federation of heterogeneous sources of 
real world data (e.g. administrative, hospital or primary care databases, disease 
registries, biobanks), currently collecting health information on around 52 
million European citizens, collaborate in the EMIF-Platform whose focus is the 
consistent exploitation of currently available patient-level data to support novel 
research. One of the main challenges for the EMIF-Platform is to deal with the 
heterogeneous characteristics of the participating data sources and facilitate 
the execution of high quality multi-national, multi-data source observational 
studies based on populations with otherwise unconceivable sample sizes and 
follow-up time span. 
In general, different strategies can be adopted to identify a population of 
interest from a single source of EHR.[4, 5] The choice of a particular case-finding 
algorithm is generally driven by both the specific research question and the data 
source peculiarities.[6] The chosen algorithm, however, can significantly affect 
the characteristics of the cases identified [4, 5] and, for this reason, should be 
carefully taken into account when discussing study results.
In multi-data source studies, tailored choices may be necessary [6-8], and the 
diversity of local case-identification algorithms may increase along with the 
heterogeneity of the data sources involved [6, 9, 10]. A transparent process 
of documentation and evaluation of local case-finding algorithms becomes 
paramount for the correct interpretation of study results as well as for the 
discussion of possible inter-data source inconsistency of study findings [10-12]. 
It must be noted that data sources available to study  European populations are 
much more heterogeneous than data sources from a single country, such as the 
United States [10]. Therefore, in order to address this issue, the EMIF-Platform 
designed a novel standard procedure for data derivation which leverages the 
experience gained from previous European multi-national, multi-data source 
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studies [2, 3, 9, 13]. In this proof-of-concept study, the identification of type 
2 diabetes mellitus (T2DM), a common chronic condition with important 
implications for future health[14], was used as a test case. 
MATERIALS AND METHODS
Data sources
Eight European data sources collecting health care information on around 20 
million subjects from six different countries participated to this study (Table 
1). Three were primary care data sources (PCDs), three were record linkage 
systems of different registries (RLDs), one was a hospital data source (HD) and 
one was a biobank (BD). In specific, the three primary care data sources were 
the Health Search IMS Health LPD database (HSD, Italy),[9, 15] the Integrated 
Primary Care Information database (IPCI, The Netherlands)[16] and The 
Health Improvement Network database (THIN, UK), in which the general 
practitioners (GPs) function as data keeper of all patient’s medical information.
[17] The three record linkage data sources were the Aarhus University Hospital 
(AUH, Aarhus, Denmark),[18, 19] PHARMO (PHARMO, The Netherlands)[20] 
and the Regional Health Authority of Tuscany (ARS, Italy),[9, 15] which collect 
data from different sources (e.g. hospital discharge records, death registries, 
drug dispensing and procedures). The HD was the Information System of 
Parc de Salut Mar Barcelona (IMASIS, Spain) that records information from 
routine healthcare activities of Hospital del Mar of Barcelona.[21, 22] The BD 
was the Estonian Genome Center of University of Tartu (EGCUT, Estonia) in 
which information from interviews of voluntary donors of biological samples 
is collected through standard questionnaires.[23] EGCUT is the only cross-
sectional data source  included in this study. In all data sources except the 
Spanish HD, IMASIS, information on a representative sample of the population 
living in the corresponding geographic area are collected. In the Italian PCD 
and in the Estonian BD only adult population is represented (>14 and >18 
years of age, respectively). The information in the corresponding databases is 
recorded using different coding systems. Diagnoses are coded according to the 
International Classification of Diseases, 9th Revision, Clinical Modification 
(ICD-9-CM) or ICD-10 (10th version), the International Classification of 
Primary Care (ICPC), READ or are as free text. Prescriptions/dispensings are 
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coded according to the Anatomical Therapeutic Chemical classification (ATC) 
or BNF/Multilex. The majority of the data sources collect records concerning 
the utilization of diagnostic procedures and laboratory results. The coding of 
these data domains are based on local service terminologies. 
Study population and design
In each participating data source the study population corresponded to all 
active subjects on January the 1st 2012 (reference date) that at the same date had 
≥16 years of age. Due to sample size issues, exception was made for EGCUT in 
which January the 1st 2009 was considered as the reference date. 
A descriptive, cross-sectional, retrospective multi-database study was performed. 
Patients with T2DM were identified within the populations selected from the 
participating data sources by using different case-finding algorithms. 
Event definition and generation of a list of component algorithms 
T2DM is a chronic clinical condition characterized by hyperglycemia due to 
insulin resistance and a progressive deficiency in insulin production.[24] It 
represents the most common form of diabetes, comprising about 90% of all 
cases of diabetes worldwide.[25] Diagnosis and follow-up of T2DM is based on 
laboratory tests for blood glucose measurements and treatment includes life 
style interventions (i.e. diet and physical exercise) and use of medications.[26]  
To identify subjects with T2DM in a healthcare data source, information 
from one or more data domains may be available. Diagnoses and/or records 
collecting information on routine patients’ clinical care and follow-up, such as 
drug prescriptions, utilization of diagnostic tests and laboratory results, can be 
used,[4, 27, 28] so that combining data from one or more of these domains, 
different case-finding strategies, with different sensitivity and positive predictive 
value (PPV), can be obtained.[4] 
As the first step of the data derivation procedure, a shared clinical definition 
of T2DM was adopted (Figure 1) and defined according to the ESC/EASD 
guideline.[29] 
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Figure 1. The standard procedure for data derivation 
Event definition 
Generation of a list of standard component algorithms based on: 
• A central, expert-based, operational event definition (top down approach) 
• Local data source experts’ knowledge and expertise (bottom-up approach) 
• Semantic harmonization of local terminologies 
Component algorithms extraction and testing 
• In each data source, all components deemed to be useful for the identification of the event of interest 
are extracted separately 
• Different combination of components are tested using logical connectors (AND, OR, AND NOT) 
Recommendation of a composite algorithm  
• Each local expert recommends a data source tailored combination of component algorithms 
Subsequently, a list of standard algorithms useful to identify cases of T2DM 
in the selected data sources was generated. Standard algorithms, referred to as 
“component algorithms”, were defi ned as rules to identify subjects with a defi ned 
pattern of records selected from a single data domain. For the identifi cation 
of T2DM, a total of four data domains were concerned: diagnoses (DIAG), 
drug prescription/dispensing (DRUG), utilization of a diagnostic test (TEST) 
or laboratory results (LABVAL). Component algorithm could be intended as 
inclusion, exclusion or refi nement criteria. Two sources of knowledge were 
leveraged and integrated for the design of component algorithms: a central 
expert-based clinical and operational defi nition of T2DM (top-down engineering) 
and the expertise provided by local data source experts with respect to the 
identifi cation of T2DM cases in their own data source (bottom-up learning).
[8] As already described in greater details in a previous published paper,[3] the 
Unifi ed Medical Language System (UMLS) was used to build a shared semantic 
foundation across the diff erent coding systems: medical concepts pertinent to 
the clinical and operational defi nition of T2DM were identifi ed and projected to 
local terminologies. The fi nal list of local codes, strings and free text keywords 
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was obtained through an iterative process involving local experts’ feedback. 
Each component algorithm was fully described by two additional rules: the first 
was the pattern of records that triggers identification of the event (for instance: 
at least two records in the same calendar year), and the second concerned the 
criteria to identify the case’s index date (e.g. date of the first record).
Data extraction and analysis: “the component algorithm strategy”
A distributed network approach was adopted in EMIF to allow partners for 
maintaining control of their data and to benefit from local data source experts 
consultation on the appropriate use of data and interpretation of results.[2, 
3] Local experts were asked to select and extract all component algorithms 
considered useful to identify T2DM cases in their data source. All person-time 
available up to the reference date was considered for algorithm application. 
Extracted data were prepared to be inputted in Jerboa, a custom-built software 
developed in the EU-ADR project[2] which was run locally to standardize the 
data aggregation process. After providing formal approval, local data source 
experts uploaded aggregated analytical datasets to a common virtual machine.
Using a custom-built analysis tool (a Microsoft Access interface for Stata [StataCorp. 
2013. Stata Statistical Software: Release 13. College Station, TX: StataCorp LP] and 
LaTeX [https://www.latex-project.org/]), local experts could test the extracted 
components in any possible logical combinations by using Boolean operators (i.e. 
AND, OR, AND NOT). This strategy, we referred to as “the component algorithm 
strategy”, allowed local experts to build more complex case-finding strategies 
(composite algorithms) by combining two or more of the extracted components as a 
mean of inclusion, exclusion or refinement criteria. Testing different combination 
of components, local experts could choose a particular composite algorithm 
that they recommended for the identification of T2DM in their data source. A 
comment describing the reasons behind the choice was recorded together with an 
estimate, either objective or subjective, of the expected sensitivity and PPV. This 
information was stored and intended as a source of reusable knowledge.
Presentation of results
Results from the application of individual components and recommended 
composite algorithms were compared across data sources and presented as 
age-specific percentages of subjects identified in the study population of the 
corresponding data source. 
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In each participating data source, the impact of extracted component was assessed 
with respect to the total number of subjects identified using the recommended 
composite algorithm, which was considered as the reference case population. 
For this purpose, we calculated: i) the percentage of subjects identified by each 
component in the reference case population and ii) the prevalence rate ratio 
(PRR) of subjects identified by the recommended composite algorithm with and 
without the use of the tested component as additional inclusion criteria, i.e. 
PRR=((N in tested component OR in recommended composite algorithm)/ N 
in recommended composite algorithm)-1
No identifiable human data were shared for this study. Permission for both re-
use of the data analyzed in this study as well as for publication of the results 
obtained was granted by each participating organizations’ review board. 
The full protocol of the research project is publicly available on the electronic 
register of observational studies of the European Network of Centers for 
Pharmacoepidemiology and Pharmacovigilance (http://www.encepp.eu/
encepp/viewResource.htm?id=11158)
RESULTS
Since this was a proof-of-concept study, results presented here are not intended 
as estimates of disease frequency. 
Overall, the EMIF-Platform provided for this study aggregated health data from 
around 12 million European citizens. 
The size of the study populations selected from the participating data sources 
ranged from 1600 to 3.4 million subjects. Components algorithms included in 
at least one recommended composite algorithms are reported in Table 2.
In Figure 2 four examples of comparisons of age band-specific results from 
individual component algorithms across data sources are shown. The full list 
of comparisons concerning all those components extracted from at least two 
data sources and included in at least one recommended composite algorithm 
are available as supporting in formation in Figure 1S. As for DIAG-based 
components very different performances were associated to the healthcare 
setting of data collection (primary, secondary, inpatient care). The component 
DRUG_ORAL (i.e. ≥2 records of non-insulin antidiabetic drugs utilization in 
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Table 2. Component algorithms description
Component 
algorithm  
acronym
Algorithm description Record retrieval rules* Case’s 
index 
date
DIAG_T2DM_
PC
Patients who have ≥1 
diagnoses of T2DM 
recorded in a primary care 
setting
Records of (Diabetes type 2) occurs in 
[diagnosis fields] of [tables collected during 
primary care]
1st 
record
DIAG_T2DM 
_SC
Patients who have ≥1  
diagnoses recorded in a 
secondary care setting
Records of (Diabetes type 2) occurs in 
[diagnosis fields] of [tables collected during 
secondary care]
1st 
record
DIAG_T2DM 
_INP
Patients who ≥1 diagnoses 
recorded during a hospital 
admission
Records of (Diabetes type 2) occurs in 
[diagnosis fields] of [tables collected during 
inpatient care]
1st 
record
DIAG_
DMUNSPEC
Patients who ≥1 diagnoses 
of unspecified diabetes 
recorded in primary, 
secondary, or inpatients 
care
Records of (Diabetes unspecified) occurs in 
[diagnosis fields] of [tables collected in primary, 
secondary, or inpatients care]
1st 
record
DIAG_
DMUNSPEC_
OTH
Patients who have ≥1 
diagnoses recorded in 
a setting other than 
primary, secondary, or 
inpatients care
Records of (Unspecified diabetes ) occurs in 
[diagnosis fields] of [tables collected in other 
settings]
1st 
record
DIAG_T1DM Patients who have ≥1 
diagnoses of T1DM 
recorded in any care 
setting
Records of (Diabetes mellitus type I) occurs 
in [diagnosis fields] of [any table collecting 
diagnoses]
1st 
record
DIAG_EXCL Patients who have ≥1 
diagnoses of conditions 
excluding T2DM other 
than T1DM recorded in 
any care setting
Records of ((Metabolic problems around 
pregnancy) OR (Metabolic/pancreatic 
problems, non type 2 diabetes) OR (Polycystic 
Ovary Syndrome) occurs in [diagnosis fields] of 
[any table collecting diagnoses]
1st 
record
DRUG_
INSULIN_
ONE
Patients who have ≥1 
recorded prescriptions/
dispensings of insulin
Records of (Insulins and analogues) occurs in 
[ATC field] of [drugs tables] 
1st 
record
DRUG_
INSULIN
Patients who have ≥2 
recorded prescriptions/
dispensings of insulin in a 
calendar year
Records of (Insulins and analogues) occurs in 
[ATC field] of [drugs tables] 
2nd 
record
DRUG_
ORAL_ONE
Patients who have ≥1 
recorded prescriptions/
dispensings of non-insulin 
antidiabetic drugs
Records of (Drugs used in diabetes, excl 
insulin) occurs in [ATC field] of [drugs tables] 
1st 
record
DRUG_ORAL Patients who ≥2 
prescriptions/dispensings 
of non-insulin 
antidiabetics in a calendar 
year
Records of (Drugs used in diabetes, excl 
insulin) occurs in [ATC field] of [drugs tables] 
2nd 
record
TEST_
GLUCO5_1YR
Patients who have ≥5 
records of utilization 
of blood glucose 
measurements within 1 
year
Records of (Blood glucose measurement) 
occurs in [code of test field] of [tables collecting 
laboratory test results or dispensings]
5th 
record
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Component 
algorithm  
acronym
Algorithm description Record retrieval rules* Case’s 
index 
date
TEST_
GLUCO2_
PYEAR_5YRS
Patients who have ≥2 
records of utilization 
of blood glucose 
measurements per year 
for 5 consecutive years
Records of (Blood glucose measurement) 
occurs in [code of test field] of [tables collecting 
laboratory test results or dispensings]
2nd 
record
LABVAL_ 
HbA1c
Patients who have 
≥2 laboratory results 
recorded from a glycated 
hemoglobin test higher 
than 6.5% (48 mmol/mol)
Records of (Glycated Haemoglobin) occurs 
in [code of test field] of [tables collecting 
laboratory test results] AND [result field] of 
the same record is higher than 6.5% (or 48 
mmol/mol, according to unit of measurement 
adopted in the table)
2nd 
record
LABVAL_
FAST_GLUC
Patients who have 
≥2 laboratory results 
recorded from a 
fasting plasma glucose 
measurement higher than 
126 mg/dl)
Records of (Fast gluc) occurs in [code of test 
field] of [tables collecting laboratory test 
results] AND [result field] of the same record is 
higher than 126 mg/dl
2nd 
record
LABVAL_
LCURVE_
GLUC
Patients who have 
≥2 laboratory results 
recorded from a glucose 
tolerance test higher than 
200 mg/dl
Records of (LcurveGLuc) occurs in [code of 
test field] of [tables collecting laboratory test 
results] AND [result field] of the same record is 
higher than 200 mg/dl
2nd 
record
*Codes and free text keywords corresponding to the medical concepts embedded in component 
algorithms (in brackets) are reported in Supplemental Table 1.
Figure 2. Comparison of results from individual component algorithms: four examples
Table 2. Continued
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Figure 3. Recommended  composite algorithms: age band-specific percentages of subjects identified on 
the relevant total study population
Data
Source
Recommended 
composite
algorithm
Comment of the local expert Sensitivity PPV
PCD-I (DIAG_
DMUNSPEC 
OR
LABVAL_
HbA1c OR
LABVAL_
FAST_GLUC 
OR
LABVAL_
LCURVE_
GLUC)
AND NOT 
(DIAG_T1DM))
The chosen composite algorithm was validated in 
HSD in a study that is undergoing  publication and 
found very high PPV (around 100% in the validation 
sample). Due to the nature of the data source and 
the very broad algorithm, sensitivity must be very 
high as well.
≥.9 ≥.9
PCD-N DIAG_T2DM_
PC OR
DRUG_
ORAL_ONE
T2DM is identified via diagnosis codes (DIAG_PC) 
or utilization of specific drugs for T2DM (non-
insulin antidiabetic drugs). It has been observed that 
there is no substantial difference between selection 
of patients with one (DRUG_ORAL_ONE) or at 
least two drug prescriptions (DRUG_ORAL). Some 
subjects with T2DM diagnosis also have a record for 
type 1 diabetes. Some GPs record type 1 diabetes to 
indicate insulin dependence (regardless of diabetes 
type) due to the former type 1 diabetes name 
’insulin-dependent diabetes’.
≥.9 ≥.9
PCD-UK DIAG_T2DM_
PC
Adding DRUG-based, as well as other possible 
inclusion criteria, components does not add almost 
anybody.
≥.9 ≥.9
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Data
Source
Recommended 
composite
algorithm
Comment of the local expert Sensitivity PPV
RLD-DK (DIAG_ T2DM 
_INP OR
DIAG_T2DM_
SC) OR
((TEST_
GLUCO5_1YR 
OR
DRUG_ORAL 
OR DRUG_
INSULIN
OR
TEST_
GLUCO2 
PYEAR 5YRS) 
AND NOT 
(DIAG_T1DM 
OR
DIAG_EXCL))
The chosen strategy to identify T2DM cases is 
similar to the strategy which is regularly used in 
this data source to identify cases of unspecified 
diabetes. This is the strategy of the Danish National 
Diabetes registry, which has been repeatedly 
validated. A recent study published in 2015 
estimated that sensitivity and PPV are 95 and 80%, 
respectively. When adapting this algorithm to the 
case of T2DM we decided to change some elements 
of the validated strategy. The main differences are: 
we used type 1 diabetes diagnoses as exclusion 
criteria, we used diagnoses of T2DM rather than 
diagnoses of unspecified diabetes, we avoided 
chiropody for diabetics as inclusion criteria and 
we did not exclude cases of gestational diabetes. As 
for insulin and other antidiabetic drugs, we used 
two prescription in one year as inclusion criteria 
rather than two prescription recorded at any time. 
The expected sensitivity and PPV of the chosen 
algorithm are possibly slightly lower but still very 
close to those of the validated algorithm.
≥.9 >.7 and  
<.9 
RLD-I DIAG_INP_
T2DM OR 
DRUG_ORAL
OR DRUG_
INSULIN OR
DIAG_T2DM_
OTH
From a validation study, the sensitivity of this 
algorithm is 76% and PPV 86%, excluding subjects 
with a record of type 1 diabetes does not improve 
the extraction validity. DIAG_ T2DM_OTH refers 
to an Italian table: disease-specific exemptions from 
copayment to healthcare.
>.7 and <.9 >.7 and 
<.9
RLD-N DRUG_ORAL The chosen strategy to identify T2DM patients has 
a very high PPV (95%). The reason we have decided 
to use only this method and not include other 
components we extracted is that the identification 
of T2DM patients based on the use of oral 
antidiabetics is extensively tested and validated 
within GPs. We are aware that this approach is 
limited to identify treated patients only, but this is 
deliberate. Although a patient could be classified as 
a T2DM patient given the strict clinical definition 
that was chosen in this process (i.e. HbA1c above 
a certain threshold), the fact that the patient is 
not treated begs the question whether it should 
be classified as a prevalent patient. The sensitivity 
of this strategy with respect to the wider class of 
patients matching the clinical definition is between 
70 and 90%.
>.7 and <.9 ≥.9
BD DIAG_T2DM_
PC
Using any other extracted component algorithm as 
additional inclusion criteria do not add any patients 
if those with a concomitant diagnosis of type 1 
diabetes are excluded.
≥.9 ≥.9
HD DIAG_T2DM_
INP AND NOT 
DIAG_T1DM
The chosen algorithm uses as inclusion criterion 
inpatients diagnoses of T2DM and exclude patients 
with diagnosis of type 1 diabetes. Other extracted 
components did not significantly affect the size of 
the population of cases identified.
≥.9 ≥.9
Figure 3. Continued
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one calendar year) and DRUG_INSULIN (i.e. ≥2 records of insulin utilization in 
one calendar year) were extracted in all the participating PCDs and RLDs and 
resulted in a comparable age band-specific percentage of subjects identified in 
the respective study populations.
The data source tailored recommended composite algorithms are shown in 
Figure 3 together with the comments of the local experts. The PCD from UK 
and the BD from Estonia adopted the component algorithm based on T2DM 
diagnoses from primary care (DIAG_T2DM_PC) only as the recommended 
choice. The HD from Spain excluded from the pool of subjects identified 
through inpatients diagnoses of T2DM (DIAG_T2DM_INP) those with a 
recorded diagnosis of type 1 diabetes (DIAG_T1DM). Three data sources (the 
PCD from Italy and the RLDs from Denmark and Italy) adopted
complex composite algorithms, based on the results of previous validation studies 
[27, 30, 31]. The Dutch PCD added a sensitive pattern of utilization of non-insulin 
antidiabetic drugs (i.e. DRUG_ORAL_ONE) as inclusion criterion, due to the 
observed low sensitivity of the DIAG-based algorithm DIAG_T2DM_PC in this 
data source. The Dutch RLD chose to include only subjects utilizing non-insulin 
antidiabetics, because the available DIAG-based component that used diagnoses 
from inpatients setting was considered unreliable by local experts. 
Through the application of the recommended composite algorithm, the lowest 
percentage of study population was identified in the Estonian BD, 3.5%, while the 
highest in the Spanish HD, 15.7%. In the RLDs it ranged from 4.1% to 7.5% while 
in PCDs from 6.8% to 8.6%. The age band-specific percentages of the total case 
populations identified using the recommended composite algorithms showed 
more comparable results across all participating data sources (Figure 3). The 
expected sensitivity of the recommended composite algorithms, as reported 
by local experts either form previous validation studies or from subjective 
judgement, was >0.9 in all data sources except for the Italian and Dutch RLDs 
for which a sensitivity between 0.7 and 0.9 was expected. As for PPV, the Italian 
and Danish RLDs only reported an expected value ranging from 0.7 and 0.9 
while for the remaining data sources the figure was >0.9.
The union of any extracted DIAG-based component among the five intended 
as inclusion criteria identified from 93 to 100% of the reference case population 
in PCDs (Table 3), 100% in both BD and HD, and from 15% to 73% in RLDs. 
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Table 3. Impact of extracted component algorithms on total case population identified in each 
participating data source through the application of the relevant recommended composite algorithm.
COMPONENT
ALGORITHMS 
(B)°
RECOMMENDED COMPOSITE ALGORITHMS (A)
RLD-I RLD-
DK
RLD-N PCD-
UK
PCD-N PCD-I BD HD
N 3391177 1372883 1405220 3278013 992924 945691 22430 15713
N in A 254045 77616 57712 253197 67096 81658 779 2466
% of A 
in N
7.5 5.7 4.1 7.7 6.8 8.6 3.5 15.7
DIAG_T2DM_
PC
≥1 diagnosis 
from primary 
care
N in B n.e. n.e. n.e. 253197 62191 43438 779 n.e.
% of B 
in A
- - - 100.0% 92.7% 52.6% 100.0% -
PRR 
if B 
added
- - - +0.0% +0.0% +0.6% +0.0% -
DIAG_T2DM_
INP
≥1 T2DM 
diagnosis 
from inpatient 
care
N in B 95303 27887 13098 n.e. n.e. n.e. n.e. 2520
% of B 
in A
37.5% 35.9% 15.1% - - - - 100.0%
PRR 
if B 
added
+0.0% +0.0% +7.6% - - - - +2.2%
DIAG_T2DM_
SC
≥1 T2DM 
diagnosis 
from secondary 
care
N in B n.e. 35744 n.e. n.e. n.e. n.e. n.e. n.e.
% of B 
in A
- 46.1% - - - - - -
PRR 
if B 
added
- +0.0% - - - - - -
DIAG_
DMUNSPEC
≥1 unspecified 
diabetes 
diagnosis 
from any 
healthcare 
setting
N in B 191999 n.e. n.e. n.e. n.e. 79035 n.e. n.e.
% of B 
in A
73.2% - - - - 94.3% - -
PRR 
if B 
added
+2.4% - - - - +2.5% - -
DIAG_ 
DMUNSPEC_
OTH
≥1 unspecified 
diabetes 
diagnosis 
from co-
payment 
exemption
N in B 149806 n.e. n.e. n.e. n.e. n.e. n.e. n.e.
% of B 
in A
59.0% - - - - - - -
PRR 
if B 
added
+0.0% - - - - - - -
DIAG_T1DM
≥1 type 1 
diabetes 
diagnoses
 from any 
healthcare 
setting
N in B 18147 17896 n.e. n.e. 8816 2050 164 78
% of B 
in A
6.9% 18.1% - - 8.8% 0.0% 2.8% 0.0%
PRR 
if B 
added
+0.2% +4.9% - - +4.3% +2.5% +18.2% +3.2%
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DIAG_EXCL
≥1 diagnoses of 
other types of
 diabetes 
or glucose 
intolerance
N in B 13741 7895 2904 n.e. n.e. 5782 n.e. 78
% of B 
in A
1.1% 1.8% 1.5% - - 0.3% - 1.7%
PRR 
if B 
added
+4.3% +8.3% +3.5% - - +6.8% - +1.5%
DIAG_T2DM_
PC OR DIAG_
T2DM_INP
OR DIAG_
T2DM_SC 
OR DIAG_
DMUNSPEC 
OR DIAG_
DMUNSPEC_
OTH
N in B 191999 43622 13098 253197 62191 79035 779 2520
% of B 
in A
73.2% 56.2% 15.1% 100.0% 92.7% 94.3% 100.0% 100.0%
PRR 
if B 
added
+2.4% +0.0% +7.6% +0.0% +0.0% +2.5% +0.0% +2.2%
DRUG_
INSULIN
≥2 
prescriptions/
dispensings of 
insulin in one 
calendar year
N in B 45522 22074 21192 41019 15020 11607 n.e. n.e.
% of B 
in A
17.9% 25.4% 25.8% 16.1% 19.0% 12.3% - -
PRR 
if B 
added
+0.0% +3.0% +10.9% +0.1% +3.4% +2.0% - -
DRUG_
INSULIN_ONE
≥1 
prescriptions/
dispensings of 
insulin
N in B 62341 23319 0 0 17719 0 18 0
% of B 
in A
21.2% 26.5% - - 22.0% - 1.5% -
PRR 
if B 
added
+3.4% +3.6% - - +4.4% - +0.8% -
DRUG_ORAL
≥2 
prescriptions/
dispensings of 
NIAD in one 
calendar year
N in B 216338 57153 57712 136370 51589 45624 - 0
% of B 
in A
85.2% 71.0% 100.0% 51.7% 76.9% 53.0% - -
PRR 
if B 
added
+0.0% +2.7% +0.0% +2.1% +0.0% +2.9% - -
DRUG_ORAL_
ONE
≥1 
prescriptions/
dispensings of 
NIAD
N in B 273952 61604 0 0 54181 62110 45 0
% of B 
in A
87.5% 72.7% - - 80.8% 70.6% 5.8% -
PRR 
if B 
added
+20.3% +6.7% - - +0.0% +5.4% +0.0% -
DRUG_
INSULIN 
OR DRUG_
INSULIN_ONE 
OR DRUG_
ORAL OR 
DRUG_ORAL_
ONE
N in B 295676 70405 64016 151576 58355 65076 40 0
% of B 
in A
93.0% 81.1% 100.0% 57.7% 82.6% 73.1% 50.0% -
PRR 
if B 
added
+23.4% +9.6% +10.9% +2.2% +4.4% +6.6% +4.1% -
Table 3. Continued
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TEST_TEST_
GLUCO5_1YR
≥5 glycated 
hemoglobin 
tests 
in 1 year
N in B 266940 16999 0 0 0 0 0 0
% of B 
in A
45.8% 21.6% - - - - - -
PRR 
if B 
added
+59.3% +0.3% - - - - - -
TEST_
GLUCO2_
PYEAR_5YRS
≥2 glycated 
hemoglobin 
tests per 
year during 5 
consecutive 
years
N in B 172784 28583 0 0 0 0 0 0
% of B 
in A
32.6% 36.1% - - - - - -
PRR 
if B 
added
+35.4% +0.7% - - - - - -
TEST_
GLUCO5_1YR 
OR
TEST_
GLUCO2_
PYEAR_5YRS
N in B 335466 34801 0 0 0 0 0 0
% of B 
in A
52.8% 44.1% - - - - - -
PRR 
if B 
added
+79.2% +0.8% - - - - - -
LABVAL_
FAST_GLUC 
≥2 fasting 
glucose values 
>126mg/dl
N in B 0 0 0 0 0 32153 0 0
% of B 
in A
- - - - - 38.6% - -
PR if B 
added
- - - - - +0.8% - -
LABVAL_
HbA1c
≥2 glycated 
hemoglobin 
value >6.5%
N in B 0 0 62400 0 44271 20196 0 0
% of B 
in A
- - 65.1% - 63.6% 24.1% - -
PRR 
if B 
added
- - +43.0% - +2.4% +0.7% - -
LABVAL_
LCURVE_
GLUC
≥2 glucose 
tolerance test
 values 
>200mg/dl
N in B 0 0 0 0 0 32 0 0
% of B 
in A
- - - - - 0.0% - -
PRR 
if B 
added
- - - - - +0.0% - -
LABAL_FAST_
GLUC OR
LABAL_HbA1c 
OR
LABAL_
LCURVE_
GLUC
N in B 0 0 62400 0 44271 38764 0 0
% of B 
in A
- - 65.1% - 63.6% 46.5 - -
PRR 
if B 
added
- - +43.0% - +2.4% +1.0% - -
Since patients can be identified by more than one component algorithms, percentages may overlap.
Grey cells correspond to component algorithms that were included in the relevant recommended 
composite algorithm.
NIAD: Non-Insulin Antidiabetic Drugs.
A= recommended composite algorithm.
B= tested component algorithm(s).
N= Study population.
PRR= prevalence rate ratio of “A or B” in N with respect to the percentage of A in N.
Table 3. Continued
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In RLDs, DRUG-based components identified from 81% to 100% of the 
respective total case population, while from 58% to 83% in PCDs. TEST-based 
components were included in the recommended composite algorithm of the 
Danish RLD only in which these algorithms identified 44% of the total case 
population. Although TEST-based components were also extracted from the 
Italian RLD, they were not included in the recommended composite algorithm 
since they would have almost doubled the total case population (PRR=+79.2%), 
thus suggesting a too low specificity. LABVAL-based algorithms were included 
in the recommended composite algorithm of the Italian PCD only: overall, 
the three components from this data domain identified 46% of the total case 
population. Notably, subjects from the same data source could be identified by 
one or more component thus the percentages reported above may overlap.  
 
DISCUSSION
Through the application of the standard data derivation procedure tested in 
this study, cases of T2DM were identified in eight distinct sources of health 
data with heterogeneous characteristics. Logical combinations of standardized 
component algorithms, each based on a single data domain, were used to build 
data source-tailored case-finding algorithms. This “component algorithm 
strategy” facilitated both benchmarking and interpretation of results across data 
sources. It also allowed the assessment of the impact of individual standardized 
component algorithms on the total population of cases retrieved in each 
participating data source that ultimately provided insight into the strengths 
and limitations of each data source with respect to the identification of T2DM 
cases.
Compared to previous projects that aimed to combine different European 
sources of EHR for research purposes,[2, 3] the main innovation of the standard 
procedure tested in this study was the use of component algorithms as 
building blocks that could be combined to create more complex case-finding 
algorithms. As demonstrated by the results presented here, in the context of a 
multi-national, multi-data source study, the “component algorithm strategy” 
represents an extremely flexible approach for generating EHR-driven[6] case-
finding algorithms in a standardized fashion: on the one hand, it allows the local 
experts’ knowledge of the EHR “natural system”[8] to be fully leveraged, avoiding 
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loss of information and assuring the correctness of the derived information, 
while, on the other hand, it facilitates the interpretation and benchmarking 
of results obtained even across data sources with very different characteristics. 
Notably, the data derivation procedure tested in this study requires that all 
component algorithms locally available for the identification of the condition 
of interest should be extracted, tested and stored regardless whether they will 
be subsequently included in the final recommended composite algorithm. This 
also gives to investigators and local experts the chance to tweak the preferred 
identification algorithm at the study design stage, according to the study 
questions.
Gaining insight into cases identified by data source-tailored case-finding algorithms
In this study, the composite algorithms recommended by local experts for 
the identification of T2DM were extremely variable, resulting, however, in a 
selection of cases that are likely to represent the best possible local approximation 
of the true case identification. Indeed, since the age-specific prevalence of 
diabetes is expected to be fairly homogeneous across the geographic areas 
we are considering,[32] the observed differences in terms of percentage of the 
corresponding study populations can be interpreted in light of both the specific 
components adopted and of relevant data sources’ characteristics. Among all 
data sources, the highest percentage of cases was identified in HD because this 
data source only captures subjects who visit the hospital, who, by definition, 
will have a higher burden of disease with respect to the general population. 
On the other extreme, the BD showed the lowest percentage, possibly because 
people volunteering to participate in this data source are slightly healthier than 
the general population. Both HD and BD identify patients with T2DM using 
DIAG-based component only. However, while in HD cases were identified 
among inpatients only who are expected to be at a more advanced stage of the 
disease and more likely to have comorbidities,[5] in BD characteristics of cases 
were probably more representative of patients with T2DM in the corresponding 
source population, because diagnoses are recorded in a primary care setting. As 
for the three primary care data sources, the Italian PCD adopted a case finding 
strategy based on data from DIAG and LABVAL. This strategy was expected to 
be very sensitive. Moreover, in a previous validation study, it was also proven 
to have the highest possible PPV. [30] Therefore, its recommended algorithm 
can be considered an excellent approximation of a true case identification and 
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the observed percentage of cases can be assumed to be a valid estimate of the 
prevalence of T2DM in the correspondent source population. In the PCD from 
UK a lower percentage of cases was identified compared to the Italian PCD. 
This result could be due to a slight underreporting of diagnoses in the data 
source. As for the Dutch PCD, the age-specific percentage of detected cases was 
almost identical to that observed in the PCD from UK. However, in the Dutch 
PCD a DRUG-based algorithm was adopted as additional inclusion criterion 
to the DIAG-based component DIAG_T2DM_PC, since the latter was not 
sensitive enough when used alone. In fact, general practitioners participating 
to the Dutch PCD often record diagnoses using free text description which 
may sometimes remain elusive to the keywords-based retrieval process. 
Among RLDs, the percentage of the population identified in the Dutch RLD 
was slightly lower than that observed in the other two RLDs from Italy and 
Denmark respectively. Indeed, local experts of the Dutch RLD recommended 
the use of one single DRUG-based component (DRUG_ORAL) as the preferred 
case-finding algorithm, while the other two data sources, on the grounds of 
previous validation studies,[27, 31] adopted more complex composite algorithms 
that allowed to increase sensitivity by including also components based on 
DIAG and/or TEST. In particular, the Danish RLD was the only data source 
collecting diagnoses from secondary care. Notably, TEST-based components, 
which identify patients through specific patterns of utilization of glycated 
haemoglobin tests, were not included in the Italian RLD since they resulted 
to be far more unspecific than in the Danish RLD. This was clearly showed 
when the impact of TEST-based components on the total population of cases 
identified in the two data sources was observed. Such a difference was probably 
due to local healthcare system organization and guidelines with respect to 
diagnosis and follow-up of diabetic patients. 
Understanding quality of a local case-finding algorithm
In studies utilizing routinely collected health data, understanding the quality 
of local case-finding algorithms is paramount for the interpretation of study 
findings[11, 33] and a fortiori in multi-data source studies. The component 
algorithm strategy proposed in this study can indirectly provide approximation 
of algorithm validity indexes, even when no formal validation studies are 
available for one or more of the participating data sources. This is attained 
through the benchmarking of components and composite algorithms across 
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data sources with similar characteristics but collecting data from different 
geographic areas or vice versa. 
Indeed, in this study, cases in PCDs were basically identified through primary 
care diagnoses and are thus expected to be fairly representative of the T2DM 
patients in the corresponding source populations. In RLDs, instead, most of 
cases were captured through non-insulin antidiabetic drugs utilization which 
cannot identify those patients at a earlier stage of the disease who are not 
on drug treatment (do diet only) and may also misclassify T2DM with other 
diseases for which the same drugs can sometimes be used (e.g. polycystic 
ovary syndrome).[4] Supposing that the validity of the latter case-finding 
algorithm was completely unknown, data reported in Table 3 can be used to 
obtain an approximation of its expected sensitivity and PPV. As an example, 
the Dutch RLD, which used a case-finding algorithm based on the utilization 
of non-insulin antidiabetics only (i.e. DRUG_ORAL) can be considered. Since 
sensitivity corresponds to the percentage of subjects with a true diagnosis of 
T2DM who also have the DRUG_ORAL pattern of non-insulin antidiabetic 
drugs utilization, this percentage can be estimated from the Dutch PCD to be 
around 77%, or slightly lower if we accept that sensitivity in the Dutch PCD is 
not 100% (the corresponding percentage in the other two PCD data sources 
is lower than 55%). PPV, instead, is the percentage of subjects utilizing oral 
antidiabetics who really have type 2 diabetes. In this case, value higher than 90% 
is expected since other indications for such drugs have a very low prevalence.
[4] In fact, this is also confirmed in both PCDs from Italy and UK where the 
component DRUG_ORAL added less than 3% of cases when used as additional 
inclusion criteria. 
Tailoring selection of components to a research question
Investigators and local experts could consider changing their preferred 
identification algorithm according to the type of study question or sensitivity 
analysis: in the case of a study involving T2DM, for instance, if specificity is 
important, they may switch to DIAG-based algorithms at the expenses of 
sensitivity; if sensitivity is important, they may add other inclusion criteria, 
like TEST-based components; if homogeneity across different data sources is 
important, they may agree to adopt a DRUG-based strategy.
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Limitations
Although this was a proof-of-concept study in which results obtained were 
not intended as estimates of disease frequencies, limitations that might 
have biased the results and comparisons discussed in this manuscript must 
be acknowledged. In particular, validation of the retrieved cases was not 
performed as well as important variables other than age were not considered 
for stratification of results.
CONCLUSIONS
Through the identification of T2DM cases, this study demonstrates that the 
standard procedure for data derivation developed within the EMIF project 
represent a methodological advancement for the execution of multi-national, 
multi-data source studies. In fact, on the basis of a shared definition of any 
event of interest, the procedure assures interoperability of heterogeneous 
EHR systems and allows establishing data-source tailored case-identification 
algorithm in a standardized fashion, providing sufficient information for 
contextualization and correct interpretation of study results and generating 
transparent and reusable documentation on the entire data derivation process.
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MAIN FINDINGS 
The main objective of this thesis was advancing the methodology of validation 
studies of case-finding algorithms that exploit diversity across available data, 
rather than collecting new data. The main case study was whether and how 
Italian administrative databases can be used to identify cases with chronic 
diseases and to monitor standards of care, using medical records as a reference 
data source. In the second part of this thesis we described how this validation 
approach compares with other initiatives in the world, and how it applies to 
European networks of diverse data sources. 
 
Part I: chronic diseases and compliance with standards of care 
in Italian Administrative Databases
Part I was devoted to address the following question: what are the optimal 
algorithms to detect chronic diseases in Italian Administrative Databases (IAD), 
and what is the validity of estimates of compliance with standards of care? The 
work is described in five chapters with the following specific questions
1.  How do the prevalence estimates derived from finding cases of chronic 
diseases in IAD compare with estimates derived from other data sources?
2.  What is the validity of algorithms detecting chronic diseases and their level 
of severity from medical records of General Practitioners?  
3.  What are the optimal case-finding algorithms in IAD to find cases of 
chronic diseases?
4.  How do estimates of compliance with standards of care derived from IAD 
compare with estimates derived from the Health Search (HSD), a database 
of medical records of the Italian College of General Practitioners?
5.  How do measures of compliance with standards of care derived from IAD 
compare with measures derived from the medical records of the General 
Practitioners?
At first in chapter 1 we demonstrated that IAD data could be used to identify four 
pre-specified chronic diseases by using codes and utilization of care patterns. 
The prevalence estimates were consistently lower than population estimates 
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from HSD and surveys, for diabetes, ischaemic heart disease and heart failure, 
but the geographic pattern was the same in all data sources. We suspected that 
IAD data may not have perfect sensitivity and specificity. 
To verify the assumption that medical records collected by GPs in HSD correctly 
identify chronic diseases, we assessed the positive predictive value (PPV) of case-
finding algorithms in primary care medical records in chapter 2. The answer 
was reassuring for type 2 diabetes, hypertension and ischaemic heart disease, 
but not for heart failure: the PPV was only 55%. Prevalence estimates from HSD 
were higher than prevalence estimated from the yearly national survey, as we 
had noticed in chapter 1, which suggests that the false negative rate was low.
Based on these results we assumed that primary care medical records were 
providing a gold standard for type 2 diabetes, hypertension and ischaemic heart 
disease. This was the key assumption we needed to address question 3, which dealt 
with finding the optimal queries for these chronic diseases in IAD.  In chapter 3 
we tested dozens of case-finding algorithms for type 2 diabetes, hypertension and 
ischaemic heart disease in IAD, using linked primary care medical records as a gold 
standard. In order to structure this process we first listed a set of simple component 
algorithms: discharge diagnosis from hospitalizations, diagnosis from exemptions 
(an Italian registry of disease-specific exemptions from copayment of health 
care), drug utilization, utilization of diagnostic services. We tested each of them 
separately, then combined them in more complex strategies: components were 
used as inclusion, exclusion or refinement criteria. For each disease we identified 
the composed algorithm with the best balance between sensitivity and positive 
predictive value. The resulting optimal algorithms all had high positive predictive 
value, but low sensitivity. In particular for ischaemic heart disease sensitivity was 
lower than 50%. Moreover, we were able to identify several strategies that may 
be chosen for studies where sensitivity is more important than specificity: drug 
utilization or utilization of diagnostic services is an important component of such 
algorithms. Vice versa, if high positive predictive value is paramount for a study, 
algorithms based on diagnostic components (inpatient and exemptions) could be 
considered, at least for sensitivity analysis.
Validity of compliance with standards of care for chronic diseases in Italian 
Administrative Databases (questions 4 and 5)
Based on the case finding algorithms from chapter 1, we compared estimates 
of compliance with standards of care (diagnostic tests and recommended drug 
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treatment) between IAD and HSD at the same geographical level (chapter 4), for 
ischaemic heart disease estimates, diabetes and heart failure. The comparison 
was reasonable. This was especially true for compliance with recommended 
therapies, whilst diagnostic tests were underreported in IAD. However, since 
we could not link the IAD and HSD data at the individual level, we doubted 
whether the observed similarities in chapter 4 were true, or a coincidence of 
a mixture of confounding factors. Linkage of the data at the individual level 
between IAD and medical records in HSD showed that the latter was true 
(chapter 5). We saw that the numerators of therapy indicators were consistently 
measured across data sources, while the numerators of diagnostic indicators 
were not. Moreover, persons in the IAD denominator had lower compliance 
with respect to the false negatives (persons with the disease but who are not 
included in the IAD denominator). These two opposite effects resulted in a 
substantial similarity between estimates from IAD and medical records, except 
for some of the diagnostic indicators. So compliance with standards measured 
with IAD for the diseases of interest compared well with measures from medical 
records, but comparability seemed to be the result of coincidence rather than 
real similarity.
Part II: deriving study variables for multi-database studies
The main research question of Part II was: how do networks of databases 
generate study variables in the different sites, and how do they assess variable 
validity?
We split the question in two parts.
6.  How is the derivation of study variables organized in existing data networks 
in Europe and in the United States?
7.  How can a network of diverse data sources in Europe streamline the 
process of data derivation?
Data derivation in existing networks
In chapter 6 we described derivation of study variables in 4 different networks: 
in Italy (MATRICE), Europe (EU-ADR) and in the United States (Mini-Sentinel 
and OMOP). 
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In Mini-Sentinel the focus was on data from different sources in the United 
States, which have a mild internal diversity: the coding system was the same 
(ICD9CM), and most of the participant nodes were providing administrative 
data. The derivation of study variables was  conducted with the simplest 
algorithm: detecting the occurrence of a code  in a set of ICD9CM diagnostic 
codes. Sensitivity of this approach was discussed, and alternatives were 
described, by systematically reviewing available literature. When literature 
review was considered insufficient, the positive predictive value of diagnostic 
codes was measured using chart review as a gold standard. Validity indices were 
not corrected for in the statistical analysis. 
In the OMOP network several algorithms based on systematic literature 
reviews were used to identify the same study variable. Coding systems for 
diagnosis, drugs and diagnostic tests were not equal across data partners, but 
were mapped to a same set of vocabularies altogether, independently on the 
study variable of interest. Instead of validating case-finding algorithms, an 
indirect form of evaluation was conducted: a set of known associations between 
the study variable and exposure to various drugs was collected from literature 
and regulatory sources. The quality of the algorithms for a study variable was 
identified with the ability to tell true from false associations. 
The MATRICE network used the automatic queries on medical records 
validated in chapter 2 to validate its study variables, and had the possibility 
of testing dozens of combinations of component algorithms and explicitly 
estimate validity indices. 
In the European EU-ADR network the heterogeneity of original data sources 
was considerably higher with respect to the country-based networks, as it 
covered different countries health care structures and data base structures. The 
overall process to derive study variables was handled as an iterative process, 
where local data experts were providing their feedback to central proposals, and 
was protocol-based. Terminology mapping from different coding systems was 
addressed per single study variable. As for the provenance (primary, secondary, 
inpatient care or death) of the records selected in each local data source, and 
additional inclusion, exclusion and refinement criteria, they were discussed 
before decisions were made, but the process was never embedded in accessible 
documents. Validation was performed for two diseases.
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A data derivation workflow for heterogeneous data sources: the component 
algorithm strategy
Based on the experiences in MATRICE and the EU-ADR project we proposed a 
data derivation workflow for the EMIF Project, a European network of diverse 
data sources (chapter 7). The main step forward was the explicit use of the 
component algorithm strategy, which  originated from the validation study in 
Italy (chapter 3).
We formalized the notion of component algorithm: in this wider context this is 
an algorithm which selects data from a single data domain (diagnosis, drugs, 
diagnostic tests, results from diagnostic tests), and specifies the provenance of 
the records (primary care, secondary care, inpatient care, death, other) as well as 
the pattern used to identify the case (at least one record, at least two records in a 
specified time frame, …) and the choice of the case date (date of the first record, 
date of the second record…). Each person is positive to one, more than one, or 
none of a list of components.
As a case study, we aimed to identify the best site-tailored case-finding 
algorithm for type 2 diabetes mellitus in 8 heterogeneous European data 
sources. We created a list of 17 components. In each data source, all the persons 
were labelled as positive or negative per component. Population frequency of 
each combination of components was counted and the resulting aggregated 
data could be shared. Each data source chose a tailored combination of 
components as their preferred case-finding algorithm: this approach combined 
standardization and flexibility, and fully documented the local choices. We 
could establish sensitivity and PPV of the component considering non-insulin 
antidiabetic drug utilization within HSD. Sensitivity resulted to be 55%, similar 
to the 59% sensitivity in IAD that we had estimated in the individual-level study. 
In the EMIF network we had a similar pair of databases from the Netherlands: a 
primary care database, and an administrative database. By analogy, we assumed 
that the sensitivity of the same drug component from the Dutch administrative 
database was similar to 77%, which was the sensitivity of the same component in 
the Dutch primary care database. So we could provide an estimate of sensitivity, 
using only aggregated data.
This way we could exploit diversity across sites, as a mean to infer validity. 
Rather than considering it a weakness, we demonstrated that it can indeed be 
considered a strength.
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GENERALIZABILITY OF FINDINGS 
 
Monitoring quality of healthcare for chronic diseases in Italy
Our validation studies covered a limited number of Italian regions and were 
conducted in a specific point in time, for a few diseases. We discuss here 
whether the results from the validation studies can be generalized.
Generalization of validity of case-finding algorithms to other chronic diseases, over 
time and for other Italian regions.
In IAD we saw some general patterns in sensitivity and positive predictive value 
of component algorithms, in different diseases and over regions. Such general 
patterns may support hypothesis generation with respect to the validity for 
other diseases, or of the same diseases over time. In the following we discuss 
this, component per component.
Validity indices of components based on inpatient and exemption diagnosis 
were similar across the three diseases: they all had high positive predictive value 
and low sensitivity, although the specific measure varied both by disease and by 
region. The three conditions had in common a relatively straightforward clinical 
definition. If we considered other chronic diseases whose diagnostic algorithm 
is more complex, as is the case for chronic obstructive pulmonary disease 
[Romanelli2016], positive predictive value of inpatient exemption diagnoses 
may be lower. We saw in chapter 2 that ambiguity in the clinical definition of 
heart failure compromised significantly the positive predictive value of a case-
finding algorithm from primary care medical records: the same is expected to 
happen for components based on inpatient and exemption diagnosis. It is not 
expected that positive predictive value changes significantly over time, unless 
new diagnostic criteria or tests become available. On the contrary, sensitivity 
may be affected by reduced use of inpatient care, but the effect could only be 
seen in the long run, if new cases are less often hospitalized.
As for drug utilization components, the positive predictive value is associated 
with prevalence of other conditions which are indications for the same drug. 
Non-insulin antidiabetic drugs have type 2 diabetes as the largely most common 
indication, therefore positive predictive value was very high. It is expected to 
be similarly high, for instance, for memantine or cholinesterase inhibitors as 
components of a case-finding algorithm for dementia, because these drugs have 
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basically no other indications. On the contrary, it is likely to be low in the case 
of patterns of utilization of respiratory drugs as with component algorithms for 
chronic obstructive pulmonary disease, as we saw in chapter 1, because asthma is 
a highly prevalent concurrent indication [Gini2015, Romanelli2016]. Sensitivity 
of a drug utilization component is associated with the strength and penetration 
of the recommendation to treat the disease, as well as to the accessibility of the 
drug: this was very high for antithrombotic therapy in ischaemic heart disease, 
but would be lower for dementia [Francesconi2007]. Validity of drug-based 
components change over time, due to the entrance of new drugs in the market, 
new indications (possibly off-label) for old drugs, new clinical guidelines and 
regulatory interventions.
Components based on utilization of diagnostic tests had promising results in 
terms of sensitivity. This family of components is commonly used in the Danish 
administrative databases, which have a similar structure in this respect to IAD 
[Carstensen2008]. This type of components is expected to provide a relevant 
contribution in the near future, when the data become available on the whole 
Italian population. However, access to this type of healthcare services in the 
healthcare system may change over time, according to new rules in copayment 
and reduced accessibility.
Our estimates relied on a sample of local health units from 5 of the 21 Italian 
regions. We adopted a convenience sampling schema, and regions in the South 
were under represented. The determinants we identified for geographical 
variation of validity indices (for instance, local off-label use of drugs) should be 
discussed with local experts when generalizing our estimates.
In summary, some patterns in the positive predictive value and sensitivity that 
we observed may be generalized over time, over regions, and potentially provide 
guidance for validity of case-finding algorithms of other diseases. However, 
we don’t recommend to generalize the estimates that we obtained for validity 
indices to other diseases. Hypotheses on validity should be generated and tested 
against external data sources, using the methodology that we will explain in the 
subsections below.
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Generalization of the validity of measures of compliance with standards of care for 
chronic diseases in Italy with Italian Administrative Databases
We demonstrated that we should be cautious when measuring compliance 
with standards of care for type 2 diabetes, hypertension and ischaemic heart 
disease from IAD. The balance between the number of false negatives and their 
reduced compliance, as well as access to diagnostic services contracted by the 
healthcare services, may change over time and between regions, and hamper 
the accuracy of estimates. 
At the population level, drug utilization is consistently recorded by IAD and 
medical records: this is likely to be the case for other drugs which are reimbursed 
by the healthcare system. In the case of compliance with recommended 
therapies for a chronic disease, in general, the obstacle to validity of IAD 
measures amounts essentially to the quality of the denominator (see previous 
subsection), and to the different level of compliance in false negatives. The 
profile of false negatives is specific per disease: diagnosis recorded in inpatient 
care detect more severe patients, who are likely to be more adherent to 
medications; drug utilization components detect a population which is more 
likely to be adherent to any drug. Generalizability of the results of chapter 5 
to this respect is limited: to understand the expected validity of the measure 
of compliance with a new standard, all those aspects should be evaluated by a 
panel of specialist and primary care physicians, hypothesis should be generated, 
and a new round of validation should be performed.
In the case of compliance with diagnostic recommendations, an additional level 
of complexity is due to uneven accessibility to diagnostic services. Interpretation 
of results and generalizability to other diseases, should be carefully discussed 
with local managers of the healthcare system.
In the next subsection a generalization of the methodology we developed in this 
thesis for validation studies on existing databases is discussed. This approach 
could be applied routinely to support interpretation of measures of compliance 
to standards of care for chronic diseases in IAD.
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GENERALIZABILITY OF METHODOLOGY
A general approach for individual-level validation studies on existing databases
In the first part of this thesis we used one data source to systematically validate 
another, at the individual patient level. We now draw the main lessons from 
this specific experience, to propose a general methodological approach. 
In its essence, the starting point to apply our approach is the following
•	 	two data sources are available on the same population, but record linkage 
at the individual level between them is not possible on a regular and 
continuous basis
•	 	in one of the data sources (“worse” data source) the optimal case-finding 
algorithm for a study variable is unknown, while in the other (“better” data 
source) a good or excellent case-finding algorithm is available
•	 	permission for record linkage on a sample of persons can be obtained for 
purposes of validation
The approach for an individual-level validation of the variable of interest 
comprises three steps
Ecological-level comparison: compare at the ecological level the population 
prevalence (or incidence) of the variable, obtained separately from the two data 
sources; compare the resulting estimates with each other and with estimates 
available from the literature or from other sources (survey data, disease 
registries): the rationale for this step is obtaining evidence that the quality of 
the two data sources is as expected, before engaging in more complex studies
Gold standard validation: validate the candidate case-finding algorithm in the 
“better” data source with manual chart review, on a small sample, to confirm its 
validity: the rationale of this step is confirming the quality of the “better” data 
source, using a traditional methodology
Individual-level validation: obtain permission to perform the record-linkage 
between the two data sources, and use the validated case-finding algorithm 
on the “better” data source as a gold standard to find the optimal case-finding 
algorithm in the “worse” data source. If the case-finding algorithm on the 
“better” data source is proven by the “Gold standard validation” step to have 
imperfect validity, it can still be used to provide information on the other data 
source, but statistical adjustment needs to be applied [Gart1966] (see section 
“Implications for research” below).
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As we saw in the previous subsections, the results of our validation studies 
cannot be generalized to other diseases, and may cease to be reliable over 
time. What is generalizable is the approach that we just described. This has 
the advantage of all the big data studies: fast, repeatable, reproducible on vast 
populations. 
Generalization to multi-database studies: component analysis
We consider now the situation when a study variable must be defined in multiple 
data sources, that are considered part of the same study. The steps described 
in the previous subsection can be used systematically, although with some 
modifications. Indeed, in a multi-database setting there are some limitations:
•	 	data sources may not be available on the same population, but rather on 
similar populations;
•	 	even if two data sources are available on the same population, individual-
level record-linkage is unlikely to be allowed, due to time or legal constraints
On the positive side, in multi-database studies more than two data sources are 
normally available. 
To fully exploit the potential of a multi-database setting, it is proposed to 
generalize the component algorithm strategy. A set of component algorithms 
must be created, each specified with data domain, provenance of data, pattern 
of records, date, and length of look-back. Sets of aggregated data like the one 
represented in Table 1 can be shared among partners. Multiple comparisons 
across data sources can be performed, as described in the remaining subsections. 
This process is referred to as component analysis. At the end of the analysis, a 
data source-tailored combination of components can be chosen as the preferred 
case-finding algorithm, depending on the characteristics of the data source, on 
the results from the component analysis, and on the requirements of the study 
protocol.
Analysis of components in a same data source
If a component is a gold standard (on the basis of a local validation study), then 
validity of the other components in the same data source can be obtained from 
direct calculation (generalization of the case of the drug utilization component 
in chapter 7)
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If a component has known validity (on the basis of a local validation study), 
then validity of the other components in the same data source can be obtained 
from statistical estimation, assuming conditional independence of the two 
components [Gart1966]
Inference of validity of a component from one data source to another
Validity of drug utilization components can sometimes be generalized from one 
source to another. We have seen that utilization of some drugs in Italy was very 
consistently measured by primary care medical records and by administrative 
data. This is likely to be the case for all drugs which are reimbursed by the 
national health care system in Italy, but do not need a specialist prescription. 
This happens not only in Italy, but also in other countries where General 
Practitioners have a “gatekeeper” role and take-over specialist prescriptions. 
The observation that medical records and administrative data, measure drug 
utilization in a consistent manner was made recently in a very general setting 
[Hripcsak2016]. Under the assumption that data utilization is measured 
consistently by different data sources in the same population, validity of a drug 
utilization component in that population is independent on the data source 
where it is measured. If in a data source a “gold standard” algorithm is available, 
then validity of drug utilization can be estimated. Based on the previous 
remark, validity of a drug utilization component is independent on the data 
source where it is measured, so we can make the assumption that the validity 
of the drug utilization component is similar in other data sources in the same 
population. 
If validity can be estimated this way in several regions, and it results in similar 
estimates, it can be argued that validity is similar even in other regions. Indeed, 
ultimately, sensitivity of drug utilization is the percentage of patients with 
a disease who are treated, and positive predictive value is the percentage of 
treated patients who are treated for that indication. Both those percentages 
are influenced by national and international clinical guidelines and regulatory 
interventions - even though local circumstances may have a relevant impact (as 
we have seen in chapter 4).
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Analysis of prevalence or incidence of the same component across different data 
sources
Prevalence or incidence of the same component can be compared across 
different data sources:  for instance, rates of hospitalized acute events, or 
prevalence of chronic diseases diagnoses in primary care, or drug utilization 
prevalence. Observed differences can be discussed. They may be attributed to 
population differences, or to differences in the underlying health care system, 
or in granularity of the coding system. If no such difference is plausible, we can 
infer that the explanation lies in difference in validity of the variable. 
Estimates of positive predictive value of a component and of prevalence of the 
disease provide an estimate of sensitivity
If positive predictive value of a component is estimated (for instance, from 
a validation study, or based on assumptions), then the expected number of 
false positives can be computed from the number of persons identified by 
the component. The number of true positives can be obtained by difference. 
If population prevalence of the disease can be obtained from an external data 
source, then the number of persons with the disease in the data source can 
be estimated. An estimate of the sensitivity is the ratio of true positives to the 
estimated number of persons with the disease. 
Table 1. Template of a dataset of aggregated data for component analysis, in the case of 3 components 
and 2 data sources.
DATA SOURCE COMPONENT 1 COMPONENT 2 COMPONENT 3 Number of subjects
A No No No
A Yes No No
A No Yes No
A No No Yes
A Yes Yes No
A Yes No Yes
A Yes Yes No
A Yes Yes Yes
B No No No
B Yes No No
B No Yes No
B No No Yes
B Yes Yes No
B Yes No Yes
B Yes Yes No
B Yes Yes Yes
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IMPLICATIONS FOR RESEARCH
Research needed to improve estimates of compliance with standards of care for 
chronic diseases based on Italian Administrative Databases
We recommend to be cautious when measuring compliance with standards 
of care for chronic diseases from IAD. A key development would be assessing 
whether a calibration of the estimates from IAD improves the estimates of 
compliance with standards of care. To do so, a statistical model should be 
built that incorporates validity indices of the denominators and concordance 
between estimates of the numerators. The result should be compared with the 
“best estimate”.
Research needed to improve validation studies on existing databases
In the absence of a true gold standard, a reference standard can still be used to 
validate another algorithm, but statistical adjustment needs to be applied. This is 
a classical approach, and relies on the assumption of conditional independence 
between the reference standard and the algorithm to be validated [Gart1966]. 
This assumption is unlikely to be met in our setting, and research is needed to 
explore how it can be mitigated.
As for multi-database studies, the component analysis we proposed in the 
“Generalizability of findings” section would benefit from further elaboration on 
several theoretical issues. First, robustness of validity estimates to violations of 
the assumptions needs to be assessed. Second, effort should be made to adapt 
the classical Hui-Walter paradigm, which was developed to validate diagnostic 
tests without a gold standard, to the case-finding algorithm situation. In this 
approach, the true disease status is modelled as a latent class, and information 
derived from applying the same test to populations with different prevalence 
is exploited to estimate the parameters of the model [Hui1980, Joseph1995]. In 
an evolution of this approach, a similar model can be estimated when several 
tests are applied to the same population [Walter1988, Johnson2001]. The 
Hui-Walter paradigm relies on assumptions that are unlikely to be met when 
case-finding algorithms are involved instead of diagnostic tests, so research is 
needed to understand how they can be mitigated. Third, in order to implement 
components across data sources which use different coding systems, mapping 
between different terminologies must be handled. Mapping must take place 
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within multiple data domains: diagnosis, drugs, diagnostic tests, interventional 
procedures. We saw that two different strategies were adopted in different 
networks: either terminology mapping was done once and for all, or it was 
tuned on a specific study variable. The first strategy requires a bigger effort of 
initial mapping, but later allows for homogeneous treatment of mapped data 
across data sources. The second is conceivably producing study variables with 
higher validity indices. Understanding determinants of validity loss would be a 
relevant achievement.
42070 Rosa Gini.indd   209 05-09-16   20:13
210
RECOMMENDATIONS 
 
Monitoring quality of healthcare for chronic diseases in Italy
Measures of compliance with standards of care for chronic diseases obtained 
from IAD should be used with caution. For the measures studied in this thesis 
the following recommendations on their use can be made:
•	 	pay-for-performance schemes for general practitioners should at present 
not be based on such measures. The validity issues are still too large and 
using them at this stage for reimbursement purposes would most likely 
introduce perverse incentives.
•	 	At regional level, IAD measures can be used alongside measures from 
primary care medical records for quality audits. The measures are 
informative when taking the local context into account.
•	 	At national level, when presenting comparisons between regions  an open 
dialogue is essential and the following should be considered:
 o  interpretation should be facilitated by presenting estimates of 
percentages of false negatives and estimates of regional use of private 
services, using as a reference
	 	 	 	validation studies from this thesis, 
	 	 	 	analysis of HSD
	 	 	 	analysis of national surveys
 o  regional managers should be encouraged to comment on the data, 
using insights derived from local audits as a basis
•	 	At national level, if compliance with standards of care is used to evaluate 
regions, calibrated estimates of true compliance should be built
•	 	When using compliance with standards of care as an outcome in policy 
evaluation studies based on IAD, the impact of misclassification should be 
assessed or discussed. 
As an additional recommendation, validation studies should be routinely 
performed on clusters of patients. This recommendation was recently endorsed 
in a report of the Italian National Institute of Health [ISS2014]. The results from 
such studies could be used to update validity parameters, using the methods 
developed in this thesis.
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Overall the compliance measures should be “handled with care”, but when applied 
with knowledge of the context and limitations of the underlying data they can 
provide meaningfull information to assess and improve the quality of care. 
Deriving variables in multi-database studies
When designing an observational study in a multi-database network, we 
recommend to adopt a component algorithm strategy, as described in the 
section “Generalizability of findings” above, to define the key study variables. In 
a feasibility phase, we encourage data sources to share aggregated data to allow 
estimates of validity indices. The combination of components meant to define 
a study variable should be tailored to each data source, in order to maximize 
validity. At the design stage, sensitivity analysis using different components to 
define variables should be designed, to assess robustness of study results with 
respect to heterogeneity in validity across sites. Including validity indices at the 
analytical step should be considered as well.
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FROM BIG DATA TO LOCAL INTELLIGENCE
We saw in this thesis how big data can be used to validate big data, and we 
recommend to exploit systematically this opportunity to enhance local 
intelligence. This is paramount to meet the expectations from policymakers, 
clinicians, patients and citizens, that big data will provide more detailed and 
reliable guidance to the choices they need to make, in order to improve health 
and health care. 
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BACKGROUND AND RESEARCH QUESTIONS
The era of big data opens new means to improve health and health care. 
Observational evidence from large populations can provide guidance to the 
choices of multiple stakeholders. Policymakers can understand how health care 
systems can be better organized, clinicians can explore more in detail all the 
treatment options, patients can put peculiarities of their own diseases at the 
centre of the clinical decisions, and citizens can obtain evidence to inform their 
political options. New methodologies need to be developed, and traditional 
tools and ways of thinking need to be renovated to adapt to the new perspective, 
to avoid drawing incorrect conclusions from studies based on this resource 
[Ray2011, Mooney 2015]. 
The methodological challenge relies not only in the observational nature of 
the studies that can be conducted on big data, but also in the heterogeneous 
characteristics of the data that is now available. We are interested in the latter. 
The objective of a validation study of a case-finding algorithm is estimating the 
validity indices  of the algorithm, that quantify to which extent the study variable 
corresponds to the true variable.
The methodology for validation studies has been developed in the context of 
validation of diagnostic tests, that is, procedures collecting clinical parameters 
from patients [Whiting2003]. The parameters of sensitivity and specificity of 
a diagnostic test are rooted in human biology and essentially depend on the 
characteristics of the population where they are estimated [Greenland1996]. 
On the contrary, validity indices of a case-finding algorithm in a database 
depend on multiple characteristics of the system, for instance completeness 
of data collection, accuracy in coding habits, granularity of the coding system, 
organization of the health care system in the geographic area where the data 
is collected – besides characteristics of the population whose data is collected. 
All those factors are subject to change from one database to another, and over 
time [Quan2009, Reich2012, Herret2013, Morley2014, Rahimi2014, Lanes2015]. 
Generalizing estimates of validity parameters of a case-finding algorithm outside 
of the environment where a validation study was executed is questionable. 
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In order to support effectively the interpretation of the results of a study, 
validation of study variables should be as close as possible to the actual dataset 
that is used for the statistical analysis. Traditional validation studies, which 
imply manual assessment of samples of records, are time-consuming and 
expensive [Hernan2011].  An alternative solution is exploiting big data to validate 
big data: this methodological advancement is emerging in the recent literature.
 
The main objective of this thesis is advancing the methodology of validation 
studies of case-finding algorithms that exploit diversity across available data, 
rather than collecting new data.
The case study that led us to this advancement was the assessment of the 
capacity of the Italian administrative database to capture cases of chronic 
disease to get estimates for the compliance with standards of care. Primary 
care medical records were the main comparative source. Part I of this thesis is 
focussed on this topic.
In Part II we exploited the results and extended the methodology of Part I to the 
context of multi-database, multi-national studies.
Validation of variables defining chronic disease and compliance with standards of 
care in Italian Administrative Databases
Italy has a universal, single-payer healthcare system.  Chronic diseases impose 
an increasing burden on the Italian aging population, and are a major threat to 
sustainability of the healthcare system [OECD2015]. 
Administrative data are collected on a large set of services provided to the 
population, and are available for secondary analysis to health policy makers. 
Secondary use of Italian Administrative Databases (IAD) to detect patients with 
chronic conditions would allow surveillance, planning, monitoring of quality 
of healthcare, as well as assessment of impact of new organizational models on 
relevant health and quality outcomes. 
The MATRICE Project, funded by the Italian Ministry of Health, was launched 
in 2011 by the Italian National Agency for Regional Healthcare Services 
(AGENAS), with the aim of defining methodologies and tools to best exploit 
administrative data for the purposes of monitoring quality of healthcare for 
patients with chronic diseases. 
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The main research question of Part I of the thesis was: what are the optimal 
algorithms  to detect chronic diseases in the IAD, and what is the validity of 
estimates of compliance with standards of care? 
We split this main question in 5 specific questions.
1.  How do the prevalence estimates derived from finding cases of chronic 
diseases in IAD compare with estimates derived from other data sources?
2.  What is the validity of algorithms detecting chronic diseases and their level 
of severity from medical records of the General Practitioners?  
3.  What are the optimal case-finding algorithms in IAD to find cases of 
chronic diseases?
4.  How do estimates of compliance with standards of care derived from IAD 
compare with estimates derived from the Health Search (HSD), a database 
of medical records of the Italian College of General Practitioners?
5.  How do measures of compliance with standards of care derived from IAD 
compare with measures derived from the medical records of the General 
Practitioners?
Validity of variables in multi-database studies
In 2004, after five year of widespread use, the anti-inflammatory drug rofecoxib 
was withdrawn from the market due to severe safety concerns. It was estimated 
that if a monitoring system had been in place querying the medical records of 100 
million patients, the adverse cardiovascular effect would have been discovered 
in just few months. After this episode, networks of researchers with regular 
access to observational healthcare data sources have been created. Methods 
and procedures have been generated to execute studies in a distributed fashion, 
to take advantage both from size and from diversity of the populations they 
could merge [Trifiro2014]. Those advantages come at the price that the level of 
complexity in deriving study variables scales up, because all the characteristics 
that have an impact on validity may be different across sites.
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Table 1.  Summary of the studies in Part I of this thesis. IAD: Italian Administrative Databases. 
Variable to 
be validated
Study 
design
Data 
sources
Diseases Setting Year Chapter
Case-finding 
algorithm
Ecological 
comparison
between 
existing 
data
IAD, 
primary 
care 
medical 
records, 
national 
survey
Ischaemic 
heart disease, 
diabetes 
mellitus, 
heart failure, 
chronic 
obstructive 
pulmonary 
disease
Population samples 
from 5 Italian regions: 
Veneto, Emilia 
Romagna, Tuscany, 
Marche and Sicily
2009 1
Case-finding 
algorithm
Individual-
level 
manual 
validation
 
Primary 
care 
medical 
records, 
manual 
assessment 
Type 2 
diabetes, 
hypertension, 
ischaemic 
heart disease 
and heart 
failure, with 
levels of 
severity
300 cases per disease, 
from 12 GPs across 
Italy
2014 3
Case-finding 
algorithm
Individual-
level 
record-
linkage 
between 
existing 
data
IAD, 
primary 
care 
medical 
records
Type 2 
diabetes, 
hypertension, 
ischaemic 
heart disease 
and heart 
failure
25 clusters of subjects, 
5 per each of the 
following regions: 
Lombardy, Veneto, 
Emilia Romagna, 
Tuscany, Puglia
2012 4
Compliance 
with 
standards of 
care
Ecological 
comparison 
between 
existing 
data
IAD, 
primary 
care 
medical 
records
Ischaemic 
heart disease, 
diabetes 
mellitus, heart 
failure
Population samples 
from 5 Italian regions: 
Veneto, Emilia 
Romagna, Tuscany, 
Marche and Sicily
2009 2
Compliance 
with 
standards of 
care
Individual-
level 
record-
linkage 
between 
existing 
data 
IAD, 
primary 
care 
medical 
records
Type 2 
diabetes, 
hypertension 
and ischaemic 
heart disease
25 clusters of subjects, 
5 per each of the 
following regions: 
Lombardy, Veneto, 
Emilia Romagna, 
Tuscany, Puglia
2012 5
This is especially true in Europe: diversity in local mechanisms of data collection 
is a consequence of the diversity among European countries in language, 
culture, political and health care organization. Notwithstanding, cross-border 
evidence is necessary to address common questions such as efficacy and safety 
of medical products and vaccines, or comparison of quality of health care. 
Part II of this thesis was devoted to investigate the process adopted by some 
existing networks to derive the study variables in each site and address their 
validity, and to propose and test a novel methodology to streamline this process.
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Research questions
The main research question of Part II was: how do networks of databases handle 
the process of generating study variables in the different sites, and how do they 
assess their validity?
We split the question in two parts.
6.  How is the derivation of study variables organized in existing data networks 
in Europe and in the United States?
7.  How can a network of diverse data sources in Europe streamline the 
process of data derivation?
MAIN FINDINGS
Chronic diseases and compliance with standards of care in Italian Administrative 
Databases
At first in chapter 1 we demonstrated that IAD data could be used to identify four 
pre-specified chronic diseases by using codes and utilization of care patterns. 
The prevalence estimates were consistently lower than population estimates 
from HSD and surveys, for diabetes, ischaemic heart disease and heart failure, 
but the geographic pattern was the same in all data sources. We suspected that 
IAD data may not have perfect sensitivity and specificity. 
To verify the assumption that medical records collected by GPs in HSD correctly 
identify chronic diseases, we assessed the positive predictive value (PPV) of case-
finding algorithms in primary care medical records in chapter 2. The answer 
was reassuring for type 2 diabetes, hypertension and ischaemic heart disease. 
Prevalence estimates from HSD were higher than prevalence estimated from 
the yearly national survey, as we had noticed in chapter 1, which suggests that 
the false negative rate was low.
Based on these results we assumed that primary care medical records were 
providing a gold standard. This was the key assumption we needed to address 
question 3.  In chapter 3 we tested dozens of case-finding algorithms for type 2 
diabetes, hypertension and ischaemic heart disease in IAD, using linked primary 
care medical records as a gold standard. In order to structure this process we 
first listed a set of simple component algorithms: discharge diagnosis from 
hospitalizations, diagnosis from exemptions, drug utilization, utilization of 
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diagnostic services. We tested each of them separately, then combined them in 
more complex strategies. The resulting optimal algorithms all had high positive 
predictive value, but low sensitivity. 
Based on the case finding algorithms from chapter 1, we compared estimates 
of compliance with standards of care (diagnostic tests and recommended drug 
treatment) between IAD and HSD at the same geographical level (chapter 
4), for ischaemic heart disease, diabetes and heart failure. The comparison 
was reasonable. This was especially true for compliance with recommended 
therapies, whilst diagnostic tests were underreported in IAD. However since 
we could not link the IAD and HSD data at the individual level, we doubted 
whether the observed similarities in chapter 4 were true, or a coincidence of 
a mixture of confounding factors. Linkage of the data at the individual level 
between IAD and medical records in HSD showed that the latter was true 
(chapter 5). Compliance with standards measured with IAD for the diseases of 
interest compared well with measures from medical records, but comparability 
seemed to be the result of coincidence rather than real similarity.
Deriving study variables for multi-database studies
In chapter 6 we described derivation of study variables in 4 different networks: 
in Italy (MATRICE), Europe (EU-ADR) and in the United States (Mini-Sentinel 
and OMOP). 
In Mini-Sentinel the focus was on data from different sources in the United 
States, which have a mild internal diversity. The derivation of study variables 
was conducted with the simplest algorithm: detecting the occurrence of a code 
in a set of ICD9CM diagnostic codes. When literature review was considered 
insufficient, the positive predictive value of diagnostic codes was measured 
using chart review as a gold standard. Validity indices were not corrected for in 
the statistical analysis. 
In the OMOP network several algorithms based on systematic literature 
reviews were used to identify the same study variable. Coding systems for 
diagnosis, drugs and diagnostic tests were not equal across data partners, but 
were mapped to a same set of vocabularies altogether, independently on the 
study variable of interest. The quality of the algorithms for a study variable was 
identified with the ability to tell true from false associations in a predefined set 
of drug-outcome pairs. 
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The MATRICE network used the automatic queries on medical records 
validated in chapter 2 to validate its study variables, and had the possibility 
of testing dozens of combinations of component algorithms and explicitly 
estimate validity indices. 
In the European EU-ADR network the heterogeneity of original data sources was 
considerably higher with respect to the country-based networks, as it covered 
different countries, health care structures and data base structures. The overall 
process to derive study variables was protocol-based. Terminology mapping 
from different coding systems was addressed per single study variable. As for the 
provenance (primary, secondary, inpatient care or death) of the records selected 
in each local data, the process was never embedded in accessible documents. 
Validation was performed for two diseases.
A data derivation workflow for heterogeneous data sources: the component 
algorithm strategy
Based on the experiences in MATRICE and the EU-ADR project we proposed a 
data derivation workflow for the EMIF Project, a European network of diverse 
data sources (chapter 7). The main step forward was the explicit use of the 
component algorithm strategy, which  originated from the validation study in 
Italy (chapter 3).
We formalized the notion of component algorithm: in this wider context this is 
an algorithm which selects data from a single data domain (diagnosis, drugs, 
diagnostic tests, results from diagnostic tests), and specifies the provenance of 
the records (primary care, secondary care, inpatient care, death, other) as well as 
the pattern used to identify the case (at least one record, at least two records in a 
specified time frame, …) and the choice of the case date (date of the first record, 
date of the second record…). Each person is positive to one, more than one, or 
none of a list of components.
As a case study, we aimed to identify the best site-tailored case-finding 
algorithm for type 2 diabetes mellitus in 8 heterogeneous European data 
sources. We created a list of 17 components. In each data source, all the 
persons were labelled as positive or negative per component. Population 
frequency of each combination of components was counted and the 
resulting aggregated data could be shared. Each data source chose a tailored 
combination of components as their preferred case-finding algorithm: this 
approach combined standardization and flexibility, and fully documented 
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the local choices.  Moreover, we could provide an estimate of sensitivity of a 
component, using only aggregated data.
This way we could exploit diversity across sites, as a mean to infer validity. 
Rather than considering it a weakness, we demonstrated that it can indeed be 
considered a strength.
Generalizability of findings
In IAD we saw some general patterns in sensitivity and positive predictive value 
of component algorithms, in different diseases and over regions, and could 
potentially provide guidance for validity of case-finding algorithms of other 
diseases. However we don’t recommend to generalize the estimates that we 
obtained for validity indices to other diseases. Hypotheses on validity should be 
generated and tested against external data sources, using the methodology that 
we will explain below.
We demonstrated that we should be cautious when measuring compliance 
with standards of care for type 2 diabetes, hypertension and ischaemic heart 
disease from IAD. The balance between the number of false negatives and their 
reduced compliance, as well as access to diagnostic services contracted by the 
healthcare services, may change over time and between regions, and hamper 
the accuracy of estimates. Interpretation of results and generalizability to other 
diseases, should be carefully discussed with local managers of the healthcare 
system.
What is generalizable is the approach that we followed. This approach could 
be applied routinely to support interpretation of measures of compliance to 
standards of care for chronic diseases in IAD.
In its essence, the starting point to apply our approach is the following
•	 	two data sources are available on the same population, but record linkage 
at the individual level between them is not possible on a regular and 
continuous basis
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•	 	in one of the data sources (“worse” data source) the optimal case-finding 
algorithm for a study variable is unknown, while in the other (“better” data 
source) a good or excellent case-finding algorithm is available
•	 	permission for record linkage on a sample of persons can be obtained for 
purposes of validation
The approach for an individual-level validation of the variable of interest 
comprises three steps
Ecological-level comparison: compare at the ecological level the population 
prevalence of the variable, obtained separately from the two data sources; 
compare the resulting estimates with each other and with estimates available 
from the literature or from other sources, to obtain evidence that the quality of 
the two data sources is as expected
Gold standard validation: validate the candidate case-finding algorithm in the 
“better” data source with manual chart review
Individual-level validation: obtain permission to perform the record-linkage 
between the two data sources, and use the validated case-finding algorithm 
on the “better” data source as a gold standard to find the optimal case-finding 
algorithm in the “worse” data source. 
We consider now the case when a study variable must be defined in several 
data sources, who want to collaborate in a same study. The approach described 
above can be used systematically, although with some modifications. Indeed, in 
a multi-database setting we have some limitations:
•	 	data sources may not be available on the same population, but rather on 
similar populations;
•	 	even if two data sources are available on the same population, individual-
level record-linkage is unlikely to be allowed, due to time or legal constraints
On the positive side, in multi-database studies more than two data sources are 
normally available. 
We proposed to generalize the component algorithm strategy. A set of component 
algorithms must be created, each specified with data domain, provenance of 
data, pattern of records, date, and length of look-back. Sets of aggregated data 
can be shared among partners. Multiple comparisons across data sources can 
be performed. 
•	 	Analysis of components in a same data source
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•	 	Inference of validity of a component from one data source to another
•	 	Analysis of prevalence or incidence of the same component across different 
data sources
•	 	Estimates of positive predictive value of a component and of prevalence of 
the disease provide an estimate of sensitivity
We refer to this process as component analysis. At the end of the analysis, a data 
source-tailored combination of components can be chosen as the preferred 
case-finding algorithm, depending on the characteristics of the data source, on 
the results from the component analysis, and on the requirements of the study 
protocol.
Implications for research
We recommend to be cautious when measuring compliance with standards 
of care for chronic diseases from IAD. A key development would be assessing 
whether a calibration of the estimates from IAD improves the estimates of 
compliance with standards of care. To do so, a statistical model should be 
built that incorporates validity indices of the denominators and concordance 
between estimates of the numerators. The result should be compared with the 
“best estimate”.
In the absence of a true gold standard, a reference standard can still be used to 
validate another algorithm, but statistical adjustment needs to be applied. This is 
a classical approach, and relies on the assumption of conditional independence 
between the reference standard and the algorithm to be validated [Gart1966]. 
This assumption is unlikely to be met in our setting, and research is needed to 
explore how it can be weakened.
As for multi-database studies, the component analysis would benefit from further 
elaboration on several theoretical issues. First, robustness of validity estimates 
to violations of the assumptions needs to be assessed. Second, effort should 
be made to adapt the classical Hui-Walter paradigm, which was developed to 
validate diagnostic tests without a gold standard, to the case-finding algorithm 
situation [Hui1980, Walter1988, Joseph1995, Johnson2001]. Third, in order to 
implement components across data sources which use different coding systems, 
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mapping between different terminologies must be handled. Mapping must 
take place within multiple data domains: diagnosis, drugs, diagnostic tests, 
interventional procedures. We saw that two different strategies were adopted in 
different networks: either terminology mapping was done once and for all, or it 
was tuned on a specific study variable. The first strategy requires a bigger effort 
of initial mapping, but later allows for homogeneous treatment of mapped data 
across data sources. The second is conceivably producing study variables with 
higher validity indices. Understanding determinants of validity loss would be a 
relevant achievement.
Recommendations
Monitoring quality of healthcare for chronic diseases in Italy
Measures of compliance with standards of care for chronic diseases obtained 
from IAD should be used with caution. For the measures studied in this thesis 
the following recommendations on their use can be made:
•	 	pay-for-performance schemes for general practitioners should at present 
not be based on such measures. The validity issues are still too large and 
using them at this stage for reimbursement purposes would most likely 
introduce perverse incentives.
•	 	At regional level, IAD measures can be used alongside measures from 
primary care medical records for quality audits. The measures are 
informative when taking the local context into account.
•	 	At national level, when presenting comparisons between regions  an open 
dialogue is essential and the following should be considered:
 o  interpretation should be facilitated by presenting estimates of 
percentages of false negatives and estimates of regional use of private 
services, using as a reference
	 	 	 	validation studies from this thesis, 
	 	 	 	analysis of HSD
	 	 	 	analysis of national surveys
 o  regional managers should be encouraged to comment on the data, 
using insights derived from local audits as a basis
•	 	At national level, if compliance with standards of care is used to evaluate 
regions, calibrated estimates of true compliance should be built
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•	 	When using compliance with standards of care as an outcome in policy 
evaluation studies based on IAD, the impact of misclassification should be 
assessed or discussed. 
As an additional recommendation, validation studies should be routinely 
performed on clusters of patients. This recommendation was recently endorsed 
in a report of the Italian National Institute of Health [ISS2014]. The results from 
such studies could be used to update validity parameters, using the methods 
developed in this thesis.
Overall the compliance measures should be “handled with care”, but when 
applied with knowledge of the context and limitations of the underlying data 
they can provide meaningfull information to assess and improve the quality of 
care. 
Deriving variables in multi-database studies
When designing an observational study in a multi-database network, we 
recommend to adopt a component algorithm strategy to define the key study 
variables. In a feasibility phase, we encourage data sources to share aggregated 
data to allow estimates of validity indices. The combination of components 
meant to define a study variable should be tailored to each data source, in order 
to maximize validity. At the design stage, sensitivity analysis using different 
components to define variables should be designed, to assess robustness of 
study results with respect to heterogeneity in validity across sites. Including 
validity indices at the analytical step should be considered as well.
From big data to local intelligence
We saw in this thesis how big data can be used to validate big data, and we 
recommend to exploit systematically this opportunity to enhance local 
intelligence. This is paramount to meet the expectations from policymakers, 
clinicians, patients and citizens, that big data will provide more detailed and 
reliable guidance to the choices they need to make, in order to improve health 
and health care. 
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SAMENVATTING 
Achtergrond en onderzoeksvragen
Het tijdperk van ‘big data’ opent tal van nieuwe mogelijkheden om de 
gezondheidszorg te laten leren en verbeteren door hergebruik van de data 
die juist in de zorg worden gegenereerd. Observationele data van grote 
populaties kunnen de keuzes van de verschillende belanghebbenden, 
richting geven. Beleidsmakers kunnen uit deze data bijvoorbeeld opmaken 
hoe de gezondheidszorg beter georganiseerd kan worden, clinici kunnen 
behandelingsopties beter verkennen en patiënten kunnen zichzelf vergelijken 
met andere patiënten met dezelfde ziekte. Nieuwe methodologieën moeten 
worden ontwikkeld, en de traditionele gereedschappen en denkwijzen moeten 
worden aangepast naar dit nieuwe perspectief. Belangrijk is dat er geen 
verkeerde conclusies worden getrokken op basis van het gebruik van deze 
bronnen [Ray2011, Mooney 2015]. De methodologische uitdagingengaan niet 
alleen over de methoden van onderzoek maar vooral ook de heterogeniteit van 
de data die nu beschikbaar zijn en komen. In dit proefschrift waren we vooral 
geïnteresseerd in het laatste.
De belangrijkste doelstelling van dit proefschrift is het bevorderen van validatie 
studies voor het identificeren van ‘ziekten’ (case finding algoritmes) op een 
wijze dat combinatie van data in verschillende systemen gebruikt wordt en 
geen nieuwe data verzameld hoeven te worden.
In dit proefschrift kijken we vooral naar de mogelijkheden van de Italiaanse 
administratieve databases (IAD) om gevallen van chronische ziektente 
identificeren, wat nodig is om de kwaliteit van zorg beter te kunnen monitoren. 
Hierbij werden de data van de IAD vergeleken met elektronische medische 
dossiers van een  huisartsen database in Italië. Deel I van dit proefschrift is 
gericht op dit onderwerp. In deel II wordt de methodologie die in deel I is 
beschreven verder uitgebreid naar de context van multinationale database 
studies.
Validatie van variabelen definiëren chronische ziekte en naleving van de normen 
van de zorg in de Italiaanse administratieve databanken
Het Matrice Project, gefinancierd door het Italiaanse ministerie van 
Volksgezondheid, werd in 2011 gelanceerd door het Italiaanse Nationaal 
Agentschap voor regionale Healthcare Services (AGENAS), met als doel 
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methoden en instrumenten te ontwikkelen die gebruikt zouden kunnen worden 
ten behoeve van het monitoren van de kwaliteit van de gezondheidszorg voor 
patiënten met chronische aandoeningen.
De centrale onderzoeksvraag in het eerste deel van het proefschrift is: wat zijn 
de beste algoritmen om chronische ziekten op te sporen in IAD, en wat is de 
validiteit van de resultaten voor monitoring van de kwaliteit van zorg? 
In dit proefschrift hebben we bewezen dat de berekeningen over het voorkomen 
van enkele chronische ziekten in IAD goed overeenkomen met de aanwezigheid 
van ziekte op populatie en individueel niveau in huisartsen gegevens in Italië. 
Een lijst van eenvoudige component algoritmen (diagnose van hospitalisaties, 
de diagnose van vrijstellingen, geneesmiddel gebruik, het gebruik van 
diagnostische testen) moet altijd worden getest om te kijken wat de impact is op 
de berekeningen. De optimale algoritmes hadden hogevoorspellende waarde, 
maar een lage gevoeligheid.
Wij adviseren om voorzichtig te zijn bij het meten van de kwaliteit van de zorg 
van chronische ziekten indien gebruik gemaakt wordt van IAD. Ze moeten 
worden gebruikt met inachtneming van de context en de beperkingen van de 
onderliggende gegevens waarna ze kunnen bijdragen aan het monitoren van de 
kwaliteit van zorg. 
Geldigheid van variabelen in Multi-database-studies
In 2004, werd het anti-inflammatoire geneesmiddelen rofecoxib uit de markt 
genomen vanwege een verhoogd risico op myocard infarct, dit was vijf jaar 
na introductie van het middel en na massaal gebruik in de Verenigde Staten. 
Deze affaire leidde tot hervorming van het vigilantie systeem in de USA en door 
Richard Plattwerd geponeerd dat als er een systeem zou zijn metde anonieme 
medische dossiersvan 100 miljoen patiëntende nadelige cardiovasculaire 
effecten  in enkele maanden ontdekt  zouden zijn. Deze discussies waren 
het begin van de FDA Amendment Act (FDA-AA). Deze verplicht de FDA om 
gedistribueerde data van tenminste 100 miljoen mensen  te gebruiken voor het 
monitoren van de veiligheid van geneesmiddelen. Dit is nu gerealiseerd in het 
Sentinel systeem.  Parallel hieraan werden in Europa en Canada methoden en 
procedures ontwikkeld om studies uit te voeren op een gedistribueerde manier. 
Hierdoor kan nu worden geprofiteerd  van zowel de grootte als van de diversiteit 
van verschillende bevolkingen [Trifiro2014]. Het combineren van data is vooral 
in Europa niet makkelijk omdat elk land zijn eigen gezondheidszorg systeem, 
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coderingen en databases heeft. Er is echter een duidelijke noodzaak om 
algemene vragen, zoals de werkzaamheid en veiligheid van geneesmiddelen en 
vaccins, of de vergelijking van de kwaliteit van de gezondheidszorg samen aan 
te pakken. In deel II van dit proefschrift beschrijven we het data transformatie 
proces in 4 verschillende netwerken: in Italië (Matrice), Europa (EU-ADR) 
en in de Verenigde Staten (Mini-Sentinel en OMOP). In Mini-Sentinellag de 
nadruk op de data van verschillende bronnen in de Verenigde Staten, die slechts 
matig verschillen. In het OMOP netwerk werden vooral methoden ontwikkeld 
om snel verschillende designs te implementeren voor signaal detectie. In 
het Europese Unie ADR-netwerk is de heterogeniteit van de oorspronkelijke 
gegevensbronnen aanzienlijk hoger dan in de nationale netwerken. In dit 
netwerk wordt niet de hele database omgezet in een geharmoniseerd model 
maar wordt protocol gericht gewerkt. 
In het EMIF Project hebben we het concept en de methode voor algoritme 
ontwikkeling op basis van componenten die werd gestart in Matrice, toegepast 
voor type 2 diabetes mellitus in 8 Europese heterogene gegevensbronnen. 
We bevelen aan dit als algemene strategie toe te passen in gedistribueerde 
netwerken. De component analyse zou gebaat zijn bij verdere uitwerking van 
verschillende theoretische vraagstukken. We zagen in dit proefschrift hoe 
gegevens in de ene databron kunnen worden gebruikt om grote hoeveelheden 
data in andere bronnen te valideren. Door de hoeveelheden data die beschikbaar 
komen in de big data era’ zou de methodologie en de mogelijkheden hiervan 
beter ontwikkeld moeten worden. Dit is van cruciaal belang om aan de 
verwachtingen van beleidsmakers, artsen, patiënten en burgers te voldoen en 
uiteindelijk de gezondheid en de gezondheidszorg te verbeteren.
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